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ABSTRACT 
This work features natural products isolated from both the marine and microbial 
environments.  Part I focuses on the elucidation of toxins from harmful algal blooms (HAB).  The 
HAB dinoflagellate Karlodinium veneficum produces a harmful suite of molecules identified as 
the karlotoxins (KmTx) that have been implicated in massive fish kills pan-globally. Nine new 
karlotoxin congeners were isolated from various Karlodinium blooms around the world and 
utilizing the structure of KmTx2 were characterized using overlaid 2D NMR techniques. Due to 
the contrasting conformational differences between KmTx and the closely related amphidinols, 
the absolute configuration of KmTx was further evaluated by extensive computational analysis of 
the J-based coupling constants (JBCA) and chemical shifts (CS) of the 1H and 13C NMR data.  In 
addition, the total synthesis of one congener is being attempted to obtain additional material for 
biological studies and further structure activity relationship (SAR) studies. The expanded SAR of 
the class is being explored for new insights for agents for the treatment of cancer and as 
angiogenesis inhibitors.  Part II focuses on the isolation and characterization of novel lactone 
lipids, scoriosin and its methyl ester, isolated from Scorias spongiosa, a fungus that is commonly 
referred to as sooty mold and can be found growing on both Fagus sylvaticus and Fagus 
grandifolia, better known as the European and American beech trees. Using a combination of 
calculated and experimental electronic circular dichroism (ECD) and CS analysis, the absolute 
configuration of the molecules was established. Both compounds displayed antimicrobial and 
antifungal activity with IC50 values in the low µM to high nM range for Cryptococcus neoformans, 
Staphylococcus aureus and methicillin-resistant Staphylococcus aureus (MRSA). The second 
iii 
 
project in Part II focuses on using matrix assisted laser desorption ionization- mass spectrometry 
(MALDI-MS) imaging to confirm production of key pharmaceutical precursor secondary 
metabolites from marine associated bacteria.  Through microbial community analysis, 
optimization of fermentation conditions and MALDI-MS imaging, the first report of a sponge-
associated bacterium (Micromonospora sp. M42) from the Indo-Pacific sponge 
Acanthostrongylophora ingens (Thiele, 1899) that produces the manzamine class of antimalarials 
is presented. 
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PART I: STRUCTURE, SYNTHESIS AND BIOLOGICAL ACTIVITY OF HARMFUL 
ALGAL BLOOM TOXINS FROM KARLODINIUM SP. 
CHAPTER 1 
Computational Validation and Revision of the Karlotoxins from Karlodinium sp. and Mechanistic 
Insight into their Tumor Cell Selectivity  
 
CHAPTER 2 
Progress towards the Total Synthesis of Congener 5 
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CHAPTER 1: COMPUTATIONAL VALIDATION AND REVISION OF THE 
KARLOTOXINS FROM KARLODINIUM SP. AND MECHANISTIC INSIGHT INTO 
THEIR TUMOR CELL SELECTIVITY 
 
Amanda L. Waters,†,‡ Joonseok Oh,†,‡ Jiangnan Peng,†,§ John Bowling,† Allen R. Place,∆ and 
Mark T. Hamann*,†,║,┴ 
 
†Department of Pharmacognosy, ║Department of Pharmacology, School of Pharmacy, and 
┴Department of Chemistry & Biochemistry, University of Mississippi, University, Mississippi 
38677. ∆Institute of Marine and Environmental Technology, University of Maryland Center for 
Environmental Sciences, Suite 236 Columbus Center, Baltimore, Maryland 21202.  
 
INTRODUCTION 
Karlodinium sp. have been intriguing scientists dating back to the late 1940’s when they 
were explored as a potential food source for oysters in the United Kingdom.1  Due to 
technological limitations of the day, the first complete structure of a KmTx was not published 
until 2010.2 Much work has been accomplished in the isolation and elucidation of new KmTx 
congeners from around the world, biological profiling of Karlodinium metabolites as a class, 
insight into their mode of action (MOA) both environmentally and from a human health 
perspective, and even revision of the absolute configuration assignment in the past four years.  
While the story of these HAB toxins and their potential as cytotoxic and antiangiogenesis agents 
3 
 
is still being written, this work presents the next installment in the story and revealing their 
promising role as possible controls of cancer. 
KmTx’s are a suite of dinoflagellate congeners shown to possess hemolytic, cytotoxic 
and ichthyotoxic activity.3 Karlodinium veneficum was first isolated on June 23, 1950 from the 
Hamoaze, over Rubble Bank, off King William Point, South Yard, Devonport and reported in 
1956 by Ballantine and Abbott.1, 4 The species was originally named Gymnodinium veneficum, 
but was later found to be identical to Karlodinium micrum, therefore, the species was renamed 
Karlodinium veneficum in 2005.5  There was little information available regarding the toxic 
molecule at that time.  The compound was shown to be an exotoxin lethal to fish and other 
animals with a molecular weight greater than 1,000; soluble in water and ethanol and insoluble in 
ether and chloroform. Due to limitations of spectroscopy at the time, even a partial structure was 
not possible.1, 4  
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 Figure 1.   Structures of the known KmTx2 (control) and nine newly isolated and characterized 
KmTx molecules from around the globe. 
 
In 1996, a devastating fish kill event occurred in Hyrock Fish Farm in Maryland. 
Associated with this event were human health issues including skin lesions, respiratory 
problems, and short-term memory loss.6  Although originally claimed to be a “Pfiesteria-
associated” fish kill, it was later revealed that K. veneficum was a co-occurring dinoflagellate. 
5 
 
Given the historical literature and the established relationship between K. veneficum toxicity both 
in nature and under laboratory conditions, it is clear that the karlotoxins are at least one of the 
responsible parties for this and other similar events.3a  
After the isolation of KmTx2 from the eastern seaboard of the US, the global distribution 
of this dinoflagellate was explored and found to be quite extensive spanning across North 
America, Europe and Australia (figure 2). At least 8 distinct strains of Karlodinium sp. have been 
isolated from around the world each producing KmTx-like molecules.7  Interestingly each strain 
produces slightly different metabolites with varying cytotoxicity and sterol binding profiles. It is 
apparent that geographical location, ecological interactions and other environmental and genetic 
factors greatly influence the production of these molecules and as such there are a seemingly 
limitless number of congeners. The new Karlodinium sp. congeners from around the world are 
presented in figure 1. 
 Figure 2.  Geographical distribution of the KmTx congeners from around the world. 
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There has been a tremendous amount of research on the configurational assignment and 
MOA of the KmTx’s in the last decade. Much of this work was driven by the structural similarity 
of KmTx to amphidinol (Am) another complex, polyketide-derived compound isolated from 
Amphidinium sp.  The first structure with partial relative configuration for a karlotoxin, KmTx1, 
was not published until 2008, and it took another two years to define the complete structure 
including the absolute configuration for KmTx2.2, 8 To date KmTx2 is the only metabolite in this 
series to have the stereochemistry completely defined.  This complex polyketide with 26 
individual stereogenic centers poses a significant challenge in terms of NMR-based structure 
elucidation.  The first complete structure of an Am, Am3 was published in 1999.9 While these 
structure share remarkable structural similarity and almost certainly are derived from the same 
biosynthetic machinery, the pyran sections (C28-C49 in KmTx2 and C30-C51 in Am3) of the 
molecules are published with the enantiomeric configuration.9   Figure 3 compares the absolute 
configuration of KmTx2 with Am3 along with other structurally related comounds elucidated 
from dinoflagellates.  The regions highlighted in red accent the differences in the absolute 
configuration between the two molecules.  The absolute configuration of Am3 was determined 
based on JBCA, nuclear overhauser effects (NOE) interactions, and a modified Mosher’s method 
coupled with chromatographic/NMR comparison of degradation products,9 while KmTx2 was 
assigned using JBCA, NOE interactions and degradation utilizing Grubb’s II catalysis and 
periodate-mediated diol degradation.2  Am3 has already undergone two relative configuration 
revisions since its publication in 1999, C2 in 2008 and C51 in 2013, both revised using synthetic 
approaches.10 Owing to the availability and advancements of computational methodologies, the 
computationally-assisted JBCA and CS of KmTx2 were undertaken to further validate and make 
adjustments if necessary to the previously assigned configuration.   
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Karatungiol A was published in 2006 from an Amphidinium sp. and has shown antifungal 
activity.11  Luteophanol A was published in 1997 also from an Amphidinium sp.  and showed no 
antifungal activity, but weak acitivity against Gram-negative bacteria.12  Lingshuiol was 
published from another Amphidinium sp. in 2004 and exhibited cytotoxicity against A-549 and 
HL-60 cells in vitro at sub-micromolar concentrations.13  Symbiopolyol was also isolated from a 
symbiotic dinoflagellate associated with the jellyfish Mastigias papua and showed inhibition 
against vascular cell adhesion molecule-1.14  Prorocentrol was published in 2011 from the 
dinoflagellate Prorocentru hoffmannianum and showed only moderate cytotoxicity against P388 
cells.15  This structure is unique among this group of compounds since it replaces one of the 
pyran rings for a furan ring and does not have the exo-methylene.  At least some of the relative 
configuration of all of these moecules is reported; however, only KmTx2 and Am3 have been 
fully characterized.  Like Am3 and KmTx2, symbiopolyol is reported to be an enantiomer of 
lingsuiol B with opposite relative configuration around the tetrahydropyran rings.14   
Aside from the aforementioned biological activity, studies have elucidated the ecological 
role of the KmTx’s as being that of a prey capture mechanism. The mechanism is based on the 
membrane pore formation where the compound forms a pore in the cell membrane with certain 
sterol interactions thus disturbing the osmotic balance of the cell through membrane 
depolarization ultimately leading to cell death through lysis.16  It has also been reported that the 
pore formation is dependent on the sterol composition of the cell.7, 16b   Cells containing 4-α 
methyl sterols (like gymnodinosterol) are resistant to the compound, whereas cells containing 4-
desmethyl sterols (like cholesterol) are susceptible to KmTx’s (figure 16).17   To date, this 
interaction has not been characterized due to the difficulty in computer based modeling on the 
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highly flexible structures of KmTx’s. Here we elaborate on the molecular nature of this 
interaction based on NMR MOA studies using different sterols. 
 
Figure 3. Comparison of KmTx2 and other dinoflagellate natural products. 
KmTx2 and Amphidinol 3 as currently published noting the opposite configuration occurring at 
C28 (KmTx2-blue) and C30 (Amphidinol 3-red) along with other similar structures elucidated 
from dinoflagellates. 
 
RESULTS AND DISCUSSION 
Higher-Throughput Structural Elucidation of New Karlotoxins Utilizing 2D HSQC 
Techniques 
The 2D NMR Heteronuclear Single Quantum Coherence (HSQC) overlay experiments 
were utilized for explicit determination of the complex planar structures of nine new congeners. 
Capitalizing on the extensive NMR data already collected for KmTx2, the next step in the 
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evolution of this suite of molecules was developing a quick and efficient way to characterize new 
KmTx molecules with relatively small quantities of material. Figure 4 illustrates the methods for 
the structure elucidation of the congeners. The two data sets are acquired and overlaid using 
MestReNova, an NMR processing software that allows for the manipulation of the data for 
overlay comparison analysis. This method allowed for the relatively quick identification of areas 
of the molecule where significant structural remodeling had occurred and provided focus for 
elucidation efforts on that specific region of the 1H-13C Heteronuclear Multiple Bond Correlation 
(HMBC), 1H- 1H Correlation Spectroscopy (COSY), 1H-1H Total Correlation Spectroscopy 
(TOCSY) and (ROESY) spectra. The HMBC, COSY, and Rotating Frame Nuclear Overhauser 
Effect Spectroscopy ROESY experiments were also overlaid, but the greatest diagnostic benefit 
was achieved from the overlaid HSQC spectrum. Figure 4a shows the areas of interest in the 
KmTx2 HSQC spectra. 
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 Figure 4. HSQC overlay experimental summary.   
A) The fingerprint regions of KmTx2 (1). B) Expansion of region I illustrating the distinctive 
chlorination pattern of olefinic resonances. C) Expansion of region II illustrating the oxygenation 
pattern of congeners 3, 4, 5, 8 and 10 that differ in the polyol section (C1-C18). D) Expansion of 
region II illustrating the oxygenation pattern of congeners 6, 7 and 9 that differ in the first pyran 
region (C29-41). 
 
Region I represents the correlations related to the alkene region of the molecules.  Using 
this method, the chlorination status of a congener was quickly established. Figure 4b shows the 
comparison between the known KmTx2 (1) and non-chlorinated congeners (4, 6, 7 and 9) in red.  
All KmTx molecules published to date share the terminal diene moiety.  When chlorinated as it 
is with 1, this contains 4 CH’s; however, when the chlorination is not present, the overlay clearly 
shows the presence of 3 CH’s and 1 CH2.  The CH2 resonance occurs at δ114.88 instead of the 
chlorinated CH resonance which appears at δ119.42.  The terminal proton resonances are also 
distinct occurring at δ5.07 and δ4.93 without terminal chlorination and δ6.23 with chlorination.  
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The chemical shifts for the remaining 3 CH’s also shift slightly due to the deshielding effects of 
the chlorine.  The pattern of shifting in the correlations is highly representative and can be seen 
for all of the congeners analyzed thus far to determine chlorination.   
Region II was another diagnostic region of the molecule. This depicts all of the 
correlations for the oxygenated carbons in the molecule.  These data allowed for the 
determination of the oxygenation pattern of the pyran rings and the polyol section.  With the 
exception of 2 where an additional β-hydroxyl is seen on the B ring, the main differences seen in 
Region II are either in the polyol section C1-18 (Figure 4c) or the first pyran region C29-41 
(Figure 4d). Out of the 9 congeners analyzed all but 2 showed a conserved pyran ring structure 
from C42-48. Upon overlay of the HSQC data, 2 showed the typical chlorinated terminal olefinic 
pattern in region I, but a slight shift of the proton signal for C67 which is the terminal alkene 
directly adjacent to the second pyran ring.  Region II showed large alterations of chemical shift 
values for C42-46 with small variation in C36-41 and C47.  The most telling piece of evidence 
was the loss of the HSQC signal at C44 from region I and the addition of an extra signal in 
region II for 2.  This was also supported by the loss of a CH2 in the DEPT spectrum at δ31.42 
and the addition of an extra CH in the region between δ70.00 and 74.60.  The addition of 16 amu 
for the mass was also observed.  This evidence suggested the addition of an OH at C44.  This 
was confirmed by HMBC correlations from H44 to C43, C45, and C46 and TOCSY correlations 
which elucidated the spin system from H48 through H42.  The relative configuration of the 
newly oxygenated C44 was established via ROESY correlations from H44 to H45 and H41. The 
HMBC, TOCSY and ROESY correlations are outlined in figure 5. Region III of the molecules 
was less resolved due to the similarity of carbon and proton chemical shifts in the molecule and 
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was primarily used for support and conformation of the differences observed in regions I and II 
as seen in the following elucidation examples. 
 
Figure 5. Key HMBC, TOCSY and ROESY correlations for 2.  
The HSQC overlay indicates that the rest of the molecule (C1-C39 and C49-C63) was identical 
to KmTx2. 
 
Congeners 6, 7 and 9 were all non-chlorinated congeners of KmTx with the characteristic 
HSQC NMR overlay pattern seen in Figure 4b.  They also all exhibited the same characteristic 
shift in Region III which indicated the replacement of the hydroxy group of C37 with a methyl 
group. The loss of the C37 and H37 methine at δ72.40 and δ4.02, respectively, and the 
appearance of the new methine signal at δ36.77 and δ2.09 was a clear indication of the loss of 
the hydroxyl group and the addition of a methyl group. In the 1D spectra this is seen as the 
addition of a CH3 signal at δ14.16 and an additional doublet in the proton spectra at δ0.80. This 
replacement was confirmed with HMBC correlations from H36 to C67 and COSY correlations 
from H37 to H36, H38a, and H38b.  The ROESY spectra help establish the relative configuration 
at C37 based on correlations between H37 and H36 and H37 and H34 (figure 6). 
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Figure 6.  Key HMBC, COSY and ROESY correlations for 6, 7 and 9. 
 
Congener 9 showed a loss of the normal HSQC signal at C10 and an increase in mass of 
79 amu.  The HSQC overlay at C8 and C9 were also perturbed.  All of this evidence points to the 
exchange of a hydroxy group for a sulfate group in this congener.  The HSQC overlay data for 7 
overlaid identically to with that of 6 with the exception of the signal intensity at C53-59. The 
mass for 7 was 14 amu greater than 6’s molecular weight. The carbon spectra also indicated the 
presence of 7 carbon signals between δ30.3 and δ30.8 where congener 6 only showed 6 signals. 
This was indicative of an additional methylene in the long aliphatic chain from C50-60. This 
scenario is common in the KmTx series and a similar situation was seen between KmTx1 and 
KmTx3.  
Congeners 3, 4 and 5 were isolated from Karlodinium veneficum strains first isolated 
from the United Kingdom.  Congeners 3 and 4 were from the original K. veneficum culture 
isolated by Mary Parke in the 1950’s. This particular strain was preserved at the Plymouth 
Marine Laboratory.  The strain was sent to Maryland where is was grown and the compounds it 
produced isolated.  The structures were elucidated using similar techniques as those mentioned 
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above, and the detailed data set is presented in the supporting information. These structures are 
the smallest congeners elucidated to date and differ significantly from KmTx2 in the C1-C18 
region which can be seen in Figure 4c.  Congeners 3 and 4 differ from each other only by the 
characteristic loss of a chlorine on the terminal diene of 4.  The structure was five carbons 
shorter than KmTx2 all of which come from the polyol region.  The HSQC overlay experiments 
showed that C23-C63 and C65-67 for KmTx2 (2) are identical to C19-49 and C60-62 for 3.  The 
difference in the structures was the loss of C64, C13-14 and C16-17 (3 CH’s, 1 CH2 and 1 CH3 
[68 amu]) from 2. The key HMBC and COSY correlations for the final assembly of C1-18 of 3 
are shown in figure 7.  This figure illustrates where the deletion of carbons from 1 occurred and 
how C1-C12 have been assigned based on HMBC and COSY. 
 Figure 7.  Similarities of KmTx2 (1) with 4. 
A) Structure of 1 with deleted carbons for 4 like congeners shown in red.  
B)  Key HMBC and COSY correlations for 4 and 3.  The HSQC overlay indicates that the rest of 
the molecule (C22-C63 and C65-67 [KmTx2 numbering]) is identical to 1.  The blue numbers 
are the corresponding carbon numbers for 1. 
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Congener 5 was also a relatively small congener, and its main structural differences were 
also in the C1-C18 region.  Region I overlaid well between 1 and 5 with the exceptions of C4 
and C5.  This molecule was the first discovered that lacked the olefin between C4 and C5.  The 
absence was clearly noted in region I of the overlay experiments with 1 where it was easily seen 
that C4 with a value of δ128.49 and C5 with a value of δ136.93 were absent.  There were also 
obvious changes from the HSQC overlay in regions II and III for C1-C8.  The loss of the 
methine C2 signal from δ73.08 and the addition of a methylene signal at δ30.13 was an 
indication that C2 is no longer an oxygenated carbon.  The subsequent shift in C1 from δ66.75 to 
δ63.33 was also an indication of a loss of the electronegative group.  The shift in the C3 group 
from δ37.58 to δ34.98 supported both the loss of the hydroxyl group at C2 and the loss of the 
alkene between C4 and C5.  Based on HMBC and COSY data shown in figure 8, C4 is now 
hydroxylated with a chemical shift of δ72.85, while C5 is now a methylene group at δ23.35.  The 
loss of the C6 methine signal at δ73.65 coupled with the addition of a methylene at δ38.46 
indicated the loss of a hydroxyl group.  C7 has shifted to δ23.26 based on its proximity to the C8 
hydroxy group.  Congener 5 was 42 amu smaller than 1.  Based on the overlay experiments, for 1 
there were 5 CH’s, 4 CH2 and 3 OH groups while 5 only had 2 CH’s, 5 CH2’s and 2 OH groups.  
The net difference is C2H2O which accounts for 5 being 42 amu smaller than 1.  C10 from 1 
overlaid well with C8 of 5 indicating that they were the same carbon on both structures.  The rest 
of the structure C10-C67 on 1 and C8-C65 on 5 were identical.  The detailed elucidation is 
presented in figure 8 including the detailed HMBC correlations (H1 to C2 and C3; H2 to C1; H3 
to C1; H4 to C3 and C6; H5 to C4; H6 to C4 and C8; H7 to C6; H9 to C8 and C10) and COSY 
correlations walking from H1 to H9. 
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Figure 8. Key HMBC and COSY correlations for 5. 
 
Congener 8 represents an interesting addition to the SAR of the KmTx congeners. The 
HSQC overlay experiments eluded to a loss of the olefinic moiety between C4 and C5 like 5 
with the addition of the oxidation of the hydroxyl group at C6 to a keto functionality.  The 
appearance of a carbon at δ211.94 indicated the presence of a ketone, and the alteration and 
connection of the chemical shifts for C5 and C7 to δ51.94 and δ52.04, respectively, by HMBC 
assigned its position.  The loss of the hydroxyl group on C2 was similar to that seen for 5. Using 
the similarities in the structures plus the HMBC placement of the ketone, 8 was quickly 
elucidated.  The remaining differences in oxidation from C1-C18 were confirmed via HMBC 
(H1 to C2; H2 to C1; H3 to C2 and C4; H5 to C4 and C6; H7 to C6, C8 and C9; H8 to C9; H9 to 
C11; H10 to CC9 and C11; H11 to C12 and C13; H13 to C12; H14 to C13; H14 to C13 and C16; 
H15 to C16) and COSY correlations that walk the correlations from C1 through C5 and then 
again from C7 through C16.  The detailed correlations are outlined in figure 9 and in detail in the 
supporting information. 
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Figure 9. Key HMBC, COSY and ROESY correlations for 8. 
 
Congener 10 was also a unique expansion to this group of congeners.  Instead of being 
isolated from a K. veneficum species, it was derived from a closely related species, K. conicum.  
It was the most southern and lowest collection temperature of all of the congeners isolated here.  
Interestingly, it exhibited no hemolytic activity.7 This is possibly due to its having the shortest 
aliphatic section of any KmTx discovered to date.  As with 6 and 7, the HSQC data for 8 and 10 
overlaid well with the exception of C53-C56.  The HSQC signal for 8 was stronger in this area 
than in 10. This coupled with the loss of 28 amu between the masses of 8 and 10 was a strong 
indication of a shortening of the aliphatic chain by 2 methylenes.  
The relative configuration of all of the KmTx congeners presented in this paper were 
assigned by comparison to the previously established KmTx2 with careful analysis of NOE 
interactions for new stereogenic centers. For those molecules (3, 4, 5, 8, 10) where KmTx2 NMR 
overlay was too different for direct comparison, computational chemical shift calculations were 
carried out to confirm the relative configuration of new stereogenic centers and link them back to 
the known absolute configuration of C21 deduced in KmTx2 by degradation chemistry. This 
method worked for congener 5 and all but one stereocenter in the polyol section for 3/4 and 8/10.  
The HSQC overlay experiments are highly sensitive and if inversion of stereochemistry was 
observed it would be detectable in the overlay experiments.  As such, we feel confident in 
assigning the relative configuration as the absolute configurations based on the comparison to the 
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rigorously established KmTx2 which extensively utilized JBCA, Grubb’s catalysis and Mosher’s 
ester analysis to determine the absolute configuration.2 
Biological Evaluation 
Each molecule with the exception of 10 (HD50 = 3.0 ± 0.3 µM) exhibited some degree of 
hemolysis using rainbow trout erythrocytes (2: 0.93 ± 0.04; 3: HD50 = 1.41 ± 0.03 µM; 4: HD50 = 
1.06 ± 0.02 µM; 6: HD50 = 0.1 ± 0.2 µM; 7: HD50 = 0.14 ± 0.03 µM) with 8 (HD50 = 0.049 ± 
0.004 µM) being the most hemolytic congener at over 26 times the potency of the KmTx2 (HD50 
= 1.3 ± 0.3 µM).  Interestingly, when injected into mice, no lethality was observed only a 
reversible anorexia with the greatest concern being necrotizing pancreatitis seen in one mouse 
treated with 1 at the highest dose.18   
Congener 8 has been tested and found to have potential anti-angiogenesis activity at 
concentrations below the cytotoxic concentration in a tubular formation assay.  The microscopic 
images of tubal formation and nuclear area for the positive and negative controls as well as three 
concentrations of 8 are shown in figure 10.  In initial screenings, it was found to have 100% 
inhibition of angiogenesis at both 10 and 2 µM concentrations.  Upon further testing, the IC50 of 
8 was determined to be 0.598 µM for inhibiting tube area formation, but a 1.077 µM IC50 for 
inhibiting nuclear area.  Congener 6 and 10 were also tested in this assay and found to be equally 
potent with 100% inhibition at both 2 µM and 10 µM at the initial screening stage.  Due to 
limited materials, the IC50 values were not obtained. 
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Figure 10. Microscopy images for tubular formation assay for 8 at various concentrations. 
 
Congener 8 was screened in the NCI 60 cell panel and showed selectivity in the 5 dose 
screening for leukemia cell lines SR (GI50 = 0.0911 µM) and CCRF-CEM (GI50 = 0.686 µM), 
non-small cell lung cancer lines HOP-62 (GI50 = 0.986 µM), NCI-H23 (GI50 = 0.903 µM) and 
HOP-92 (GI50 = 0.456 µM), ovarian cancer cell line IGROV1 (GI50 = 0.644 µM), renal cancer 
cell line SN12C (GI50 = 0.908 µM) and breast cancer cell line BT-549 (GI50 = 0.541 µM).  
Figure 11 illustrates how 8 compares to other FDA approved cancer drugs (eribulin [NSC 
707389], taxol [NSC 125973], methotrexolate [NSC 740], and cisplatin [NSC 119875]) as well 
as amphotericin B (NSC 527017) which has a similar structure.  Figure 12 shows the one dose 
mean values for each cell line.  From these data, the cell lines for which 8 shows selective 
cytotoxicity are illustrated with bars to the right.  It is apparent that 8 has no effect on colon, 
CNS or melanoma cancers.  Congener 8 was also screened against ovarian cancer cell line 
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(OVCAR5) to produce a concentration response curve comparable to doxorubicin (figure 13).  
The IC50 for 8 was found to be 7.76 µM compared to the doxorubicin control of 0.652 µM. 
 
 Figure 11. Comparison of select NCI 60 cell panel GI50 for 8 vs controls and MOA pattern 
comparison. 
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 Figure 12. One dose mean graph for 8 NCI 60 cell panel results. 
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 Figure 13. Ovarian cancer cell line concentration response curve. 
 
Structural Activity Relationship 
The SAR relationship of KmTx1-3 and their chlorinated and sulfonated derivatives was 
discussed in the Van Wagnor paper in 2010.19  This was the first publication that expanded the 
KmTx family of congeners.  It was determined that the size of the lipophilic arm played an 
important role in the hemolytic activity.  For example, KmTx1 which has the longest lipophilic 
arm was shown be the most potent hemolytic agent, while 1 with the shortest was less potent by 
almost an order of magnitude.  The chlorination of the terminal diene was shown not to have a 
substantial effect on activity while the sulfonation at C10 greatly reduces the hemolytic activity.  
These same trends were seen throughout the amphidinol family of marine compounds.20  
This report expands the published number of congeners from 7 to 16.  These molecules 
also possess not only different functional groups not previously reported from this series, but 
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also variations in key portions of the molecules which allows for inference of more SAR 
information for the development of future optimized leads from this class.  Congeners 2, 5 and 9 
were unable to be tested due to insufficient material being isolated from the dinoflagellates. The 
structural similarities of the relationship between 6 and 9 and KmTx3 and its sulfated derivative, 
suggests that the sulfonation at C10 (R2) will greatly reduce the hemolytic activity.  As for the 
rest of the molecules, the revealed that the shorter the lipophilic arm, the less potent the activity.  
The contrast was especially clear between 7 and 10 which contain the longest and shortest 
lipophilic arm lengths.  It is important to note that 10 has the shortest lipophilic arm length ever 
reported and shows no hemolytic activity.   
However, for antiangiogenic activity, the chain length does not seem to make a 
significant difference since the biological activity results showed equal angiogenesis inhibition 
for congeners 6, 8 and 10.  This suggests that the angiogenesis activity can be separated from the 
hemolytic activity and the SAR for angiogenesis involves a different part of the molecule than 
the SAR for the hemolytic activity.  Another interesting development in the evolution of the 
congener structures was the isolation of a ketone functionality at C6.  This functional group 
appeared in both 8 and 10.  Congener 8 shared many structural similarities with 1. The only 
exception being the oxygenation pattern and oxidation of the double bond between C1-9 (R1).  
Congener 8 is the most potent hemolytic congener published to date, and this indicated that the 
polyol section of the molecule does play an important role in its activity.  Congeners 3 and 4 
contain the smallest polyol section published for a karlotoxin, yet exhibit hemolytic activity 
similar to that of 1.  This indicated that the size of the polyol chain was not as important as the 
oxygenation pattern. Congeners 3 and 4 also differ from each other by the terminal diene 
chlorination (R9) which gave 3 slightly greater hemolytic activity as discussed above for the 
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other karlotoxin congeners.19  Congeners 6 and 7 differ from KmTx2 (1) and KmTx3 
respectively by the exchange of a hydroxy group at C37 (R7) for a methyl group.  This exchange 
does not affect the hemolytic activity of the molecules as they are comparable with the published 
values for KmTx2 (1) and KmTx3.   
As summarized in figure 14, the longer the lipophilic arm, the more potent cytotoxic 
activity the KmTx series possesses.  If the chain length (n) was reduced to 6 carbons or less, all 
of the cytotoxic activity was lost.  The addition of a sulfate group at C10 (R2) rendered the 
compound up to 20 times less potent.  The chlorination pattern of the terminal diene (R9) 
increased activity slightly.  The alteration of the polyol chain (R1) in size does not affect the 
activity, but alterations in the oxygenation patterns had drastic effects.  The replacement of a 
hydroxy group for a methyl group at position C37 (R7) did not affect the activity. 
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 Figure 14. The key SAR functionalities involved in the karlotoxins biological activity. 
a=HD50 values obtained from Van Wagoner et al.19 
 
Cholesterol Binding Studies 
During the original Karlodinium studies done by Ballantine and Abbot, it was discovered 
that adding cholesterol in the presence of the compound will eliminate all cytotoxic activity.4b  
Similar results were observed when conducting ichthyotoxicity assays.  Given this data, surface 
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plasmon resonance (SPR) was used to quantify and compare this binding interaction with several 
different types of sterols.  The findings suggested that the 4-α methyl sterols exhibited little to no 
binding affinity for 1 whereas 4-desmethyl sterols (like cholesterol) had a significantly higher 
binding affinity (figure 15).17a  
 
Figure 15. SPR binding curves for KmTx vs different sterols. 
 
Upon further exploration of this phenomenon, it was determined that Karlodinium 
exploits this selectivity as a feeding mechanism.  K. veneficum is a mixotroph, meaning that it 
utilizes photosynthesis through autotrophy as well as being involved in a predator prey 
relationship through heterotrophy.21  The heterotrophy relationship involves Cryptophyceae 
(cryptophytes) as a food source.  Studies have shown that K. veneficum grows better with growth 
rates of 0.52-0.75 divisions/day when mixotophically grown, as opposed to a maximum of 0.55 
divisions/day when feeding autotrophically.  The unique nature of the membrane composition of 
the predator vs the prey allows Karlodinium to feed.  Karlodinium sp. membranes are primarily 
composed of gymnodinosterol, a 4α-methyl sterol, whereas cryptophyte membranes are 
primarily composed of brassicasterol, a 4-desmethyl sterol similar to cholesterol (figure 16).  As 
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Karlodinium floats around the water column, it collides with the cryptophyte releasing its 
exotoxin (karlotoxin).  This exotoxin then non-specifically permeabilizes the cell plasma 
membrane of the cryptophyte ultimately resulting in cell death through osmotic lysis.17a  
Unfortunately, the massive fish kills associated with these HAB’s are a result of the similarity in 
structure of brassicasterol and cholesterol.  When Karlodinium collides into fish gills instead of a 
crytophyte, the same mechanism occurs resulting in fish gill cell membrane lysis.  The 
unintended end result is ecological devastation. 
 
Figure 16. Structures of ecologically relevant sterols. 
 
Further exploration was needed to understand this interaction on a molecular level.  For 
that reason, HSQC overlay studies were conducted to give insight into the unique MOA of the 
cholesterol/congener detoxification data.  Using a series of increasing ratios of congener added to 
cholesterol, HSQC NMR experiments were conducted using identical experimental parameters 
to ensure that changes in the data were a direct result of congener/cholesterol interaction.  Figure 
17 summarizes this data.  The blue HSQC spectrum indicates 2 mg of 8.  The red spectrum was 
what occurred when 0.2 mg of cholesterol was added to the NMR tube and data was re-acquired.  
Finally the green spectra indicates the interaction when 0.3 mg of cholesterol was added.  There 
were definitive shifts in the HSQC spectra for certain carbons mainly around the pyran ring 
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systems, while other carbons on the exterior of the structure like C1 were untouched by the 
addition of cholesterol.  The specific carbons that showed chemical shift variations with the 
addition of cholesterol are highlighted in pink in the KmTx structure in figure 17.   
Experiments were conducted that added more than the 0.3 mg cholesterol per 2 mg 
congener.  This data indicated that at 0.4 mg the perturbation of the cholesterol binding signals 
was receding and broadening and at 0.5 mg the signals were close to the original congener with 
no cholesterol added but were extremely broad.  These results were most likely due to the 
interaction of cholesterol with itself vs the congener. The solubility of cholesterol in the solvent 
solution of 20:1 MeOD:CDCl2 was probably exceeded leading to the formation of nanoparticles 
of cholesterol resulting in an isotropy effect on the sample thus causing the observed broadening.  
The broadening signals is another indicator that cholesterol/cholesterol interactions are more 
prevalent than cholesterol/congener interactions signaling that binding saturation has been 
achieved. 
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Figure 17. Preliminary cholesterol binding studies. 
HSQC overlay experiments for 8 with varying amounts of cholesterol.  Generic KmTx structure 
with atoms perturbed by the cholesterol binding highlighted in pink. 
 
The same experiments were carried out using ergosterol and gymnodinosterol to confirm 
the binding site of sterol on KmTx and identify any dynamic differences in the binding pocket 
when different sterols were bound.  These experiments showed that the binding variations were 
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unique to cholesterol and that while binding does occur based on SPR studies, it is not detectable 
on the NMR timescale or with the solvents compatible with the NMR experiment (figure 18).   
 
 Figure 18. HSQC overlay of 8 vs gymnodinosterol and ergosterol. 
 
Based on the current SAR and NMR studies, the sterol recognition elements are found in 
the pyran ring portion of the molecule while triglyceride, sphingolipid and various other lipid 
interactions could be dictated by the polyene moiety accounting for the cytotoxic activity. We 
hypothesize that the polyol section interacts with proteins and carbohydrates in the membrane 
thus ensuring a full contact membrane binding mechanism (figure 19).22  This would be similar 
to these interactions seen for AmB and other sterol binding agents.23   
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 Figure 19.  Hypothetical cell membrane (lipid raft) interaction with KmTx2. 
A) Hypothetical binding of KmTx with the cell membrane components.   
B) Hypothetical pore formation of KmTx molecules from the side view and top view.    
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Perhaps the most classic example of an MOA involving sterol binding and selectivity is 
amphotericin B (AmB).  AmB is the last line of defense for severe systemic fungal infections.  
However, clinical applications are reserved for life-threatening infections where severe side 
effects such as nephrotoxicity, are an acceptable risk.24  The mechanism of AmB is based in part 
on its ability to preferentially bind ergosterol (main component of fungal cell membranes) vs 
cholesterol (main component of mammalian cell membranes).  The other proven MOA of AmB 
is membrane permeabilization via channel formation.25  Empirical evidence suggests that this is a 
novel strategy that microbes cannot develop resistant strategies against.  Due to the similarities 
of the proposed MOA of KmTx and AmB, it was crucial to explore the comparison of these 2 
molecules further.  With data available from the CellMiner Database Version 1.426 (Genomic 
and Bioinformatics Group at the Laboratory of Molecular Pharmacology, Center for Cancer 
Research, NCI, NIH, DHHS), comparison of known cancer standards and other pharmaceuticals 
that have been run using the NCI 60 cell panel were directly compared to the data obtained for 8.  
Figure 11 illustrates the comparison of the –logGI50 values of 8, eribulin, taxol, methotrexalate, 
cisplatin and AmB.  As the graph illustrates, 8 is much more potent against most cell lines than 
AmB with selectivity that is much better than cisplatin.  These results emphasize the novelty of 
this class as a potential cancer lead. 
Additionally, a more traditional analysis using the Compare27 algorithm was done on the 
NCI 60 cell data for 8.  Using the Pearson correlation coefficients, a comparison of 8 and AmB 
calculated a 0.254 correlation value.  Any values under 0.7 are considered statistically 
insignificant.  Therefore, 8 and AmB do not share a similar MOA.  The closest correlations to 8 
were synthetic products not in clinical trials where the MOA have not yet been well defined 
(citratohydragtogallium(III), 0.766; 2,3-Bis-(4-chlorophenyl)-5-hydroxymethyltetrahydrofuran-
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3-ol, 0.6989; and Autol Red RLP, 0.669).  The Cellminer database also allowed for the mining of 
gene correlations seen to be upregulated or downregulated based on the NCI data for a given 
congener.  The top 10 gene correlations are listed in table 1.  Utilizing the online STRING 
(Search Tool for the Retrieval of Interacting Genes/Proteins) 9.0 database, the definition of the 
gene/protein and further downstream and upstream targets in the MOA pathway were 
identified.28  Figure 20 illustrates the relatedness of the 10 genes.  When the web of protein 
interactions was expanded further, all but 4 of the genes identified share some common pathway 
(figure 21).  Interestingly, this pathway appears to be heavily influenced by extracellular 
receptors (IL2RA and IL2B) which are imbedded in the cell membrane.  Therefore, our 
hypothesis is that the sterol binding interactions of KmTx are affecting the cell membrane thus 
having an impact on membrane integrity and possibly cellular signaling that depends on 
extracellular receptors to function properly.  The proposed pore formed by the KmTx molecules 
seems to resemble an aquaporin or water channel.  This is further supported by the 0.644 
correlation with Aquaporin 9.  While this values is not indicate a significant similarity in gene 
interactions (>0.7) it does give insight that a similar mechanism might be responsible for the 
activity seen in the NCI data.  Recently the ABCA1 protein, responsible for transfer of cellular 
cholesterol across the plasma membrane, has been shown to play a role in the buildup of 
cholesterol in cancer cells over normal cells leading to avoidance of the normal cell-death 
signaling cycle.29  These data further support the mechanistic rationale for cholesterol targeting 
as a potential cancer treatment strategy. 
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 Figure 20. STRING analysis for top 10 gene relatedness. 
 
 
Figure 21. STRING network expansion for top 10 genes based on CellMiner. 
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Table 1. Top 10 Gene Correlations based on CellMiner data and STRING. 
 
Computational Validation and Revision of KmTx2 through JBCA and CS 
Computational Validation of JBCA for C27-30 
The first approach to verifying the absolute configuration of 1 was to use computation 
methods to validate the JBCA.  Unlike the JBCA of other molecular regions performed on 1, the 
JBCA of C28-C29 resulted in vicinal homo-coupling constants that were considered 
“intermediate” in value.  As such, computation analysis of the three staggered conformers at that 
position (gauche+, gauche-, and anti) will give us simulated values to compare with the actual 
measured values.  The C28 position was determined based on degradation analysis to be the R 
configuration,2 as such that position remained fixed.  For comparison, the three conformers for 
the opposite configuration starting at C29 were also analyzed.  In order to obtain a more accurate 
computer simulation, the relative configuration of C29-C32 on both models was fixed based on 
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the JBCA.2 The NOE data from 1 was also analyzed and integrated to establish relative distance 
constraints for the pyran ring.  Using the experimental data available, the computational time was 
significantly reduced employing these constraints.  After the structures were constrained, a 
conformation search was conducted using Schrödinger MacroModel.  Using an 80% or higher 
Boltzmann distribution cutoff, the conformers were submitted to the supercomputer for 
optimization 09 and then again for coupling constant analysis using Gaussian.  The tabulated 
data are listed in figure 22.  The total absolute deviation (TAD) compared the absolute value of 
the difference between the calculated and the experimental values.  The chemical shifts for this 
KmTx fragment were also analyzed using both traditional mean absolute error calculations and 
DP4 probability statistics30 and yielded more evidence to support the published structural 
assignment.2  As figure 22 illustrates, the computation work supports the published relative 
configuration of C28-C29 of 1 in the anti conformation. 
 Figure 22. Computational analysis of the coupling constants for C27-C30 compared with the 
experimental values.  
Dashed yellow line in the 3D representation indicate NOE correlations employed to constrain the 
pyran ring. 
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Computational Validation of the Structure of KmTx2 via Chemical Shift Analysis 
Validation of Am3 revision for KmTx2 
A recent revision for the relative configuration of C50-C51 bond in Am310a prompted the 
need to undertake the verification of the assignment for the corresponding bond on 1 (C48-C49).  
First, the revision of Am3 at C51 was confirmed using the GIAO NMR shift calculation upon a 
conformational search using the standard procedures described in the experimental section. This 
served both as validation for the method on a molecule of this size as well as further 
confirmation of the Am3 revision.  The data are shown in figure 23a and clearly support the 
structural revision of Am3.  Upon further analysis of the JBCA for C50-51 bond in Am3, the 
2J(C51, H50) value of -2.5 Hz is considered an “intermediate” value thus resulting in the 
missassignment of C51.  The original range for this system is -4 to -6 Hz for large values and 2 
to 0 Hz for small values.31 
 Figure 23. Confirmation of amphidinol structural revision using DP4 calculations. 
A) Two diastereomers for the relative configuration revision at C51 showing DP4 probability 
supporting the structural revsions made by Ebine et al.10a 
B) Original JBCA for amphidinol 3.  2J(C51, H50) value of -2.5 Hz is considered an “intermediate” 
value resulting in the missassignment of C51.  The “large” value for 3J(C44, H43) leads to an 
unambiguous assignment of configuration. 
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Based on the validation of this method to confirm the revision in Am3, the same method 
was explored to identify if a similar revision was necessary for 1.  In addition, the calculations 
were extended to include C41 as well as C49 to verify that the DP4 calculation would agree with 
the JBCA assignment when a “large” value was observed.  The large values (7-10 Hz for this 
diol system) for 3JH, H are indicative of a structure with no significant conformational changes 
occurring, thus giving a reliable JBCA.31  Four possible diastereomers of C40-C51 were 
designed. The bonds between C42-C43, C47-C48 and the pyran ring were constrained based on 
NOE interactions and JBCA as previously described. Even though 2J(C47, H48) fell in the 
“intermediate” range,2 the C47-C48 bond was also constrained given the large observed 3J(H47, 
H48) value2 indicating no major conformational conversion occurred in this bond.31 The DP4 
probability analysis was conducted with experimental and predicted CS of the four diastereomers 
and the results indicated that diastereomer 1 was the most relevant diastereomer with a 
probability of 86.5% among the four candidates in terms of the shielding constants. Figure 24 
illustrates the four diastereomers and their probabilities. This result implies that the original 
relative assignment of C48-C49 based on JBCA is incorrect and the revision for Am3 holds true 
for 1 as well.  Like in Am3, the 2J(C51, H50) value of 3.5 Hz in 1 is considered an “intermediate” 
value resulting in the missassignment of C51.  Moreover, these calculation attempts suggest that 
JBCA assignments should be employed with care especially when dealing with “intermediate: 
and “small” values and when appropriate confirmed using the CS method unless a vicinal 
coupling constant of two protons in an associated bond is “large”.31  
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 Figure 24. Confirmation of karlotoxin structural revision using DP4 calculations. 
A) Four diastereomers investigating the relative configuration revision at C49 and C41 based on 
the amphidinol 3 revision.   
B) Original JBCA for karlotoxin 2.  3J(C50, H48) value of 3.5 Hz is considered an “intermediate” 
value resulting in the missassignment of C49.  The “large” value for 3J(H42, H41) leads to an 
unambiguous assignment of configuration.   
 
Validation of KmTx2 Using CS Calculations 
Given that the GIAO NMR shift calculations have been validated to correctly assign the 
relative configuration of certain stereogenic centers in 1, the extension of this methodology was 
to expand this technique in order to verify ambiguities of the JBCA in the original assignment of 
1 caused by the highly flexible carbon skeleton.  Therefore, the two intermediate values of 
vicinal homo-coupling constants found the in structural assignment were explored.  C36-C37 
based on the “medium” value of 3J(H36, H37) implied that noticeable conformational changes occur 
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in solution and C28-C29 which was discussed previously.  Four possible diastereomers shown in 
figure 25 were created to address these concerns.  It is important to note here that earlier attempts 
at analyzing these data using only fragments of the structure provided unreliable results 
depending on the length of the fragment being analyzed.  It soon became apparent that the 3D 
structure played an important role in the analysis of the highly flexible structures under analysis.  
For the early trials that only employed relatively rigid pyran ring systems, this problem was not 
seen.  Therefore when analyzing the larger, flexible fragments, the entire structure of KmTx2 
was taken into account and analyzed using the DP4 applet.30a  The results for this phase of the 
project showed that the relative configuration of the published structure of 1 for C36-C37 and 
C28-C29 were correct based on this computational method.   
 
Figure 25. Four possible diastereomers for GIAO NMR shift analysis 
1) 1 published structure with C49 modification.   
2) 1 inversion of stereochemistry at C29-C49.  
3) 1 inversion of stereochemistry C37-C49.   
4) 1 inversion of stereochemistry C29-C36. 
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Validation of KmTx2 polyol chain relative configuration 
The GIAO NMR shift calculation method has shown to be an effective tool for verifying 
the relative configuration of 1.  Given the limited sample amounts available from other 
environmentally isolated karlotoxins, this technique was employed to aid in the confirmation of 
the relative configuration of new stereogenic centers found in the polyol section of the new 
congeners.  It is undesirable to do the small-scale chemistry necessary on all of these samples to 
determine the absolute configurations of each new polyol variation when that material could be 
better spent on biological testing.  Therefore, validation was once again undertaken using DP4 
calculations on this series of molecules. 
The first calculation performed was a validation of the technique on the previously 
established relative configuration of the polyol of 1.  For this validation, four different 
diastereomers were employed to give varying configurations at C7 and C10 (figure 26).  The 
GIAO NMR shift analysis was undertaken using the complete structure for each of these 
diastereomers and all CS data was entered into the DP4 applet.  The results showed that using the 
entire molecule, DP4 could accurately predict the correct relative configuration of KmTx2 that 
was established experimentally by extensive Mosher’s ester analysis.  Diastereomer 1 showed a 
100% probability of being the correct stereochemical assignment and also showed the lowest 
TAD value of the four. 
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Figure 26. Validation of KmTx2 polyol relative configuration. 
 
Based on the validation of this computational method to verify the configuration of the 
polyol chain for 1, computational attempts were made to determine the relative configuration of 
the polyol chain of 3, 4, 5, 8, and 10.  Figure 27 shows where the relative configurations were 
altered to make the appropriate diastereomers.  Again, the entire structure was used to calculate 
the chemical shift values and conduct the DP4 analysis. In the polyol section calculations, every 
carbon that did not have a direct overlap with the HSQC of 1 was analyzed. This not only allowed 
us to determine the relative configuration of each polyol chain, but relate it back to the absolute 
configuration painstakingly determined for 1 at C21.  This method gave a conclusive answer for 5 
(figure 28), but could not arrive at an answer for all stereocenters in 3/4 (figure 29) and 8/10 (figure 
30).  For these congeners, there was a consensus for all but one of the stereocenters in each case.  
The proton TAD and DP4 calculations supported one conformation and the carbon TAD and DP4 
supported another conformer with only one stereocenter being opposite.  For this reason, that one 
ambiguous stereocenter in each of the polyol chains was left unassigned.  Interestingly, when both 
carbon and proton data were taken into account for the DP4 analysis a different conformer with no 
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discernible pattern was supported.  Upon further examination of the TAD data, it is clear that this 
occurs because that conformer strikes a balance between the lowest TAD for proton and carbon.  
Statistically this is not unexpected; however, taking the carbon and proton data independently 
appears to give a clearer answer.  The end result is that C10 for congeners 3/4 and C8 for congeners 
8/10 will remain unassigned.   
 
 
Figure 27. Polyol fragments analyzed by DP4 to assign relative configuration. 
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Figure 28. Assignment of relative configuration of the polyol for 5. 
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Figure 29. Assignment of relative configuration of the polyol for 4. 
Conformer 3 (2S, 6R, 10R, 14S) shows the lowest TAD and highest DP4 percentage for proton 
and conformer 8 (2S, 6R, 10S, 14S) shows the lowest TAD and highest DP4 for carbon.  Based 
on this data the relative configuration for C2, C6, and C14 can be established, but C10 remains 
ambiguous. 
46 
 
 
Figure 30. Assignment of relative configuration of the polyol for 8. 
Conformer 1 (4S, 8R, 12R) shows the lowest TAD and highest DP4 percentage for proton and 
conformer 8 (4S, 8S, 12R) shows the lowest TAD and highest DP4 for carbon.  Based on this 
data the relative configuration for C4 and C12 can be established, but C8 remains ambiguous. 
 
 
CONCLUSION 
While nearly a 1,000 fold difference in cellular toxicity has been observed between 
karlotoxin congeners, the cholesterol binding properties of the KmTx’s does not vary to this 
extent.  Based on the current SAR and NMR studies, the sterol recognition elements are found in 
the pyran ring portion of the molecule while triglyceride, sphingolipid and various other lipid 
interactions could be dictated by the polyene moiety accounting for the cytotoxic activity. We 
hypothesize that the polyol section interacts with proteins and carbohydrates in the membrane 
thus ensuring a full contact membrane binding mechanism. This would be similar to these 
interactions seen for AmB and other sterol binding agents.23 This suite of molecules exhibits an 
interesting cytotoxic MOA through cholesterol binding coupled with an intriguing possibility to 
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develop angiogenesis inhibitors.  The 60 cell panel cancer screen shows selectivity of 8 for NSC 
lung cancer and leukemia with much reduced CNS toxicity.  Relative to the standard controls, 
this is particularly unique among anti-cancer agents. Added to that the ability of these molecules 
to serve as angiogenesis inhibitors through a separate, yet unknown mechanism at this time, 
makes them a potential candidate for development as cancer leads.  After analysis of the 
computational data, there are minor revisions to 1 at C49.  This revision was made based on 
computational data and structural revisions made to Am3.10a  Using computational methods for 
both JBCA and CS analysis, it is suggested that the absolute configuration of 1 at C28 and C37 
is indeed assigned correctly.  
Over the past 30 years, HAB’s such as K. veneficum are becoming more frequent and 
problematic with global climate warming and other environmental changes, increasing in 
frequency, intensity and geographical distibution.32 According to the National Oceanic and 
Atmospheric Administration (NOAA), the economic impact (massive fish, sea bird, large 
mammal kills, and human health costs) of HAB’s on the United States is $82 million per year.33  
This makes marine biotoxins a major financial, ecological and human health problem worldwide. 
The structural elucidation methodologies used here have been applied successfully with other 
marine molecules such as corozalic acid (an okadaic acid biosynthetic precursor) and 
halichondrin derivatives for efficient structural assignments.34 This paper is the first to apply 
these methodologies as a systematic approach for structure elucidation of the complex polyketide 
system from Karlodinium. The assembled data set and the methodologies that generated it have 
the potential to be a powerful, time-saving tool for the rapid elucidation of large closely related 
polyketide structures. The resulting NMR and MS data could be utilized to screen for the 
presence of congeners from HAB’s relatively quickly. 
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HAB’s are devastating to not only the environment, but also the economy.  Gaining an 
understanding of why the organisms produce such devastating molecules and how these 
molecules function in the environment gives us a better understanding of how to mitigate these 
devastating events. Karlodinium is an intriguing example of why such toxic molecules are 
produced and their ultimate utility to the producing organism.  Being able to capitalize on this 
interaction to improve human health is an unexpected benefit.  Through mining the biological 
activity of KmTx for anticancer potential and making progress towards understanding its MOA 
through NMR studies, we are one step closer to understanding the role of these HAB toxins and 
turning them into something that benefits society. 
 
EXPERIMENTAL SECTION 
General Experiments 
The 1H, 13C, DEPT, COSY, HSQC, HMBC, TOCSY NOESY, and ROESY spectra of all 
congeners were measured on a Bruker Avance or a Varian INOVA 600 MHz NMR equipped 
with a 3 mm probe.  The UV spectrum was obtained using a Hewlett Packard 8452A diode array 
spectrometer.  ESIMS and HRESIMS were obtained on a Bruker MicroTof mass spectrometer. 
Optical Rotation was determined using an Autopol V polarimeter (Rudolph, Flanders, NJ, USA) 
with a sample tube 0.5 mL of path length 25 mm.  All organic solvents and water used were of 
HPLC grade or better. Syringe filters PFTE (13 mm diameter, 0.2 µm pore size) and GF/F (13 
mm diameter, 1 µm pore size) filters were obtained from Whatman. Final purification was 
accomplished using C18 and NH2 bonded stationary phases.  
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Culturing 
K. veneficum strain CCMP 2064 that produces the standard 1 for the overlay experiments 
was acquired from the Center for the Culture of Marine Phytoplankton (CCMP). The strain was 
isolated in November 1998 from a fish-kill on the Wilmington River, Georgia and deposited on 
May 3, 2003.  The strain is unialgal but not axenic and was cultured phototrophically in 15 psu 
filtered (0.22 μm) natural seawater combined with f/2 nutrients and vitamins without Si-1 at 100 
Einstein m-2s-1 and 20°C ambient temperature.35 Cell densities were measured using a Coulter 
Multisizer II (Beckman-Coulter) counter and cells mL-1 determined using Accucomp (Version 
2.01) software.  Compound 2 was also isolated from this strain of algae. 6 and its derivative 9 
were isolated from CCMP 1974 collected in May 1995 in Chesapeake Bay, VA (37.85 N, 76.1 
W).  Compound 7 was isolated from CCMP 1975 collected in July 1996 from Hyrock Farms, 
MD (38.733 N 76.9 W).  Compound 10 was isolated from a Karlodinium conicum species 
(KDCSO15) collected from the Southern Ocean (44.683 S, 147.117 E).  Compound 8 was 
isolated from an Australian isolate of K. veneficum from the Swan River Estuary upstream of 
Perth, Australia (31.59 S, 115.52 E).  Compounds 3 and 4 and 5 were isolated from the type 
species (PLY#103) for K. veneficum originally isolated in 1950 from Plymouth Sound, UK 
(50.364 N, 04.182 W) and PLY #706 from Carbis Bay, Cornwall UK, respectively.     
Metabolite Isolation 
The KmTx2 standard was isolated by the following procedure.  To obtain adequate 
quantities of metabolite for structural characterization, 5.8 x109 cells (40 L of culture) were 
grown with NaH13CO3 (50 mg/L) for 28 days, filtered onto 125 mm GF/F filters (Whatman), and 
the metabolite (>95% of recovered material) from the filtrate was concentrated on three 55 g C18 
columns (AnaLogix, Sorbtech Technologies) in parallel.  Extraction of the cells with MeOH only 
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provided 5% of the recovered metabolite.  The columns had been activated by passing 200 mL 
methanol followed by 200 mL HPLC-grade water through each column. Metabolite was eluted 
using 200 mL methanol:water starting at 100% water and continuing in 20% increments to 100% 
methanol.   The 60% and 80% methanol fractions were collected, pooled and dried under 
vacuum at 40°C. The concentrated metabolite from the pooled 60-80% C18 eluent was then 
purified using reverse phase chromatography on a semi-preparative scale C18 column 
(Phenomenex Hyperprep HS C18-80S, 250 X 10 mm, 5 µ), at a flow rate of 4 mL min-1. 
Fractions corresponding to KmTx 2 were collected using a fraction collector (61364A, AFC, 
Agilent) based on known retention times. Fractions with the same elution times were pooled and 
dried under vacuum and re-suspended in methanol:H2O (80:20). From the total 40 L, 2.5 mg of 
enriched material was obtained.  Known aliquots of the purified metabolites were placed onto a 
tared aluminum weigh boat in triplicate, dried at 60°C overnight and weighed the following day 
on a Mettler UMT2 microgram balance.  The A235 was 3.554 X 105. All other cultured 
metabolites samples were grown and isolated in the same manner as above with the exception of 
the 13C labeling. 
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 Figure 31.  Generic isolation scheme for congener purification with specific strain, location, 
congener yields. 
 
Hemolytic Assays  
The techniques and procedures used to generate the hemolytic data are described in depth 
in previous literature and were performed at the Institute of Marine and Environmental 
Technology, University of Maryland Center for Environmental Sciences under the direction of 
Dr. Allen Place.3a, 36  Erythrocyte suspensions were prepared according to the method used by 
Edvardsen et al.37  Blood was obtained from the caudal vein of rainbow trout (Oncorhynchus 
mykis) obtained from the Center for Environmental Sciences Aquaculture Research Center.  
Heparin treated needles and 10 units mL-1 of additional heparin (Sigma Chemical Co.) were 
added to prevent clotting.  Erythrocyte suspensions were washed 3 times (2500 x g for 5 min) 
with ice cold buffer (150 mM NaCl, 3.2 mM KCl, 1.25 mM MgSO4, 12.2 mM Tris base, pH 
adjusted to 7.4 and sterile filtered) and stored at 4oC for no longer than 10 days in Tris buffer 
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with 3.75 mM CaCl2 at 50% original concentration.  Hemolytic assay was performed in a 96-
well, V-bottom, non-treated, polystyrene plate (Corning Inc.).  KmTx samples were diluted with 
Tris Buffer + CaCl2 (100 µL total) and added to a 5% erythrocyte suspension (100 µL).  The 
plates were then sealed with Falcon 3073 pressure sensitive film (Becton Dickinson Labware), 
incubated on an orbital shaker (80-100 rpm) at 20oC for 1 h, centrifuged (2500 X g for 5 min), 
100 µL supernatant transferred to another 96-well plate, absorbance of released hemoglobin read 
at 540 nm.  The positive control was saponin (10 µg) (Sigma Chemical Co.) and all tests were 
performed in quadruplicate.3a  
Angiogenesis Assays 
The angiogenesis assays were conducted by Eli Lilly Open Innovation Drug Discovery 
Program (OIDD).  The techniques and procedures are outlined in Lee et al.38  Human clonal 
endothelial colony forming cells (ECFC, Engenator) were cultured in Endothelia growth 
medium-microvascular 2 (EGM-2MV, Lonza) containing 10% fetal bovine serum (FBS) (EGM-
2MV+FBS), expanded to passage 7 and rapidly frozen and stored over liquid N2.  Human 
adipose derived stem cells (ADSC, Zen Bio) were pooled from donor samples, cultured in EGM-
2MV+FBS, expanded to passage 5 and rapidly frozen and stored over liquid N2.  The two cell 
lines were then co-cultured.  ECFCs were thawed, diluted and incubated for 24 h, washed with 
PBS, suspended with trypsin and grown in EGM-2MV+FBS for an additional 48 h.  ADSCs 
were thawed, diluted, centrifuged and suspended in Optimized Media (TCS Cellworks), 
transferred at 5,000 cells/ well to a 384-well Cell Bind plate (Corning), incubated at room 
temperature for 5 min. and finally placed in a CO2 incubator overnight.  ECFCs after the 48 h 
incubation were washed with PBS, suspended with trypsin, diluted in EGM-2MV+FBS, 
centrifuged, suspended in Optimized Media and passed through a sterile 23 gauge needle.  They 
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were then overlaid onto the ADSC cells in the 384-well plate at 500 cell/well and incubated in 
the CO2 incubator for 2 h.  The wells were then treated with rhVEGF (10 ng/mL, R&D systems) 
plus sutent (500 nM) as a positive control, DMSO (0.5% (v/v)) as a negative control or 
compounds of interest in DMSO (0.5% (v/v)) at indicated concentrations for 96 hours.  Cells 
were then fixed (3.7% formaldehyde-PBS buffer for 20 min, 0.1% TX-100-PBS for 20 min, 
washed 2 times with PBS),  incubated with mouse Anti-Human CD31 antibody (63 ng/mL in 
PBS containing 1% BSA at 4oC overnight, BD Pharmigen, 550389), washed with PBS, 
incubated with Alexa 488 goat secondary antibody (3 µg/mL in PBS for 1 h) to visualize 
endothelial tube area, washed twice more with PBS and finally stained with Hoechst (2 µg/mL) 
to visualize the cell nuclei.  The fixed and stained cell co-culture was analyzed with an Array 
Scan VTI (Thermo Scientific) using 5X objective and collecting 4, non-adjacent frames per well.  
Nuclei and CD31 were visualized using the XF93-Hoechst and XF93-Alexa-488 mirror emission 
filter pairs.  Endothelial tube features were determined with Cellomics Tube Formation V3 
applications utilizing the CD31 channel and loss of valid nuclear objects with the Hoechst 
staining was determined by the Target Activation V3 application. 
National Cancer Institute (NCI)-60 Developmental Therapeutics Program (DTP) Human 
Tumor Cell Line Screen 
Testing of 8 in the NCI-60 cell panel was performed by the NIH NCI DTP.  The specific 
techniques and procedures used are published in a series of papers.39 Compounds are first tested 
at a single dose of 10 µM in the NCI-60 cell panel and then move on to a 5 dose testing range to 
determine the IC50 value for each cell line.  Cell lines are grown in RPMI 1640 medium with 5% 
fetal bovine serum and 2 mM L-glutamine.  Cells are inoculated at 5,000 to 40,000 cells/well, 
depending on doubling time of cell line, into 96 well microtiter plates in 100 µL.  Plates are 
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incubated at 37oC, 5% CO2, 95% air, 100% relative humidity for 24 h.  A measurement of cell 
population is taken before addition of compound by fixing in situ with TCA (Tz).  Compounds 
are dissolved in DMSO at 400-fold the maximum test concentration for stock storage solution.  
Compounds are diluted to two times the final maximum concentration with complete medium 
containing 50 µg/mL gentamicin.  Four additional 10-fold serial dilutions are prepared.  100 µL 
of each dilution are added to the growing cells in the microtiter plates.  Plates are then incubated 
for an additional 48 h under the same conditions as before.  Assays are terminated and cells are 
fixed in situ with either an addition of 50 µL of cold 50% (w/v) TCA and incubated for 60 min at 
4oC for adherent cells or by adding 50 µL of 80% TCA for suspension cells.  Supernatant is 
discarded and plates are washed 5 times with water and air dried.  Next, 100 µL of 
sulforhodamine B (SRB) solution 0.4% (w/v) in 1% acetic acid is added to each well and plates 
are incubated at room temperature for 10 min.  Plates are then washed five times with 1% acetic 
acid and air dried to remove unbound dye.  The bound dye is solubilized with 10 mM trizma 
base, and the absorbance reading at 515 nm is recorded.  Growth inhibition percentages are 
calculated as follows:  
[(Ti-Tz)/(C-Tz)] X 100 for concentrations for which Ti ≥ Tz 
[(Ti-Tz)/Tz] X 100 for concentrations for which Ti < Tz 
Where Tz = time zero, C = control growth, and Ti = test growth in the presence of drug at 
the different concentration levels 
In addition, growth inhibition of 50% (drug concentration resulting in 50% reduction of 
the net protein increase as measured by SRB staining, GI50), total growth inhibition (drug 
concentration resulting in total growth inhibition, TGI) and LC50 (drug concentration resulting in 
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50% reduction in the measured protein at the end of the drug treatment as compared to the 
beginning) are also calculated from the growth inhibition percentage equations.39a  
GI50 from [(Ti-Tz)/(C-Tz)] X 100 = 50 
TGI from Ti = Tz 
and LC50 from [(Ti-Tz)/Tz] X 100 = -50 
Ovarian Cancer Cell Concentration Response Curve 
Testing for 8 in OVCAR5 cells was conducted by plating 7,500 cell per well (total 
volume 100 µL) into 2-96 well plates which were incubated for 24 hrs at 37oC, 5% CO2, 95% air 
and 100% humidity.  One plate was then fixed with 20% TCA (time zero).  Varying 
concentrations of congener (30, 10, 3, 1, 0.3, 0.1, 0.03 µM in DMSO and DMSO vehicle blank) 
were added to the second 96-well plate and incubated for 48 hrs, the treatment media was 
aspirated off the cells were fixed with 100 µL of cold 20% TCA with incubation at 4oC for 12 
hrs.  Both plates were then washed 5 times with tap water, dried at room temperature, 100 µL of 
0.04% (w/v) SRB was added to the plates, incubated 30 min at room temperature, washed 4 
times with 1% (v/v) acetic acid, dried at room temperature, and 200 µL 10 mM Tris base (pH 
10.3) was added to the plates which were then incubated with shaking at 37oC for 20 min and 
read using ELISA at 505 nm.  
NMR Processing Procedures 
Comprehensive NMR data sets were collected for every KmTx sample available.  
Individual experiments were then compared to the known KmTx2 standard data set. Utilizing the 
NMR processing software MestReNova v.7.1.0-9185, both the 1D and the 2D data sets were 
overlaid.  The 2D HSQC experiments were the most useful in identifying the major differences 
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in the structure.  Once a region of the molecule was identified that differed from the standard, 
additional NMR experiments were used to assign and confirm the new KmTx structures. 
HSQC Sterol Binding Experiments 
Standards were prepared by adding 2.0 mg (7.08 mM) 8 in 200µL MeOD with 10µL 
CDCl2 to a 3 mm NMR tube.  Helium was used to remove dissolved O2 and achieve cleaner 
NMR signals.  HSQC and ROESY experiments were completed using a Varian 600 MHz NMR 
at 25oC.  In a separate NMR tube, 2.0 mg (7.08 mM) 8 in 200µL MeOD and 0.2 mg (2.46 mM) 
cholesterol in 10µL CDCl2 were combined and data acquired identically to the standard.  The 
two data sets were then overlaid utilizing MestReNova 7.0.3-8830.  This process was repeated 
using 0.3 mg cholesterol dissolved in CDCl2.   
Computational Calculations 
The calculation procedures were referenced with previous studies.30a, 40 All 
conformational searches were conducted employing Macromodel (Version 9.9, Schrodinger 
LLC.) program with “Mixed torsional/Low Mode sampling” in MMFF force field. The searches 
were performed in the gas phase with a 50 kJ/mol energy window limit and 10,000 maximum 
number of steps to fully explore all low-energy conformers. All minimization processes were 
carried out utilizing Polak-Ribiere Conjugate Gradient (PRCG) method, 10,000 maximum 
iterations and a 0.001 convergence threshold. For the conformational search, NMR experimental 
data was incorporated for the generation of constraints as followed. 1) The bonds of each 
diastereomer were constrained with a 1,000 force constant unless observed homo- and hetero-
coupling constants associated with the bonds exhibited  the “medium” ranges.9 2) The pyran 
rings were constrained to reflect their actual conformation that matched with the observed NMR 
data based on a distance deduced from the NOE spectrum. The GIAO shielding constants of all 
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conformers within 10 kJ/mol of the global minimum were calculated utilizing Gaussian 09 
package (Gaussian Inc.) at the B3LYP/6-31G(d,p) level in the gas phase. The CS values were 
calculated according to the equations described in previous studies.30a, 40 The calculation of DP4 
probability was facilitated using an applet available at “http://www-
jmg.ch.cam.ac.uk/tools/nmr/DP4/”. The predicted CS values of diastereotopic protons were 
compared with the closet experimental values of those protons unless sufficient NMR 
information was available for the assignment of each proton. 
Congener Data  
Karlotoxin 2 (1): Colorless oil; 1H and 13C NMR Table 2; UV (MeOH) λmax 237 nm; [α]22D +18 
(c 0.001, MeOH); C67H121O24Cl HRESIMS Obsd. [M+Na]+ m/z 1367.7844 (Calcd. [M+Na]+ m/z 
1367.7834; error = -0.8 ppm). 
2: Colorless oil. 1H and 13C NMR Table 2; UV (MeOH) λmax 237 nm; [α]22D +16 (c 0.001, 
MeOH); C67H121O25Cl HRESIMS Obsd. [M-H]- m/z 1359.7795 (Calcd for [M-H]- m/z 
1359.7807; error = 0.5 ppm). 
3: Colorless oil. 1H and 13C NMR Table 2; UV (MeOH) λmax 237 nm; C62H112O22Cl based on 
HRESIMS Obsd. [M+Na]+ m/z 1265.7252 (Calcd for [M+Na]+  m/z 1265.7153; error = -8.2 
ppm. 
4: Colorless oil. 1H and 13C NMR Table 2; UV (MeOH) λmax 228 nm; C62H112O22 based on 
HRESIMS Obsd. [M+Na]+ m/z 1231.7631 (Calcd. for [M+Na]+  1231.7543; error = -7.6 ppm). 
5: Colorless oil. 1H and 13C NMR Table 2; UV (MeOH) λmax 237 nm; C65H119O23Cl based on 
HRESIMS [M+Na]+ m/z 1325.7728 (Calcd for [M+Na]+  1325.7728; error = 1.2 ppm). 
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6: Colorless oil. 1H and 13C NMR Table 2; UV (MeOH) λmax 228 nm; [α]22D +9 (c 0.1, MeOH); 
C68H124O23 based on HRESIMS [M-H]- m/z 1307.8458 (Calcd. for [M-H]- 1307.8461; error = -
0.6 ppm. 
7: Colorless oil. 1H and 13C NMR Table 2; UV (MeOH) λmax 228 nm; [α]22D +8 (c 0.1, MeOH); 
C69H126O23 based on HRESIMS [M-H]- m/z 1321.8585 (Calcd. for [M-H]- 1321.8611; error = 1.6 
ppm. 
8: Colorless oil. 1H and 13C NMR Table 2; UV (MeOH) λmax 237 nm; [α]22D +18 (c 0.001, 
MeOH); C67H121O24Cl based on HRESIMS [M-H]- m/z 1343.7844 (Calcd. for [M-H]- 
1343.7858; error = 0.6 ppm). 
9: Colorless oil. 1H and 13C NMR Table 2; UV (MeOH) λmax 228 nm; [α]22D +3 (c 0.2, MeOH); 
C68H124O26S, based on HRESIMS [M-H]-  m/z 1387.7999 (Calcd for [M-H]- 1387.8023; error = 
1.4 ppm). 
10: Colorless oil. 1H and 13C NMR Table 2; UV (MeOH) λmax 237 nm; [α]22D +15 (c 0.001, 
MeOH); C65H117ClO24, based on HRESIMS [M-H]- m/z 1315.7567 (Calcd. for 1315.7551; error 
= -2.1 ppm.) 
For the 2D HSQC overlay experiments detailed in figures 32-92, KmTx 2 is always depicted 
in blue.  The compound that is being overlaid with KmTx 2 is always in red.  Signals that are the 
same for both structures are circled in black.  When a compound is being compared to something 
other than KmTx 2 the colors are defined in the first page of the compound data. 
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Table 2. 1H and 13C NMR Data for Compounds 1-10. 
 
 
 
Carbon 
δ (ppm)
Mult.
Proton 
δ (ppm)
Mult.
J  value 
(Hz)
Carbon 
δ (ppm)
Mult.
Proton 
δ (ppm)
Mult.
J  value 
(Hz)
Carbon 
δ (ppm)
Mult.
Proton 
δ (ppm)
Mult.
J  value 
(Hz)
Carbon 
δ (ppm)
Mult.
Proton 
δ (ppm)
Mult.
J  value 
(Hz)
Carbon 
δ (ppm)
Mult.
Proton 
δ (ppm)
Mult.
J  value 
(Hz)
1a 3.52 dd 11.4, 4.2 3.52 dd 11.4, 4.2
1b 3.46 dd 5.6, 11.4 3.46 dd 5.6, 11.4
2a 1.7 m ---
2b 1.59 m ---
3a 2.18 dt 14.4, 6.6 2.18 dt 14.4, 6.6 1.58 m ---
3b 2.29 dt 14.4, 6.6 2.29 dt 14.4, 6.6 1.44 m ---
4 128.49 CH 5.69 dt 15.0, 7.2 128.49 CH 5.69 dt 15.0, 7.2 128.93 CH 5.65 dt 7.8, 6.7 128.93 CH 5.65 dt 7.8, 6.7 72.85 CH 3.59 dd 2.4, 8.6
5a 1.62 m ---
5b 1.4 m ---
6a 1.43 m ---
6b 1.5 m ---
7a 1.54 m --- 1.54 m --- 1.62 m ---
7b 1.4 m --- 1.4 m --- 1.4 m ---
8a 1.55 m --- 1.55 m --- 1.63 m --- 1.63 m ---
8b 1.38 m --- 1.38 m --- 1.4 m --- 1.4 m ---
9a 1.50 m --- 1.50 m --- 1.51 m --- 1.51 m --- 1.50 m ---
9b 1.46 m --- 1.46 m --- 1.41 m --- 1.41 m --- 1.42 m ---
10a
10b
11a 1.50 m --- 1.50 m --- 1.51 m --- 1.51 m --- 1.41 m ---
11b 1.42 m --- 1.42 m --- 1.41 m --- 1.41 m --- 1.48 m ---
12a 1.62 m --- 1.62 m --- 1.63 m --- 1.63 m ---
12b 1.41 m --- 1.41 m --- 1.4 m --- 1.4 m ---
13a 1.55 m --- 1.55 m --- 1.67 m ---
13b 1.38 m --- 1.38 m --- 1.27 m ---
14a
14b
15a 1.67 m --- 1.67 m --- 1.6 m --- 1.6 m ---
15b 1.27 m --- 1.27 m --- 1.54 m --- 1.54 m ---
16a 1.54 m --- 1.54 m ---
16b 1.32 m --- 1.32 m ---
17a 1.63 m ---
17b 1.55 m ---
18a 1.61 m ---
18b 1.37 m ---
19a 1.63 m --- 1.63 m ---
19b 1.55 m --- 1.55 m ---
20a 1.61 m --- 1.61 m ---
20b 1.37 m --- 1.37 m ---
21a 1.69 m --- 1.69 m ---
21b 1.52 m --- 1.52 m ---
22a 1.54 m --- 1.54 m ---
22b 1.46 m --- 1.46 m ---
23a 1.70 m --- 1.70 m --- 1.69 m ---
23b 1.28 m --- 1.28 m --- 1.52 m ---CH2--- 33.02 CH2 33.02 CH2 35.2573.92 CH 3.33 m --- 73.92 CH 3.33 m
CH2 71.53 CH 3.87 m ---3.69 dd 9.0, 1.8 24.37 CH2 24.3773.65 CH 3.69 dd 9.0, 1.8 73.65 CH
m ---CH2 35.25 CH2 73.92 CH 3.3334.93 CH 1.90 m --- 35.2534.93 CH 1.90 m ---
9.0, 1.8m --- 73.65 CH 3.69 dd3.87 m --- 71.53 CH 3.8731.45 CH2 31.45 CH2 71.53 CH
--- 34.93 CH 1.90 m ---m --- 73.92 CH 3.33 m32.53 CH2 32.53 CH2 73.92 CH 3.33
31.45 CH29.3 74.29 CH 3.65 brd 9.3m --- 74.29 CH 3.65 brd72.98 CH 3.62 m --- 72.98 CH 3.62
CH235.21 CH 1.88 m ‐‐‐ 32.536.0, 4.2 35.21 CH 1.88 m ‐‐‐79.90 CH 3.14 dd 6.0, 4.2 79.90 CH 3.14 dd
CH2 72.98 CH 3.62 m ---1.98 m --- 31.71 CH2 31.7133.23 CH 1.98 m --- 33.23 CH
79.90 CH 3.14 dd 6.0, 4.240.86 CH2 40.86 CH2 36.46 CH2 36.46 CH2
---m --- 33.23 CH 1.98 m3.6 m --- 73.47 CH 3.6CH 3.65 m --- 73.47 CH70.35 CH 3.65 m --- 70.35
40.86 CH239.73 CH2 1.48 m --- 34.7939.73 CH2 1.48 m ---
---23.21 CH2 70.35 CH 3.65 m23.13 CH2 23.13 CH2 23.21 CH2
CH2 34.79 CH2
39.73 CH238.41 CH2 38.41 CH2 38.74 CH2 38.74 CH2
23.13 CH2 1.62 m ------ 72.56 CH 3.56 m ---m --- 72.56 CH 3.56 m72.30 CH 3.55 m --- 72.30 CH 3.55
38.69 CH2 38.41 CH238.29 CH2 38.29 CH2 38.69 CH2
dd 3.9, 8.7CH2 23.21 CH2 72.52 CH 3.5722.81 CH2 22.81 CH2 23.21
38.19 CH2 38.29 CH2CH2 1.53 m --- 38.19 CH238.33 CH2 1.53 m --- 38.33
--- 23.30 CH2m --- 74.25 CH 4.01 m4.02 m --- 74.25 CH 4.0173.65 CH 4.02 m --- 73.65 CH
38.33 CH27.1, 14.5 136.95 CH 5.49 dt 7.1, 14.5dd 15.0, 7.2 136.95 CH 5.49 dt136.93 CH 5.54 dd 15.0, 7.2 136.93 CH 5.54
m --- 34.98 CH22.21 m --- 41.75 CH2 2.2137.58 CH2 37.58 CH2 41.75 CH2
3.61 brd 9.5 30.13 CH2CH 3.61 brd 9.5 72.53 CH73.08 CH 3.65 m --- 72.5373.08 CH 3.65 m ---
6.0dd
Position
KmTx 2 (1) 2 3 4 5
dd 4.5, 11.8 67.6 CH2 3.4766.75 CH2 66.75 CH2 67.6 CH2 4.5, 11.8 63.33 CH2 3.58 t3.47
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Carbon 
δ (ppm)
Mult.
Proton 
δ (ppm)
Mult.
J  value 
(Hz)
Carbon 
δ (ppm)
Mult.
Proton 
δ (ppm)
Mult.
J  value 
(Hz)
Carbon 
δ (ppm)
Mult.
Proton 
δ (ppm)
Mult.
J  value 
(Hz)
Carbon 
δ (ppm)
Mult.
Proton 
δ (ppm)
Mult.
J  value 
(Hz)
Carbon 
δ (ppm)
Mult.
Proton 
δ (ppm)
Mult.
J  value 
(Hz)
24a 1.54 m ---
24b 1.46 m ---
25a 1.69 m --- 1.69 m --- 1.70 m ---
25b 1.52 m --- 1.52 m --- 1.28 m ---
26a 1.54 m --- 1.54 m ---
26b 1.46 m --- 1.46 m ---
27a 1.70 m --- 1.70 m --- 1.84 brt 12.0 1.84 brt 12.0
27b 1.28 m --- 1.28 m --- 1.70 m --- 1.70 m ---
28 36.37 CH 1.76 m --- 36.37 CH 1.76 m --- 74.57 CH 4.12 dt 10.8, 2.0 74.57 CH 4.12 dt 10.8, 2.0 68.42 CH 3.91 dt 10.2, 1.7
29a 1.84 brt 12.0
29b 1.70 m ---
30 68.42 CH 3.91 dt 10.2, 1.7 68.42 CH 3.91 dt 10.2, 1.7 73.02 CH 3.73 m --- 73.02 CH 3.73 m --- 74.57 CH 4.12 dt 10.8, 2.0
31a 1.84 brt 12.0 1.84 brt 12.0
31b 1.70 m --- 1.70 m ---
32 74.57 CH 4.12 dt 10.8, 2.0 74.57 CH 4.12 dt 10.8, 2.0 77.97 CH 3.40 m --- 77.97 CH 3.40 m --- 73.02 CH 3.73 m ---
33 73.02 CH 3.73 m --- 73.02 CH 3.73 m --- 72.40 CH 4.02 m --- 72.40 CH 4.02 m --- 70.89 CH 3.85 m ---
34a 2.04 m --- 2.04 m ---
34b 1.70 m --- 1.70 m ---
35a 2.45 m --- 2.45 m ---
35b 2.15 m --- 2.15 m ---
36a 2.04 m ---
36b 1.70 m ---
37a 2.45 m ---
37b 2.15 m ---
38a 2.04 m --- 2.04 m ---
38b 1.70 m --- 1.69 m ---
39a 2.45 m --- 2.46 dt 5.0, 12.6
39b 2.15 m --- 2.17 m ---
40a 2.12 m --- 2.12 m ---
40b 1.58 m --- 1.58 m ---
41 76.82 CH 4.23 d 9.0 76.80 CH 4.21 d 9.0 67.21 CH 4.07 m --- 67.21 CH 4.07 m --- 70.25 CH 4.06 m ---
42a 2.12 m ---
42b 1.58 m ---
43 70.25 CH 4.06 m --- 74.57 CH 3.76 dd 2.6, 9.0 80.55 CH 3.74 brd 10.4 80.55 CH 3.74 brd 10.4 67.21 CH 4.07 m ---
44a 2.12 m ---
44b 1.58 m ---
45 67.21 CH 4.07 m --- 73.17 CH 3.8 dd 3.2, 9.4 74.13 CH 4.39 dd 7.2, 3.0 74.13 CH 4.39 dd 7.2, 3.0 80.55 CH 3.74 brd 10.4
46 68.56 CH 4.05 m --- 68.62 CH 3.9 d 9.6 128.36 CH 5.61 dd 15.0, 7.2 128.36 CH 5.61 dd 15.0, 7.2 71.75 CH 3.99 dd 10.2, 2.4
47 80.55 CH 3.74 brd 10.4 80.15 CH 3.73 dd 3.0, 10.0 136.00 CH 5.81 dt 15.0, 7.2 136.00 CH 5.81 dt 15.0, 7.2 74.13 CH 4.39 dd 7.2, 3.0
48 71.75 CH 3.99 dd 10.2, 2.4 71.75 CH 3.99 dd 10.2, 2.4 33.68 CH2 2.11 m --- 33.68 CH2 2.11 m --- 128.36 CH 5.61 dd 15.0, 7.2
49 74.13 CH 4.39 dd 7.2, 3.0 74.13 CH 4.39 dd 7.2, 3.0 30.47 CH2 1.44 m --- 30.47 CH2 1.44 m --- 136.00 CH 5.81 dt 15.0, 7.2
50 128.36 CH 5.61 dd 15.0, 7.2 128.36 CH 5.61 dd 15.0, 7.2 30.35 CH2 1.34 m --- 30.35 CH2 1.34 m --- 33.68 CH2 2.11 m ---
51 136.00 CH 5.81 dt 15.0, 7.2 136.00 CH 5.81 dt 15.0, 7.2 30.39 CH2 1.34 m --- 30.39 CH2 1.34 m --- 30.47 CH2 1.44 m ---
52 33.68 CH2 2.11 m --- 33.68 CH2 2.11 m --- 30.57 CH2 1.34 m --- 30.57 CH2 1.34 m --- 30.35 CH2 1.34 m ---
53 30.47 CH2 1.44 m --- 30.47 CH2 1.44 m --- 30.65 CH2 1.34 m --- 30.65 CH2 1.34 m --- 30.39 CH2 1.34 m ---
31.42 CH2 70.42 CH 4.19 dd CH 4.05 m ---71.75 CH 3.99 dd 10.2, 2.4 68.561.7, 3.0 71.75 CH 3.99 dd 10.2, 2.4
68.56 CH 4.05 m3.87 m --- 68.56 CH 4.0574.89 CH 3.39 brd 8.4 71.77 CH --- 31.42 CH2m ---
CH2151.54 C --- --- --- 31.42 31.42 CH2 74.89 CH 3.39151.24 C --- --- ---
9.0m --- 76.82 CH 4.23 d4.06 m --- 70.25 CH 4.06
brd 8.4
27.41 CH2 27.67 CH2 70.25 CH
8.4 151.24 C --- --- ---brd 8.4 74.89 CH 3.39 brd31.42 CH2 31.90 CH2 74.89 CH 3.39
27.41 CH29.0 76.82 CH 4.23 d 9.0m --- 76.82 CH 4.23 d72.40 CH 4.02 m --- 72.72 CH 4.02
CH2151.24 C --- --- --- 31.426.9, 1.3 151.24 C --- --- ---77.97 CH 3.40 m --- 77.89 CH 3.38 dd
CH2 72.40 CH 4.02 m ---3.85 m --- 27.41 CH2 27.4170.89 CH 3.85 m --- 70.89 CH
m ---31.42 CH2 77.97 CH 3.4073.02 CH 3.73 m --- 31.4273.02 CH 3.73 m ---
---m --- 73.02 CH 3.73 m3.85 m --- 70.89 CH 3.8534.52 CH2 34.52 CH2 70.89 CH
CH2
3.73 m --- 34.52 CH2CH 3.73 m --- 73.02 CH80.03 CH 3.10 dd 7.2, 3.6 73.0280.03 CH 3.10 dd 7.2, 3.6
7.2, 3.634.52 CH2 80.03 CH 3.10 dd33.02 CH2 33.02 CH2 34.52 CH2
10.2, 1.7 36.37 CH 1.76 m ---dt 10.2, 1.7 68.42 CH 3.91 dt24.37 CH2 24.37 CH2 68.42 CH 3.91
3.10 dd 7.2, 3.6 33.02 CH2CH 3.10 dd 7.2, 3.6 80.03 CH35.25 CH2 35.25 CH2 80.03
m --- 24.37 CH21.76 m --- 36.37 CH 1.76CH 3.87 m --- 36.37 CH71.53 CH 3.87 m --- 71.53
Position
KmTx 2 (1) 2 3 4 5
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Carbon 
δ (ppm)
Mult.
Proton 
δ (ppm)
Mult.
J  value 
(Hz)
Carbon 
δ (ppm)
Mult.
Proton 
δ (ppm)
Mult.
J  value 
(Hz)
Carbon 
δ (ppm)
Mult.
Proton 
δ (ppm)
Mult.
J  value 
(Hz)
Carbon 
δ (ppm)
Mult.
Proton 
δ (ppm)
Mult.
J  value 
(Hz)
Carbon 
δ (ppm)
Mult.
Proton 
δ (ppm)
Mult.
J  value 
(Hz)
54 30.35 CH2 1.34 m --- 30.35 CH2 1.34 m --- 30.28 CH2 1.42 m --- 30.28 CH2 1.42 m --- 30.57 CH2 1.34 m ---
55 30.39 CH2 1.34 m --- 30.39 CH2 1.34 m --- 33.68 CH2 2.11 m --- 33.68 CH2 2.11 m --- 30.65 CH2 1.34 m ---
56 30.57 CH2 1.34 m --- 30.57 CH2 1.34 m --- 137.16 CH 5.75 dt 15.0, 7.2 136.14 CH 5.71 dt 15.0, 7.2 30.28 CH2 1.42 m ---
57 30.65 CH2 1.34 m --- 30.65 CH2 1.34 m --- 127.52 CH 6.05 dd 15.0, 10.8 132.35 CH 6.05 dd 15.5, 10.6 33.68 CH2 2.11 m ---
58a
58b
59a 5.07 d 14.6
59b 119.42 CH 6.23 d 13.1 4.93 d 10.8
60 137.16 CH 5.75 dt 15.0, 7.2 137.16 CH 5.75 dt 15.0, 7.2 13.40 CH3 0.90 d 7.1 13.40 CH3 0.90 d 7.1 135.20 CH 6.45 dd 13.2, 10.8
61 127.52 CH 6.05 dd 15.0, 10.8 127.52 CH 6.05 dd 15.0, 10.8 16.72 CH3 0.98 d 7.8 16.72 CH3 0.98 d 7.8 119.42 CH 6.23 d 13.1
62a 5.03 s --- 5.03 s ---
62b 5.08 s --- 5.08 s ---
63a
63b
64a
64b
65a 5.03 s ---
65b 5.08 s ---
66 16.72 CH3 0.98 d 7.8 16.72 CH3 0.98 d 7.8
67a 5.03 s --- 5.04 s ---
67b 5.08 s --- 5.11 s ---
68a
68b
69a
69b
113.42 CH2 113.27 CH2
CH213.24 CH3 0.93 d 7.2 113.4213.24 CH3 0.93 d 7.2
7.8d 7.2 16.72 CH3 0.98 d17.44 CH3 0.99 d 7.2 17.44 CH3 0.99
7.2d 13.1 13.24 CH3 0.93 d119.42 CH 6.23 d 13.1 119.42 CH 6.23
7.2113.42 CH2 17.44 CH3 0.99 dCH 6.45 dd 13.2, 10.8 113.42 CH2135.20 CH 6.45 dd 13.2, 10.8 135.20
6.05 dd 15.0, 10.833.68 CH2 2.11 m --- 33.68 CH2 2.11
5.75 dt6.45 dd 13.2, 10.8 138.62 CH 6.31
m --- 114.88 CH2 127.52 CH
CH2 1.42 m --- 135.20 CH30.28 CH2 1.42 m --- 30.28 15.0, 7.2dt 17.0, 10.4 137.16 CH
Position
KmTx 2 (1) 2 3 4 5
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Carbon 
δ (ppm)
Mult.
Proton 
δ (ppm)
Mult.
J  value 
(Hz)
Carbon 
δ (ppm)
Mult.
Proton 
δ (ppm)
Mult.
J  value 
(Hz)
Carbon 
δ (ppm)
Mult.
Proton 
δ (ppm)
Mult.
J  value 
(Hz)
Carbon 
δ (ppm)
Mult.
Proton 
δ (ppm)
Mult.
J  value 
(Hz)
Carbon 
δ (ppm)
Mult.
Proton 
δ (ppm)
Mult.
J  value 
(Hz)
1a 3.52 dd 11.4, 4.2 3.52 dd 11.4, 4.2 3.52 dd 11.4, 4.2
1b 3.46 dd 5.6, 11.4 3.46 dd 5.6, 11.4 3.46 dd 5.6, 11.4
2a 1.70 m --- 1.70 m ---
2b 1.60 m --- 1.60 m ---
3a 2.18 dt 14.4, 6.6 2.18 dt 14.4, 6.6 2.18 dt 14.4, 6.6 1.58 m --- 1.58 m ---
3b 2.29 dt 14.4, 6.6 2.29 dt 14.4, 6.6 2.29 dt 14.4, 6.6 1.45 m --- 1.45 m ---
4 128.49 CH 5.69 dt 15.0, 7.2 128.49 CH 5.69 dt 15.0, 7.2 128.49 CH 5.69 dt 15.0, 7.2 68.77 CH 4.08 dd 10.4, 3.0 68.77 CH 4.08 m ---
5a
5b
6a
6b
7a
7b
8a 1.55 m --- 1.55 m --- 1.55 m ---
8b 1.38 m --- 1.38 m --- 1.38 m ---
9a 1.50 m --- 1.50 m --- 1.53 m --- 1.50 m --- 1.50 m ---
9b 1.46 m --- 1.46 m --- 1.48 m --- 1.46 m --- 1.46 m ---
10a 1.50 --- 1.50 ---
10b 1.33 --- 1.33 ---
11a 1.50 m --- 1.50 m --- 1.57 m --- 1.50 m --- 1.50 m ---
11b 1.42 m --- 1.42 m --- 1.46 m --- 1.46 m --- 1.46 m ---
12a 1.62 m --- 1.62 m --- 1.62 m ---
12b 1.41 m --- 1.41 m --- 1.41 m ---
13a 1.50 m --- 1.50 m ---
13b 1.45 m --- 1.45 m ---
14a 1.62 m --- 1.62 m ---
14b 1.40 m --- 1.40 m ---
15a 1.67 m --- 1.67 m --- 1.67 m --- 1.65 m --- 1.65 m ---
15b 1.27 m --- 1.27 m --- 1.27 m --- 1.24 m --- 1.24 m ---
16a
16b
17a
17b
18a
18b
19a 1.63 m --- 1.63 m --- 1.63 m ---
19b 1.55 m --- 1.55 m --- 1.55 m ---
20a 1.61 m --- 1.61 m --- 1.61 m --- 1.61 m --- 1.61 m ---
20b 1.37 m --- 1.37 m --- 1.37 m --- 1.37 m --- 1.37 m ---
21a
21b
22a
22b
23a
23b m ---3.33 m --- 73.92 CH 3.33CH 3.33 m --- 73.92 CH73.92 CH 3.33 m --- 73.9273.92 CH 3.33 m ---
9.0, 1.8dd 9.0, 1.8 73.65 CH 3.69 dd3.69 dd 9.0, 1.8 73.65 CH 3.69CH 3.69 dd 9.0, 1.8 73.65 CH73.65 CH 3.69 dd 9.0, 1.8 73.65
1.90 m ---CH 1.90 m --- 34.93 CH34.93 CH 1.90 m --- 34.93--- 34.93 CH 1.90 m ---34.93 CH 1.90 m
CH2 31.45 CH2 31.45 CH231.45 CH2 31.45 CH2 31.45
CH2 1.60 m ---33.02 CH2 1.60 m --- 33.0232.53 CH2 32.53 CH2 32.53 CH2
3.62 m ---CH 3.62 brd 6.8 72.98 CH72.98 CH 3.62 m --- 72.98--- 72.98 CH 3.62 m ---72.98 CH 3.62 m
brt 3.33.12 brt 3.3 79.24 CH 3.12CH 3.14 dd 6.0, 4.2 79.24 CH79.90 CH 3.14 dd 6.0, 4.2 79.9079.90 CH 3.14 dd 6.0, 4.2
---m --- 36.51 CH 1.74 m1.98 mCH 1.98 m --- 33.23 CH33.23 CH 1.98 m --- 33.23
CH2 33.07 CH2CH2 40.86 CH2 40.86 CH2 33.0740.86
--- 36.51 CH 1.74
22.94 CH2CH 3.65 m --- 22.94 CH270.35 CH 3.65 m --- 70.3570.35 CH 3.65 m ---
39.73
61.11 CH 4.13 m ---
m --- 38.62 CH2 38.62 CH21.48 m --- 39.73 CH2 1.48CH2 1.48 m --- 39.73 CH2
CH2 72.11 CH 3.58 m ---23.13 CH2 23.13 CH2 23.13
38.45 CH2 38.55 CH2 38.55 CH238.41 CH2 38.41 CH2
CH2 mm --- 24.19 CH2 m 24.193.55 m --- 80.67 CH 4.36CH 3.55 m --- 72.30 CH72.30
38.47 CH238.29 CH2 38.29 CH2 38.47 CH238.29 CH2
10.4, 3.0 68.77 CH 4.08 m ---22.81 CH2 68.77 CH 4.08 dd22.81 CH2 22.81 CH2
52.04 CH2 2.64 m ------ 52.04 CH2 2.64 d 7.5m --- 38.33 CH2 1.53 m1.53 m --- 38.33 CH2 1.5338.33 CH2
C --- --- ---211.94 C --- --- --- 211.94--- 73.65 CH 4.02 m ---m --- 73.65 CH 4.02 m73.65 CH 4.02
2.62 m ---CH2 2.62 d 7.5 51.94 CH2136.93 CH 5.54 dd 15.0, 7.2 51.9415.0, 7.2 136.93 CH 5.54 dd 15.0, 7.2136.93 CH 5.54 dd
34.90 CH237.58 CH2 37.58 CH2 34.90 CH237.58 CH2
m73.08 --- 30.07 CH2 30.07 CH23.65 m --- 73.08 CH 3.65CH 3.65 m --- 73.08 CH
Position
6 7 9 8 10
63.24 CH2 3.59 t 6.4CH2 63.24 CH2 3.59 t 6.466.75 CH2 66.75 CH2 66.75
63
 
 
 
Carbon 
δ (ppm)
Mult.
Proton 
δ (ppm)
Mult.
J  value 
(Hz)
Carbon 
δ (ppm)
Mult.
Proton 
δ (ppm)
Mult.
J  value 
(Hz)
Carbon 
δ (ppm)
Mult.
Proton 
δ (ppm)
Mult.
J  value 
(Hz)
Carbon 
δ (ppm)
Mult.
Proton 
δ (ppm)
Mult.
J  value 
(Hz)
Carbon 
δ (ppm)
Mult.
Proton 
δ (ppm)
Mult.
J  value 
(Hz)
24a
24b
25a 1.69 m --- 1.69 m --- 1.69 m --- 1.69 m --- 1.69 m ---
25b 1.52 m --- 1.52 m --- 1.52 m --- 1.52 m --- 1.52 m ---
26a 1.54 m --- 1.54 m --- 1.54 m --- 1.54 m --- 1.54 m ---
26b 1.46 m --- 1.46 m --- 1.46 m --- 1.46 m --- 1.46 m ---
27a 1.70 m --- 1.70 m --- 1.70 m --- 1.70 m --- 1.70 m ---
27b 1.28 m --- 1.28 m --- 1.28 m --- 1.28 m --- 1.28 m ---
28 36.42 CH 1.72 m --- 36.42 CH 1.72 m --- 36.42 CH 1.72 m --- 36.37 CH 1.76 m --- 36.37 CH 1.76 m ---
29a
29b
30 68.50 CH 3.86 d 9.8 68.50 CH 3.86 d 9.8 68.50 CH 3.86 d 9.8 68.42 CH 3.91 dt 10.2, 1.7 68.42 CH 3.91 dt 10.2, 1.7
31a 1.86 m --- 1.86 m --- 1.86 m --- 1.84 brt 12.0 1.84 brt 12.0
31b 1.60 m --- 1.60 m --- 1.60 m --- 1.70 m --- 1.70 m ---
32 76.16 CH 4.20 d 9.0 76.16 CH 4.20 d 9.0 76.16 CH 4.20 d 9.0 74.57 CH 4.12 dt 10.8, 2.0 74.57 CH 4.12 dt 10.8, 2.0
33 73.67 CH 3.46 dd 3.9, 12.3 73.67 CH 3.46 m --- 73.67 CH 3.46 m --- 73.02 CH 3.73 m --- 73.02 CH 3.73 m ---
34a
34b
35a
35b
36a
36b
37a
37b
38a 1.98 m --- 1.98 m --- 1.98 m --- 2.04 m --- 2.04 m ---
38b 1.58 m --- 1.58 m --- 1.58 m --- 1.70 m --- 1.70 m ---
39a 2.43 dt 5.0, 11.5 2.43 m --- 2.43 m --- 2.45 m --- 2.45 m ---
39b 2.11 m --- 2.11 m --- 2.11 m --- 2.15 m --- 2.15 m ---
40a
40b
41 76.63 CH 4.20 d 9.0 76.63 CH 4.20 d 9.0 76.63 CH 4.20 d 9.0 76.82 CH 4.23 d 9.0 76.82 CH 4.23 d 9.0
42a
42b
43 70.25 CH 4.06 m --- 70.25 CH 4.06 m --- 70.25 CH 4.06 m --- 70.25 CH 4.06 m --- 70.25 CH 4.06 m ---
44a 2.12 m --- 2.12 m --- 2.12 m --- 2.12 m --- 2.12 m ---
44b 1.58 m --- 1.58 m --- 1.58 m --- 1.58 m --- 1.58 m ---
45 67.21 CH 4.07 m --- 67.21 CH 4.07 m --- 67.21 CH 4.07 m --- 67.21 CH 4.07 m --- 67.21 CH 4.07 m ---
46 68.56 CH 4.05 m --- 68.56 CH 4.05 m --- 68.56 CH 4.05 m --- 68.56 CH 4.05 m --- 68.56 CH 4.05 m ---
47 80.55 CH 3.74 brd 10.4 80.55 CH 3.74 brd 10.4 80.55 CH 3.74 brd 10.4 80.55 CH 3.74 brd 10.4 80.55 CH 3.74 brd 10.4
48 71.75 CH 3.99 dd 10.2, 2.4 71.75 CH 3.99 dd 10.2, 2.4 71.75 CH 3.99 dd 10.2, 2.4 71.75 CH 3.99 dd 10.2, 2.4 71.75 CH 3.99 dd 10.2, 2.4
49 74.13 CH 4.39 dd 7.2, 3.0 74.13 CH 4.39 dd 7.2, 3.0 74.13 CH 4.39 dd 7.2, 3.0 74.13 CH 4.39 dd 7.2, 3.0 74.13 CH 4.39 dd 7.2, 3.0
50 128.36 CH 5.61 dd 15.0, 7.2 128.36 CH 5.61 dd 15.0, 7.2 128.36 CH 5.61 dd 15.0, 7.2 128.36 CH 5.61 dd 15.0, 7.2 128.36 CH 5.61 dd 15.0, 7.2
51 136.00 CH 5.81 dt 15.0, 7.2 136.00 CH 5.81 dt 15.0, 7.2 136.00 CH 5.81 dt 15.0, 7.2 136.00 CH 5.81 dt 15.0, 7.2 136.00 CH 5.81 dt 15.0, 7.2
52 33.68 CH2 2.11 m --- 33.68 CH2 2.11 m --- 33.68 CH2 2.11 m --- 33.68 CH2 2.11 m --- 33.68 CH2 2.11 m ---
53 30.47 CH2 1.44 m --- 30.47 CH2 1.44 m --- 30.47 CH2 1.44 m --- 30.47 CH2 1.44 m --- 30.47 CH2 1.44 m ---
31.42 CH231.42 CH2 31.42 CH2 31.42 CH231.42 CH2
74.89 CH 3.39 brd 8.4 74.898.0 75.02 CH 3.37 brd 8.0brd 8.0 75.02 CH 3.37 brd CH 3.39 brd 8.4
C --- --- --- 151.24 C151.86 C --- --- --- 151.24---
75.02 CH 3.37
C --- --- --- --- ---
CH227.69 CH2 27.69 CH2 27.69
151.86 C --- --- ---151.86
31.42 CH2 31.42 CH232.54 CH2 32.54 CH2 32.54 CH2
CH2 27.41 CH2 27.41
4.02 m ---CH 4.02 m --- 72.40 CH36.77 CH 2.09 brd 8.3 72.408.3 36.77 CH 2.09 brd 8.336.77 CH 2.09 brd
m ---3.40 m --- 77.97 CH 3.40CH 4.49 d 2.4 77.97 CH77.51 CH 4.49 d 2.4 77.5177.51 CH 4.49 d 2.4
---m --- 70.89 CH 3.85 m3.64 m --- 70.89 CH 3.85CH 3.64 m ---CH 3.64 m --- 74.27
CH 3.73 m --- 73.02 CH75.63 CH 4.36 dt 2.8, 8.1 73.022.8, 8.1 75.63 CH 4.36 dt 2.8, 8.175.63 CH
74.27 CH74.27
CH2 34.52 CH2
3.73 m ---
34.28 CH2 34.28 CH2 34.28
4.36 dt
3.10 dd 7.2, 3.6dt 9.4, 3.4 80.03 CH 3.10 dd3.07 dt 9.4, 3.4 79.97 CH 3.07
34.52 CH2
79.97 CH79.97 7.2, 3.6 80.03 CH
CH2 33.02 CH2 33.02 CH233.02 CH2 33.02 CH2 33.02
CH 3.07 dt 9.4, 3.4
24.37 CH2 24.37 CH2 24.37 CH2
CH2 35.25 CH2CH2 35.25 CH2 35.25 CH2 35.2535.25
24.37 CH2 24.37 CH2
71.53 CH 3.87 m ------ 71.53 CH 3.87 m ---m --- 71.53 CH 3.87 m3.87 m --- 71.53 CH 3.8771.53 CH
7 9 8 10
Position
6
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Carbon 
δ (ppm)
Mult.
Proton 
δ (ppm)
Mult.
J  value 
(Hz)
Carbon 
δ (ppm)
Mult.
Proton 
δ (ppm)
Mult.
J  value 
(Hz)
Carbon 
δ (ppm)
Mult.
Proton 
δ (ppm)
Mult.
J  value 
(Hz)
Carbon 
δ (ppm)
Mult.
Proton 
δ (ppm)
Mult.
J  value 
(Hz)
Carbon 
δ (ppm)
Mult.
Proton 
δ (ppm)
Mult.
J  value 
(Hz)
54 30.35 CH2 1.34 m --- 30.35 CH2 1.34 m --- 30.35 CH2 1.34 m --- 30.35 CH2 1.34 m --- 30.57 CH2 1.34 m ---
55 30.39 CH2 1.34 m --- 30.39 CH2 1.34 m --- 30.39 CH2 1.34 m --- 30.39 CH2 1.34 m --- 30.65 CH2 1.34 m ---
56 30.57 CH2 1.34 m --- 30.57 CH2 1.34 m --- 30.57 CH2 1.34 m --- 30.57 CH2 1.34 m --- 30.28 CH2 1.42 m ---
57 30.65 CH2 1.34 m --- 30.65 CH2 1.34 m --- 30.65 CH2 1.34 m --- 30.65 CH2 1.34 m --- 33.68 CH2 2.11 m ---
58a
58b
59a
59b
60 136.14 CH 5.71 dt 15.0, 7.2 33.68 CH2 2.11 m --- 136.14 CH 5.71 dt 15.0, 7.2 137.16 CH 5.75 dt 15.0, 7.2 135.20 CH 6.45 dd 13.2, 10.8
61 132.35 CH 6.05 dd 15.5, 10.6 136.14 CH 5.71 dt 15.0, 7.2 132.35 CH 6.05 dd 15.5, 10.6 127.52 CH 6.05 dd 15.0, 10.8 119.42 CH 6.23 d 13.1
62a
62b
63a 5.07 d 14.6 5.07 d 14.6
63b 4.93 d 10.8 4.93 d 10.8
64a 5.07 d 14.6
64b 4.93 d 10.8
65a 5.03 s ---
65b 5.08 s ---
66 16.72 CH3 0.98 d 7.8 13.24 CH3 0.93 d 7.2 16.72 CH3 0.98 d 7.8 16.72 CH3 0.98 d 7.8
67a 5.03 s ---
67b 5.08 s ---
68a 4.99 s --- 4.99 s ---
68b 5.08 s --- 5.08 s ---
69a 4.99 s ---
69b 5.08 s ---
6.7 113.10 CH2
113.10 CH2
d 6.7 113.42 CH2
113.10 CH2 14.16 CH3 0.80 d
0.98 d 7.8 14.16 CH3 0.80CH3 0.80 d 6.7 16.72 CH3
0.93 d 7.2 113.42 CH2
14.16
CH3 0.93 d 7.2 13.24 CH317.44 CH3 0.99 d 7.2 13.2413.24 CH3 0.93 d 7.2
16.72 CH3 0.98 d 7.87.2 16.78 CH3 0.96 d 6.5114.88 CH2 17.44 CH3 0.99 d17.44 CH3 0.99 d 7.2
d 7.26.23 d 13.1 13.24 CH3 0.93dt 17.0, 10.4 114.88 CH2 119.42 CH114.88 CH2 138.62 CH 6.31
d 7.26.45 dd 13.2, 10.8 17.44 CH3 0.99CH 6.31 dt 17.0, 10.4 135.20 CH132.35 CH138.62 CH 6.31 dt 17.0, 10.4
33.68 CH2 2.11 m --- 127.52--- 33.68 CH2 2.11 m ---m --- 30.28 CH2 1.42 m33.68
6.05 dd 15.5, 10.6 138.62
15.0, 7.21.42 m --- 137.16 CH 5.75CH2 1.42 m --- 30.28 CH230.39 CH2
CH 6.05 dd 15.0, 10.8CH2 2.11
dt
7 9 8 10
1.34 m --- 30.2830.28 CH2 1.42 m ---
Position
6
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Figure 32. HSQC of KmTx2 with the key overlay regions outlined in red. 
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Figure 33. Detailed HSQC assignment of KmTx2 for region I. 
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Figure 34. Detailed HSQC assignment of KmTx2 for region II. 
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Figure 35. Detailed HSQC assignment of KmTx2 for region III.
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Figure 36. 1H of congener 2. 
 
Figure 37. DEPT of congener 2. 
71 
 
 
Figure 38. Expanded DEPT of congener 2. 
  
 
 
 
Figure 39. Congener 2 vs 1 HSQC overlay for region I. 
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Figure 40. Congener 2 vs 1 HSQC overlay for region II. 
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Figure 41. Congener 2 vs 1 HSQC overlay for region III. 
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Table 3. Table of Significant NMR Correlations for 2. 
Position 
KmTx 2 (1)  44-OH-KmTx 2 (2) 
Carbon δ 
(ppm) Mult. 
Proton δ 
(ppm) Mult.
J value
(Hz) 
 
Carbon δ
(ppm) Mult.
Proton δ
(ppm) Mult. 
J value
(Hz) HMBC TOCSY ROESY
36a 77.97 CH 3.40 m --- 77.89 CH 3.38 dd 6.9, 1.3 No significant change  in NMR overlay 36b 
37a 72.40 CH 4.02 m --- 72.72 CH 4.02 m --- No significant change  in NMR overlay 37b 
38a 31.42 CH2 2.04 m --- 31.90 CH2 2.04 m --- No significant change  in NMR overlay 38b 1.70 m --- 1.69 m --- 
39a 27.41 CH2 2.45 m --- 27.67 CH2 2.46 dt 
5.0, 
12.6 No significant change  in NMR overlay 39b 2.15 m --- 2.17 m --- 
40a 151.24 C --- --- --- 151.54 C --- --- --- No significant change  in NMR overlay 40b 
41 76.82 CH 4.23 d 9.0 76.80 CH 4.21 d 9.0 C43, C67  H43, H44
42a 74.89 CH 3.39 brd 8.4 71.77 CH 3.87 dd 6.6,6.7  H43, H44, H45, H46, H47, H48  42b 
43 70.25 CH 4.06 m --- 74.57 CH 3.76 dd 2.6, 9.0 C42 H42, H44, H45, H46, H47, H48 H41, H44
44a 31.42 CH2 2.12 m --- 70.42 CH 4.19 dd 1.7, 3.0 C43, C45, C46
H42, H43, H45, 
H46, H47, H48 
H41, 
H43, H4444b 1.58 m --- 
45 67.21 CH 4.07 m --- 73.17 CH 3.8 dd 3.2, 9.4 C46 H42, H43, H44, H46, H47, H48 H44 
46 68.56 CH 4.05 m --- 68.62 CH 3.9 d 9.6  H42, H43, H44, H45, H47, H48  
47 80.55 CH 3.74 brd 10.4 80.15 CH 3.73 dd 3.0, 10.0 
C43, 
C45, C48
H42, H43, H44, 
H45, H46, H48  
67a 113.42 CH2 5.03 s --- 113.27 CH2 5.04 s --- No significant change  in NMR overlay 67b 5.08 s --- 5.11 s --- 
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Figure 42. HMBC of 2. 
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Figure 43. TOCSY of 2. 
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Figure 44. ROESY of 2. 
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Figure 45. 1H of 3. 
 
Figure 46.  DEPT of 3.
 
 
 
Figure 47.  Congener 3 vs 1 HSQC overlay for region I. 
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Figure 48. Congener 3 vs 1 HSQC overlay for region II. 
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Figure 49. Congener 3 vs 1 HSQC overlay for region III. 
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Table 4. Table of Significant NMR Correlations for 3. 
Position 
(KmTx2) 
KmTx 2 (1) 59-E-Chloro-KmTx 4 (3) 
Carbon δ 
(ppm) Mult. 
Proton δ
(ppm) Mult.
J value
(Hz) 
Carbon δ
(ppm) Mult.
Proton δ 
(ppm) Mult.
J value 
(Hz) HMBC COSY 
1a 66.75 CH2 3.52 dd 11.4, 4.2 67.6 CH2 3.47 dd 4.5, 11.8 C2 H2 1b 3.46 dd 5.6, 11.4
2 73.08 CH 3.65 m --- 72.53 CH 3.61 brd 9.5 C1 H1, H3 
3a 37.58 CH2 2.18 dt 14.4, 6.6 41.75 CH2 2.21 m --- C2, C4, C5 H2, H4 3b 2.29 dt 14.4, 6.6
4 128.49 CH 5.69 dt 15.0, 7.2 128.93 CH 5.65 dt 7.8, 6.7 C5 H3, H5 
5 136.93 CH 5.54 dd 15.0, 7.2 136.95 CH 5.49 dt 7.1, 14.5 C7 H4, H6 
6 73.65 CH 4.02 m --- 74.25 CH 4.01 d 11.3 C4, C5 H5, H7 
7a 38.33 CH2 1.53 m --- 38.19 CH2 1.54 m --- C8 H6, H8 7b 1.4 m --- 
8a 22.81 CH2 1.55 m --- 23.21 CH2 1.63 m --- C7, C9, C10 H7, H9 8b 1.38 m --- 1.4 m --- 
9a 38.29 CH2 1.50 m --- 38.69 CH2 1.51 m --- C7, C11 H8, H10 9b 1.46 m --- 1.41 m --- 
10 72.30 CH 3.55 m --- 72.56 CH 3.56 m ---  H9, H11 
11a 38.41 CH2 1.50 m --- 38.74 CH2 1.51 m --- C9, C12 H10, H12 11b 1.42 m --- 1.41 m --- 
12a 23.13 CH2 1.62 m --- 23.21 CH2 1.63 m --- C13 H11 12b 1.41 m --- 1.4 m --- 
13a 39.73 CH2 1.48 m --- 34.79 CH2 1.55 m --- C14  13b 1.38 m --- 
14 70.35 CH 3.65 m --- 73.47 CH 3.6 dd 1.8, 9.2 C16, C17  
15a (19a) 32.53 CH2 1.63 m --- 36.46 CH2 1.6 m --- C16  15b (19b) 1.55 m --- 1.54 m --- 
83
 
 
16a (20a) 31.45 CH2 1.61 m --- 31.71 CH2 1.54 m --- C17, C60 H15, H17 16b (20b) 1.37 1.32 m --- 
17 (21) 34.93 CH 1.90 m --- 35.21 CH 1.88 dt 2.0, 6.5 C60 H16, H18, H60
18 (22) 73.65 CH 3.69 m --- 74.29 CH 3.65 brd 9.3 C60 H17 
19 (23) 73.92 CH 3.33 m --- 73.92 CH 3.33 m --- No Significant Change  in NMR overlay 
60 (65) 137.16 CH 5.75 dt 15.0, 7.2 13.40 CH3 0.90 d 7.1  H17 
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Figure 50.  HMBC of 3. 
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Figure 51.  COSY of 3. 
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Figure 52. TOCSY of 3. 
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Figure 53. 1H of 4.  
 
 
 
Figure 54.  Congener 3 vs 4 HSQC for region I. 
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Figure 55.  Congener 3 vs 4 HSQC for region II. 
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Figure 56.  Congener 3 vs 4 HSQC for region III. 
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Figure 57.  1H of 5. 
 
Figure 58.  DEPT of 5.
 
 
 
Figure 59.  Congener 5 vs 1 HSQC for region I. 
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Figure 60.  Congener 5 vs 1 HSQC for region II. 
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Figure 61.  Congener 5 vs 1 HSQC for region III. 
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Table 5.  Table of Significant NMR Correlations for 5. 
Position 
(KmTx2) 
KmTx 2 (1) 
 
KmTx 5 (5) 
Carbon δ 
(ppm) Mult. 
Proton δ 
(ppm) Mult. 
J value 
(Hz) 
Carbon δ 
(ppm) Mult. 
Proton δ 
(ppm) Mult. 
J value 
(Hz) HMBC COSY
1a 66.75 CH2 3.52 dd 11.4, 4.2 63.33 CH2 3.58 t 6.0 C2, C3 H2 1b 3.46 dd 5.6, 11.4
2a 73.08 CH 3.65 m --- 30.13 CH2 1.7 m --- C1 H1, H32b 1.59 m --- 
3a 37.58 CH2 2.18 dt 14.4, 6.6 34.98 CH2 1.58 m --- C1 H2, H43b 2.29 dt 14.4, 6.6 1.44 m --- 
4 (6) 73.65 CH 4.02 m --- 72.85 CH 3.59 dd 2.4, 8.6 C3 H3, H5
5a (7a) 38.33 CH2 1.53 m --- 38.33 CH2 1.62 m --- C4 H4, H65b (7b) 1.53 m --- 1.4 m --- 
6a (8a) 22.81 CH2 1.55 m --- 23.30 CH2 1.43 m --- C4, C8 H5, H76b (8b) 1.38 m --- 1.5 m --- 
7a (9a) 38.29 CH2 1.50 m --- 38.29 CH2 1.62 m --- C6 H6, H87b (9b) 1.46 m --- 1.4 m --- 
8 (10) 72.30 CH 3.55 m --- 72.52 CH 3.57 dd 3.9, 8.7  H7, H9
9a (11a) 38.41 CH2 1.50 m --- 38.41 CH2 1.50 m --- C8, C10 H8 9b (11b) 1.42 m --- 1.42 m --- 
10a (12a) 
23.13 CH2 
1.62 m --- 
23.13 CH2 1.62 m --- 
No significant 
change in 
NMR overalay
10b 
(12b) 1.41 m --- 
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Figure 62.  HMBC of 5. 
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Figure 63.  COSY of 5.
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Figure 64.  1H of 6. 
 
Figure 65. DEPT of 6.
 
 
 
Figure 66.  Congener of 6 vs 1 for region I. 
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Figure 67. Congener of 6 vs 1 for region II. 
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Figure 68. Congener of 6 vs 1 for region III. 
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Table 6. Table of Significant NMR Correlations for 6. 
Position 
(KmTx2) 
KmTx 2 (1) 
 
KmTx 6 (6) 
Carbon 
δ 
(ppm) 
Mult.
Proton 
δ 
(ppm)
Mult. J value(Hz) 
Carbon 
δ 
(ppm)
Mult.
Proton 
δ 
(ppm)
Mult. J value(Hz) HMBC COSY ROESY
28 36.37 CH 1.76 m --- 36.42 CH 1.72 m --- No significant change in the NMR Overlay 
29 80.03 CH 3.10 dd 7.2, 3.6 79.97 CH 3.07 dt 9.4, 3.4  H30  
30 68.42 CH 3.91 dt 10.2, 1.7 68.50 CH 3.86 d 9.8  H29, H31  
31a 34.52 CH2 1.84 brt 12. 0 34.28 CH2 1.86 m ---  H30, H32  31b 1.70 m --- 1.60 m --- 
32 74.57 CH 4.12 dt 10.8, 2.0 76.16 CH 4.20 d 9.0  H31, H33  
33 73.02 CH 3.73 m --- 73.67 CH 3.46 dd 3.9, 12.3  H32 H37 
34 73.02 CH 3.73 m --- 75.63 CH 4.36 dt 2.8, 8.1 C32, C36  H37 
35 70.89 CH 3.85 m --- 74.27 CH 3.64 m ---    
36 77.97 CH 3.40 m --- 77.51 CH 4.49 d 2.4 C37, C67 H37 H37 
37 72.40 CH 4.02 m --- 36.77 CH 2.09 brd 8.3  H36, H38, H67 
H33, 
H34, 
H36 
38a 31.42 CH2 2.04 m --- 32.54 CH2 1.98 m ---  H37, H39  38b 1.70 m --- 1.58 m --- 
39a 27.41 CH2 2.45 m --- 27.69 CH2 2.43 dt 
5.0, 
11.5  H38, H68  
39b 2.15 m --- 2.11 m --- 
40 151.24 C --- --- --- 151.86 C --- --- ---    
41 76.82 CH 4.23 d 9.0 76.63 CH 4.20 d 9.0  H68  
103
 
 
42 74.89 CH 3.39 brd 8.4 75.02 CH 3.37 brd 8.0 No significant change in the NMR Overlay 
60 137.16 CH 5.75 dt 15.0, 7.2 136.14 CH 5.71 dt 
15.0, 
7.2  H59, H61  
61 127.52 CH 6.05 dd 15.0, 10.8 132.35 CH 6.05 dd 
15.5, 
10.6  H60, H62  
62 135.20 CH 6.45 dd 13.2, 10.8 138.62 CH 6.31 dt 
17.0, 
10.4  H61, H63  
63a 119.42 CH 6.23 d 13.1 114.88 CH2 5.07 d 14.6  H63b, H62  63b 4.93 d 10.8 H63a, H62
67      14.16 CH3 0.80 d 6.7  H37  
68a 
(67a) 113.42 CH2 
5.03 s --- 
113.10 CH2
4.99 s --- No significant change in the NMR 
Overlay 68b 
(67b) 5.08 s --- 5.08 s --- 
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Figure 69.  HMBC of 6. 
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Figure 70.  COSY of 6. 
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Figure 71.  TOCSY of 6. 
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Figure 72.  ROESY of 6. 
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Figure 73.  1H of 7. 
 
Figure 74.  Expanded DEPT of 7.
 
 
 
Figure 75. Congener 7 vs 6 HSQC for region I. 
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Figure 76.  Congener 7 vs 6 HSQC for region II. 
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Figure 77.  Congener 7 vs 6 HSQC for region III. 
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Figure 78.  1H of 9.
 
 
 
Figure 79.  Congener 9 vs 6 HSQC for region I. 
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Figure 80. Congener 9 vs 6 HSQC for region II.  
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Figure 81.  Congener 9 vs 6 HSQC for region III. 
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Figure 82.  1H of 8. 
 
Figure 83.  13C of 8.
 
 
 
Figure 84. Congener 8 vs 1 HSQC for region I. 
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Figure 85. Congener 8 vs 1 HSQC for region II. 
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Figure 86. Congener 8 vs 1 HSQC for region III. 
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Table 7.  Table of Significant NMR Correlations for 8. 
Position
KmTx 2 (1)  KmTx 8 (8) 
Carbon δ 
(ppm) Mult.
Proton δ
(ppm) Mult.
J value 
(Hz)  
Carbon δ
(ppm) Mult.
Proton δ 
(ppm) Mult.
J value 
(Hz) HMBC COSY 
1a 66.75 CH2 3.52 dd 11.4, 4.2  63.24 CH2 3.59 t 6.4 C2 H2 1b 3.46 dd 5.6, 11.4
2a 73.08 CH 3.65 m ---  30.07 CH2 1.70 m --- C1 H1, H3 2b 1.60 m --- 
3a 37.58 CH2 2.18 dt 14.4, 6.6  34.90 CH2 1.58 m --- C2, C4 H2, H4 3b 2.29 dt 14.4, 6.6 1.45 m --- 
4 128.49 CH 5.69 dt 15.0, 7.2  68.77 CH 4.08 dd 10.4, 3.0  H3, H5 
5a 136.93 CH 5.54 dd 15.0, 7.2  51.94 CH2 2.62 d 7.5 C4, C6 H4 5b 
6 73.65 CH 4.02 m ---  211.94 C --- --- ---   
7a 38.33 CH2 1.53 m ---  52.04 CH2 2.64 d 7.5 C6, C8 H8 7b 
8a 22.81 CH2 1.55 m ---  68.77 CH 4.08 dd 10.4, 3.0 C9 H7, H9 8b 1.38 m --- 
9a 38.29 CH2 1.50 m ---  38.47 CH2 1.50 m --- C11 H8, H10 9b 1.46 m --- 1.46 m --- 
10a 72.30 CH 3.55 m ---  24.19 CH2 1.50 m --- C9, C11 H9, H11 10b 1.33 --- 
11a 38.41 CH2 1.50 m ---  38.55 CH2 1.50 m --- C12, C13 H10, H12 11b 1.42 m --- 1.46 m --- 
12a 23.13 CH2 1.62 m ---  61.11 CH 4.13 m ---  H11, H13 12b 1.41 m --- 
13a 39.73 CH2 1.48 m ---  38.62 CH2 1.50 m --- C12, C13 H12, H14 13b 1.45 m --- 
14a 70.35 CH 3.65 m ---  22.94 CH2 1.62 m --- C13 H13, H15 14b 1.40 m --- 
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15a 40.86 CH2 1.67 m ---  33.07 CH2 1.65 m --- C13, C16 H14, H16 15b 1.27 m --- 1.24 m --- 
16 33.23 CH 1.98 m ---  36.51 CH 1.74 m --- C64 H15, H17, H64
17 79.90 CH 3.14 dd 6.0, 4.2  79.24 CH 3.12 brt 3.3 No significant change  in NMR overlay 
18 72.98 CH 3.62 m ---  72.98 CH 3.62 brd 6.8 No significant change  in NMR overlay 
19a 32.53 CH2 1.63 m ---  33.02 CH2 1.60 m --- No significant change  in NMR overlay 19b 1.55 m --- 
20a 31.45 CH2 1.61 m ---  31.45 CH2 1.61 m --- No significant change  in NMR overlay 20b 1.37 m --- 1.37 m --- 
64 17.44 CH3 0.99 d 7.2  16.78 CH3 0.96 d 6.5 C16 H16 
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Figure 87.  HMBC of 8. 
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Figure 88. COSY of 8. 
124
125 
 
 
Figure 89. 1H of 10.
 
 
 
Figure 90. Congener 10 vs 8 for HSQC region I. 
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Figure 91. Congener 10 vs 8 for HSQC region II. 
127
 
 
 
Figure 92. Congener 10 vs 8 for HSQC region III. 
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CHAPTER 2: PROGRESS TOWARDS THE TOTAL SYNTHESIS OF 5 
 
INTRODUCTION
The total synthesis of the karlotoxins is the next essential step to fully understanding 
these compounds potential on human health.  Given that the dinoflagellate only produces ~2 
mg/40 L of culture, large-scale production through aquaculture is impractical and cost 
prohibitive.  Total synthesis will produce enough material to complete all of the in vitro studies 
as well as several animal studies and give a better picture of the feasibility of KmTx to become a 
potential therapeutic drug lead for cancer treatment.  The total synthesis will also definitively 
answer the absolute configuration question that has been plaguing KmTx2 since the publication 
of its structure in 2010 and confirm the extensive computational work done in chapter 1.  Since 
most of the KmTx’s share an identical pyran core which is essential for activity, 5 was chosen 
for the first total synthetic attempt due to the relative simplicity of it polyol section.  The olefin at 
C4 in KmTx2 complicates some of the elongation steps and at this juncture is better addressed 
when producing analogues for further SAR studies. 
 Figure 93 illustrates the convergence and chemical economy of this synthesis and figure 
94 gives the retrosynthetic strategy to be employed for the formation of 5.  The pyran rings and 
their stereochemistry are obtained from (D)-mannose, while the polyol section is comprised of 2 
units of (S)-glycidol and 2 units of D-tartaric acid.  These starting materials are relatively 
inexpensive and readily provide the necessary configurations of 11 out of the 27 stereogenic 
centers. The synthesis is broken into 7 major fragments.  Of those fragments, this dissertation 
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focuses on the scaling of fragments 2 (C6-C9) and 3 (C10-C17) and the development of the 
synthetic method for the creation of fragment 5 (C24-C35).   
The scheme for the total synthesis is dependent on the successful completion of all 
fragments.  Initially fragments 1, 2, 3 and 4 will be coupled together using the Julia-Kocienski 
olefination thus completing the polyol section.  Then fragment 5, the first pyran ring, will be 
coupled to the polyol section using the same method.  Fragment 6 will be coupled to fragment 7 
using another Julia-Kocienski olefination reaction and finally, fragments 1-5 with a terminal 
modification (polyol section and the first pyran ring) will be coupled to fragments 6-7 (aliphatic 
chain and the second pyran ring) using a Suzuki coupling. Fragments 6 and 7 have already been 
partially synthesized and are reported in Tomioka et al.41  
 
 Figure 93.  Fragment division, convergence and chemical economy of 5 synthesis. 
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 Figure 94.  Overall retrosynthesis and fragment attachment scheme for 5. 
 
RESULTS AND DISCUSSION 
Fragment 2 was formed from the same intermediate as fragment 1.  First, (S)-glycidol was 
benzylated to protect the primary alcohol.  Figure 95 shows the synthetic scheme for the creation 
of fragment 2.  The epoxide was opened and the chain length extended using a modified Grignard 
reagent.  This gave a yield of 72% over the initial 2 steps.  Next, the secondary alcohol was 
protected by a tert-butyldimethylsilyl (TBS) group (yield 90%).  Next, ozonolysis was used to 
cleave the olefin into an aldehyde which was then reduced to an alcohol.  The alcohol was 
converted to a 1-phenyl-1H tetrazole-5-thiol using the Mitsunobu reaction.  Finally the thiol was 
oxidized to a sulfone in preparation for the Julia-Kocienski olefination.  One particular problem 
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that was not seen on small-scale but occurred upon scale-up of this series of reactions was the 
decomposition of the thioether during oxidation.  Initially acetone was used as a solvent, but upon 
scale-up this produced an undesirable side product that was difficult to isolate from the product 
and greatly reduced overall yields.  This problem was solved by switching to ethanol as a solvent.  
The overall reaction yield for the final 3 steps was 56%. 
 Figure 95. Synthetic scheme for fragment 2 (C6-C9). 
  
Fragment 3 was synthesized from a common intermediate with fragment 4.  D-tartaric 
acid was esterified using thionyl chloride and methanol.  Then, the diol was protected with an 
acetonide functionality.  The esters were reduced to alcohols and finally the compound was 
mono-benzylated.  This intermediate was generated with an overall yield of 28%.   
For fragment 3 (figure 96), the alcohol was oxidized to an aldehyde using oxalyl chloride.  
The aldehyde was then used to extend the chain length in a Horner-Wadsworth-Emmons (HWE) 
reaction.  The resulting olefin was selectively methylated using the Gilman methylation.  This 
occurred in a 76% yield over 3 steps with a 9:1 E:Z selectivity.  Next, diisobutylaluminium 
hydride (DIBAL) was used to reduce the ester to an alcohol which was then subjected to a 
Brown allylation to extend the chain length.  These two steps occurred in 55% yield.  Finally the 
secondary alcohol was protected by a TBS group followed by ozonolysis to convert the olefin to 
an aldehyde.  The aldehyde was then reduced to an alcohol which underwent a Mitsunobu 
reaction to yield a thiol followed by oxidation to the sulfone.  The overall yield for these 5 steps 
was 36%.    
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 Figure 96. Synthetic scheme for fragment 3 (C10-C17). 
 Fragment 5 was synthesized from the common intermediate for fragments 5 and 6.  The 
common intermediate is formed by acetylating D-mannose.  The pentacetate derivative was then 
treated with (allyltrimethyl)silane, BF3-Et2O, and trimethylsilyl trifluoromethanesulfonate 
(TMSOTf) in acetonitrile to deprotect and extend the 5 position of the pyran.  Next the rest of the 
acetyl groups were removed with the use of NaOMe and the primary alcohol was protected using 
tert-butyldiphenylsilyl (TBDPS) (figure 97).  These reactions were well characterized in 
brevetoxin B IJK ring system synthesis and no modifications were made to their procedure.42   
 Figure 97. Synthesis of fragment 5 and 6 common intermediate. 
Fragment 5 utilizes the common intermediate generated above.  The first step was an 
ozonolysis to cleave the double bond to a terminal aldehyde.  Then a chain elongation utilizing 
an HWE-type Wittig reaction was performed to add C26, and finally the protection of the 
remaining exposed alcohol on the pyran ring was performed.  These 3 steps gave an overall yield 
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of 55%.  The fragment was then elongated again through the reduction of the ester to an alcohol 
and oxidation back to an aldehyde to react in another HWE-type Wittig reaction to add C24.  
This was achieved in a 75% overall yield with 9:1 E:Z selectivity.  Then, the α, β-unsaturated 
ester was reacted in a Sharpless reaction using AD-mix β to give the selective orientation of the 
newly created diol.   Unfortunately this reaction suffered from low yields (25%).  The original 
scheme for the production of fragment 5 included protecting the newly created diol with an 
acetonide protecting group.  After several different trials that included extending the reaction 
time, heating, changing the acid catalyst for the protection, the acetonide protected product was 
not obtained.  This led to the protection of the diol with TBS protecting groups.  This reaction 
resulted in a virtually complete conversion to the protected product.  The final addition to the 
carbon backbone of the fragment is a methylation achieved with stereoselectivity on C26 using a 
Gillman methylation. The overall scheme for fragment 5 is presented in figure 98.   
 Figure 98. Synthetic scheme for fragment 5 (C24-C35). 
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To develop the synthetic methodologies for fragment 5, two different scale-up reactions 
have been performed.  The first was on a 500 mg scale of the common intermediate (C27-C35).  
This material was consumed during the optimization of the first 7 steps of fragment 5 synthesis.  
The next scale-up was on 1.2 g of the common intermediate (C27-C35).  As mentioned above the 
yield after the Sharpless reaction was only 25%.  This translates into 155 mg of diol to optimize 
the Gillman methylation.  Several attempts at the Gillman methylation were performed that 
included varying equivalents of CuI and methyl lithium solution as well as temperature and time 
factors.  However, none of these reaction attempts were successful, and they consumed all of the 
material created from the large scale-up.  The earlier Gillman methylation in fragment 3 shared 
several common structural motifs with fragment 5.  The one exception being the protecting 
group of the diol.  One hypothesis for the failure of this penultimate reaction is the steric 
hindrance caused by the bulky TBS protecting groups.  Future optimization trials can be 
achieved after scale-up reactions on the common intermediate for fragments 5 and 6 and scale-up 
of the reactions leading to the diol in fragment 5 have been completed (12 steps).  In future 
optimization trials, different protecting groups, possibly a carbonate or a benzaldehyde acetal, 
will need to be tested to achieve the final methylation. 
 
CONCLUSIONS 
 The completion of fragments 2, 3 and 5 in large-scale will be a large step forward in the 
completion of the total synthesis of a KmTx.  While chapter 1 attempts to addresses the absolute 
configuration issues of KmTx using computational approaches, the most definitive approach to 
confirming the configuration of a natural product is total synthesis of the proposed structure.  
With the completion of the synthesis, this direct comparison will be possible.  In addition, 
completion of the total synthesis will provide the much needed material for additional in vitro 
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testing and in vivo analysis for lead optimization of the anticancer potential.  The modular design 
of the total synthesis will also provide greater opportunities for the SAR modifications discussed 
in chapter 1.  Individual components can be altered and reinserted into the total synthetic scheme 
with minimal interference in the method.  All of these factors make the completion of the total 
synthesis of KmTx a priority in the future.  
 
EXPERIMENTAL SECTION  
Fragment 2: C6-C9 
 
1) To a solution of (S)-(−)-glycidol (663 µL, 10 mmol, 1 equiv.) in anhydrous tetrahydrofuran 
(THF) (30 mL) at 0oC was added NaH (345 mg, 15 mmol, 1.5 equiv.) followed by BnBr 
(1427 µL, 12 mmol, 1.2 equiv.) and tetrabutylammonium iodide (TBAI) (37 mg, 0.1 mmol, 
0.1 equiv.) under argon atmosphere. The reaction was stirred and slowly warmed to room 
temperature (RT) overnight (ON), and then quenched with saturated NH4Cl (10 mL), 
extracted with ethyl acetate (3 X 30 mL). The ethyl acetate extraction was concentrated and 
washed with water (10 mL), brine (3 X 10 mL), and passed through an anhydrous Na2SO4 
column eluted with 300 mL ethyl acetate, concentrated under vacuum to yield colorless oily 
crude benzylether.43  
137 
 
2) The crude product was dissolved in anhydrous THF (240 mL) at -78oC and CuI (1.9 g, 10 
mmol, 1 equiv.) added followed by vinyl magnesium bromide solution (1.6 M in THF) (18.8 
mL, 30 mmol, 3 equiv.) under nitrogen atmosphere. The reaction was kept stirring and 
slowly warmed to -20oC over 45 min, and kept stirring for an additional two hours before 
being quenched with 20 mL saturated NH4Cl. The reaction was warmed to RT and kept 
stirring for one hour. The organic layer was diluted with 20 mL ethyl acetate and partitioned. 
The aqueous layer was extracted with ethyl acetate (3 X 20 mL). The combined organic layer 
and ethyl acetate extraction were then concentrated, and washed with water (20 mL) and 
brine (3 X 10 mL).44 The crude material was purified on silica gel column washed with 
hexane/ethyl acetate (4:1) to yield light yellow oil. (1.4 g, 7.2 mmol, 72 % over two steps). 
C12H16O2; TLC (Rf=0.4), hexane/ethyl acetate (4:1). 
3) 2,6-lutidine (6.7 mL, 57.5 mmol, 2 equiv.) was added to the purified product (5.5 g, 28.7 
mmol, 1 equiv.) in one portion under nitrogen atmosphere, and the mixture was cooled to 
0oC.  Then tert-butyldimethylsilyl trifluoromethanesulfonate [TBDMSOTf , 2 equiv. 
(prepared from Corey’s protocol45)] was added by dripping.46 The reaction was kept stirring 
for ten min at 0oC before being quenched with saturated NH4Cl (10 mL) and then diluted 
with 5 mL ethyl acetate. The organic layer was separated, and the aqueous layer was 
extracted with ethyl acetate (3 X 10 mL). The organic extractions were combined and 
directly loaded on a silica gel column and eluted with hexane followed by hexane/ethyl 
acetate (50:1) to provide colorless oil (7.9 g, 25.8 mmol, 90 %). C18H30O2Si; TLC (Rf=0.5), 
hexane/ethyl acetate (50:1) 
4) The product was then dissolved in 20 mL DCM and cooled to -78oC. An ozone stream was 
bubbled through the solution until the color changed to a light blue (approximately 30 min on 
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this scale), and this color was maintained for more than 15 min without fading after the 
ozone was removed. Then, argon was bubbled through until the solution returned colorless 
(approximately 15 min). Next, 10 mL dimethylsulfide was added continuously by seven 
portions. The reaction was kept stirring at -78oC for 20 min before slowly being warmed to 
RT over 20 hours, and during this period of time it was monitored by TLC developed with 
hexane/ethyl acetate (50:1) until a signal spot for the product was observed (rf=0.5).47 
5) The reaction mixture was then cooled to 0oC under nitrogen atmosphere and tert-butanol (5 
mL), TBAI (37 mg, 0.1 mmol, 0.05 equiv.), and NaBH4 (1.1 g, 30 mmol, 15 equiv.), were 
added in sequence.48 The reaction was slowly warmed to RT and allowed to stir for fifteen 
hours before being quenched with saturated NH4Cl (10 mL). The organic layer was separated 
and washed with brine (3 X 5 mL), and the aqueous layer was extracted with ethyl acetate (3 
X 25 mL). The organic extractions were combined and concentrated under vacuum to yield a 
light yellow crude alcohol which was then azeotroped with benzene (3 X 1 mL) to provide a 
dry reactant for the next step.  
6) To a separate reaction vial, triphenylphosphine (629 mg, 2.4 mmol, 1.2 equiv.) was dissolved 
in 5 mL anhydrous THF and diethyl azodicarboxylate solution (DEAD) (40% in toluene) (1 
mL, 2.4 mmol, 1.2 equiv.) was added by dripping at 0oC under argon. The mixture was 
stirred for fifteen minutes and then 1-phenyl-1H-tetrazole-5-thiol (PTSH) (428 mg, 2.4 
mmol, 1.2 equiv.) was added in one portion. The crude alcohol from the previous reaction 
was dissolved in 5 mL anhydrous THF and added at 0oC to the reaction. The reaction mixture 
was slowly warmed to RT and allowed to stir ON.  The THF was then removed under 
vacuum to yield the crude thioether.49  
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7) To another flask, H2O2 (30 wt. % in H2O) (5.6 mL, 50 mmol, 25 equiv.) was added to 
ammonium molybdate tetrahydrate (AMT) (1.2 g) to yield a fresh yellow solution.  This was 
then added to another reaction vial containing the crude thioether dissolved in 10 mL acetone 
at 0oC.50 The reaction mixture was slowly warmed to RT and stirred ON.  Finally the reaction 
was quenched with saturated NH4Cl (10 mL). The organic layer was separated and washed 
with brine (3 X 5 mL). The aqueous layer was extracted with ethyl acetate (3 X 10 mL).  The 
organic extracts were combined and concentrated under vacuum and loaded onto a silica gel 
column to be eluted with hexane/ethyl acetate (9:1) to yield light brown viscous oil (563 mg, 
1.1 mmol, 56 % over four steps). C24H34N4O4SSi; TLC (Rf=0.4), hexane/ethyl acetate (9:1); 
1H NMR (400 MHz, CDCl3) δ 7.76-7.55 (m, 5H), 7.44-7.25 (m, 5H), 4.54 (d, J=3.59 Hz, 
2H), 4.09 (m, 1H), 3.94-3.75 (m, 2H), 3.47 (dd, J=9.73, 5.01 Hz, 1H), 3.36 (dd, J=9.57, 6.60 
Hz, 1H), 2.40-2.00 (m, 2H), 0.90 (s, 9H), 0.10 (s, 3H), 0.07 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ 153.4, 137.8, 133.0, 131.5, 129.7, 128.5, 127.8, 127.8, 127.7, 125.1, 73.4, 73.2, 
68.9, 52.3, 27.0, 25.8, 18.1, -4.5, -4.9. HRESIMS m/z [M+H]+ cald. 503.2143, obsd. 
503.2167 (err -4.81 ppm). 
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 Figure 99.  13C of fragment 2. 
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 Figure 100.  1H of fragment 2. 
 
Fragment 3 and 4 Common Intermediate 
O O
HO OH
HOOC COOH
1) SOCl2, MeOH, 0oC to RT, 1h, reflux, 2 h
2) Dimethoxypropane, PPTS, reflux, 48 h
3) NaBH4, EtOH, 0oC to RT, 6 h
4) Ag2O, BnBr, toluene, RT, 20 h
HO OBn
 
 
1) To a round bottom flask, D-(−)-tartaric acid (32.5 g, 216 mmol, 1 equiv.) was dissolved in 
500 mL anhydrous methanol and cooled to 0oC. To another round bottom flask, thionyl 
chloride (109 mL, 1.3 mol, 6 equiv.) was cooled to 0oC and the tartaric acid solution slowly 
added via cannulation. The reaction mixture was warmed to RT over one hour and then 
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refluxed at 75oC for two hours. The solvent was removed by using rotary evaporator to yield 
a colorless liquid. 
2) To the product, 2,2-dimethoxypropane (500 mL, 4.1 mol, 19 equiv.) and pyridinium p-
toluenesulfonate (3.8 g, 15.1 mmol, 0.07 equiv.) were added.51 The reaction mixture was 
refluxed at 80oC for two days. The solvent was removed by vacuum to yield dark-red oil. 
3) To the product, 400 mL anhydrous ethanol was added followed by the addition of finely 
ground sodium borohydride (47 g, 2.5 mol, 11.6 equiv.) at 0oC. The reaction mixture was 
warmed to RT over three hours and kept stirring ON.   The reaction was then quenched by 
adding 200 mL of saturated NH4Cl solution at 0oC. This mixture was kept stirring for three 
hours at RT and then concentrated in vacuum to remove most of the organic solvent and 
water. The crude mixture was azeotroped with benzene (3 X 50 mL). The residue was 
suspended with 300 mL ethyl acetate, filtered through a coarse fritted disc and washed with 
ethyl acetate (3 X 50 mL) to remove most of the borate side product. The organic extract was 
evaporated to yield reddish oil. 
4) Benzyl bromide (51.4 mL, 432 mmol, 2 equiv.) was added to the product then the mixture 
was further dissolved in 100 mL toluene. Silver oxide (75 g, 324 mmol, 1.5 equiv.) was 
added. 52 The reaction mixture was kept stirring at RT for twenty hours, filtered through a 
coarse fritted disc and washed with ethyl acetate (3 X 100 mL). The organic extract was 
concentrated and then purified on silica gel with hexane/ethyl acetate (7:1) then hexane/ethyl 
acetate (3:1) to yield light yellow oil (15.3 g, 61 mmol, 28 % over four steps). C14H20O4; 
TLC (Rf=0.3), hexane/ethyl acetate (3:1); 1H NMR (400 MHz, CDCl3) δ 7.29-7.22 (m, 5H), 
4.52 (s, 2H), 4.03-3.99 (m, 1H), 3.92-3.87 (m, 1H), 3.71-3.67 (dd, J=11.82, 3.88 Hz, 1H), 
3.63-3.58 (m, 2H), 3.55-3.51 (m, 1H), 2.63 (brs, 1H), 1.39 (s, 3H), 1.38 (s, 3H); 13C NMR 
143 
 
(101 MHz, CDCl3) δ 137.77, 128.40, 127.74, 127.67, 109.31, 79.44, 76.65, 73.52, 70.47, 
62.39, 27.02, 26.97. HRESIMS m/z [M+Na]+ cald. 275.1254, obsd. 275.1237 (err 6.11 ppm). 
 Figure 101. 13C of common intermediate for fragment 3 and 4. 
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 Figure 102.  1H of common intermediate for fragment 3 and 4. 
 
Fragment 3: C10-C17. 
6) TBSOTf, DIPEA, DCM, 0oC to RT, 1h
7) O3, PPh3, DCM, -78oC, 1 h
8) NaBH4, i-propanol, TBAI, EtOH, 0oC  to RT, ON
9) PPh3, PTSH, DEAD, THF, RT, ON
10) H2O2, AMT, acetone, RT, 48h, then 80oC, 12 h
O O
OBn
OTBSS
N
N N N
O O
4) DIBAL, DCM, -78oC, 3 h
5) Brown's Ipc reagent, allyMgBr, diethyl ether, -78oC to 0oC, 3 h
1) Oxalyl chloride, DMSO, DIEPA, DCM, -78oC to 0oC, 3 h
2) HWE reagent, NaH, THF, 0oC to RT, 3 h
3) Gilman reagent, TMSCl, THF, -78oC to 0oC, 3 h
O O
HO OBn 10
12
14
17
62
 
1) Oxalyl chloride (3.4 mL, 39.6 mmol, 2 equiv.) was dissolved in 100 mL anhydrous 
dichloromethane (DCM) under argon atmosphere and cooled to -78oC. Dimethyl sulfoxide 
(5.6 mL, 79.2 mmol, 4 equiv.) dissolved in 5 mL anhydrous DCM was added drop wise. The 
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reaction mixture was stirred for fifteen minutes before the addition of the fragment 3 and 4 
common intermediate (5.0 g, 19.8 mmol, 1 equiv.) dissolved in 5 mL anhydrous DCM. The 
reaction was allowed to run until white precipitate was observed.  The suspension was kept 
stirring for another fifteen minutes at -78oC. Then N,N-diisopropylethylamine (14 mL, 79.2 
mmol, 4 equiv.) was added drop wise, and the solution returned to its original colorless state. 
The reaction mixture was then warmed to -5oC over three hours and finally to RT.  It was 
then quenched and washed with brine (3 X 100 mL). The organic solvent was removed by 
using rotary evaporator to yield the crude aldehyde.  
2) To a round bottom flask, Horner–Wadsworth–Emmons reagent (4.4 g, 19.8 mmol, 1 equiv.) 
dissolved in 14 mL anhydrous THF was added to sodium hydride (60 % in mineral oil) (475 
mg, 19.8 mmol, 1 equiv.) at 0oC.  The reaction was kept stirring for 15 minutes. The crude 
aldehyde was azeotroped with benzene (3 X 10 mL) and added with 5 mL anhydrous THF to 
the reaction mixture. After stirring for 10 minute at 0 oC, thick viscous precipitate was 
observed, and the stirring was blocked. The reaction flask was then warmed to RT and 
sonicated for two hours. The solution was decanted into a round bottom flask and 
concentrated to yield a viscous oil.  The precipitate from the decantation was dissolved in 10 
mL water then extracted with hexane (3 X 10 mL). The hexane extractiona were combined 
and washed with brine (3 X 20 mL) and concentrated to yield the crude α,β-unsaturated 
ester.53 
3) To another round bottom flask, CuI (7.5 g, 39.6 mmol, 2 equiv.) was added to 20 mL 
anhydrous THF under argon atmosphere. Methyl lithium solution (3M in THF) (26.4 mL, 
79.2 mmol, 4 equiv.) was added to the CuI suspension at -10oC. After stirring at -10oC for 30 
minute, the colorless solution was cooled to -78oC.  Trimethylsilyl chloride (TMSCl) (7.5 
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mL, 59.4 mmol, 3 equiv.) was added to the reacted followed by the addition of the crude α,β-
unsaturated ester dissolved in 20 mL anhydrous THF. The reaction mixture was stirred at -
78oC for one hour and then warmed to 0oC for 30 minutes and kept stirring at 0oC for an 
additional 1.5 hour before quenching with 20 mL saturated NH4Cl solution and 20 mL 0.1M 
NH4OH. This mixture was stirred ON by which time the aqueous layer turned a bright blue 
color and the organic layer became light yellow. The aqueous layer was extracted with 
hexane (3 X 40 mL), and the hexane extraction was combined with the organic layer, washed 
with brine (3 X 40 mL), and then concentrated to yield a yellow oil.54 This mixture was 
loaded onto silica gel and eluted with hexane/ethyl acetate (5:1) to yield a colorless oil (5.1 g, 
15.0 mmol, 76 % over three steps).  
4) To a solution of the ester (5.6 g, 16.6 mmol, 1 equiv.) in 80 mL anhydrous DCM at -78oC, 
DIBAL reagent (1M in toluene) (50 mL, 50 mmol, 3 equiv.) was added drop wise under 
argon atmosphere. After stirring at -78oC for three hours, 17 mL methanol followed by 17 
mL saturated Rochelle salt solution was added. The reaction mixture was kept stirring for six 
hours until two clean layers appeared. The aqueous layer was extracted with hexane (3 X 30 
mL), and the hexane extraction was combined with the organic layer, and then concentrated 
to about 20 mL. The concentrated solution was washed with brine (3 X 20 mL), and then 
further concentrated until all organic solvent was removed to yield colorless oily crude 
aldehyde.55 
5) To a round bottom flask, (−)-B-methoxydiisopinocampheylborane (7.9g, 25 mmol, 1.5 
equiv.) was dissolved in 50 mL anhydrous diethyl ether, and then cooled to -78oC. 
Allylmagnesium bromide solution (1M in diethyl ether) (21.6 mL, 21.6 mmol, 1.3 equiv.) 
was then added drop wise under argon atmosphere. The reaction mixture was warmed to RT 
147 
 
over 30 minutes, and then stirred for 45 minutes before being cooled to -78oC again. The 
crude aldehyde dissolved in 10 mL diethyl ether was added at -78oC and kept stirring for one 
hour and then slowly warmed to 0oC. The reaction mixture was stirred at 0oC for one hour 
before careful addition of 30 mL H2O2 (30 wt%) and 30 mL 4M NaOH solution. After 
stirring at RT ON, the organic layer was separated, and the aqueous layer was extracted with 
ethyl acetate (3 X 60 mL).56 The ethyl acetate extraction was combined with the organic 
layer and concentrated to about 40 mL, then washed with brine (3 X 40 mL). The organic 
solvent was evaporated to yield oily crude product which was then mixed with silica gel and 
loaded on a silica column and eluted with hexane/ethyl acetate (8:1) then hexane/ethyl 
acetate (5:1) to yield colorless oil (3.1 g, 9.2 mmol, 55 % over two steps). TLC (Rf=0.3), 
hexane/ethyl acetate (5:1). 
6) To a solution of the alcohol (3.1 g, 9.2 mmol) in 10 mL anhydrous DCM, N,N-
diisopropylethylamine (4.8 mL, 27.5 mmol, 3 equiv.) was added. The solution was cooled to 
0oC before slowly adding freshly prepared TBSOTf (2.4 mL, 13.7 mmol, 1.5 equiv.). The 
reaction mixture was stirred at 0 oC for 30 min and RT for another 30 min, and then diluted 
with 10 mL DCM and washed with brine (3 X 20 mL). The organic layer was concentrated 
and then azeotroped with benzene (3 X 10 mL) to yield crude silylether.    
7) The silylether was then dissolved in 150 mL DCM and cooled to -78oC. An ozone stream 
was bubbled through until the color of the solution turned light blue (approximately 60 
minutes on this scale), and this color was maintained for 15 min without fading after the 
ozone was removed. Then, an argon stream was bubbled through until the solution turned 
colorless (approximately 15 min). Next, 1.5 mL dimethylsulfide was added to consume the 
rest of the dissolved ozone. Triphenylphosphine (3.1 g, 11.9 mmol, 1.3 equiv.) was added, 
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and the reaction mixture was kept stirring at -78oC for 20 min.  Then, the reaction was slowly 
warmed to RT.47  
8) The reaction mixture was then cooled to 0oC followed by the addition of 20 mL isopropanol, 
TBAI (168 mg, 0.46 mmol, 0.05 equiv.), and finely ground NaBH4 (2.9 g, 91 mmol, 10 
equiv.), in sequence.48 The reaction was slowly warmed to RT and stirred ON before 
quenching with saturated NH4Cl (50 mL) and then saturated Rochelle salt solution (50 mL). 
After stirring for six hours at RT, the organic layer was separated and washed with brine (3 X 
100 mL), and the aqueous layer was extracted with ethyl acetate (3 X 50 mL). The ethyl 
acetate extraction was combined with the organic layer and concentrated to yield light yellow 
crude alcohol which was then azeotroped with benzene (3 X 10 mL).  
9) To a reaction round bottom flask, triphenylphosphine (3.6 g, 13.7 mmol, 1.5 equiv.) was 
dissolved in 30 mL anhydrous THF followed by adding DEAD (40% in toluene) (6.2 mL, 
13.7 mmol, 1.5 equiv.) drop wise at 0oC under argon. The mixture was stirred for 15 min 
before adding PTSH (2.5 g, 13.7 mmol, 1.5 equiv.). The crude alcohol was then dissolved in 
10 mL anhydrous THF and added to the reaction mixture at 0oC. The reaction mixture was 
slowly warmed to RT and allowed to stir ON.49  
10) The solvent was removed and the thioether was dissolved in 20 mL acetone. H2O2 (50 wt. % 
in H2O) (20 mL, 295 mmol, 32 equiv.) was added to AMT (9.1 g)  in a 100 mL beaker to 
yield a yellow solution which was then added in to the acetone solution at 0oC.50 The reaction 
mixture was slowly warmed to RT and stirred for 48 hours, then refluxed at 80oC for 12 
hours. The acetone was then removed and the residue was partitioned between water and 
ethyl acetate. The organic layer was separated, and the aqueous layer was extracted with 
ethyl acetate (3 X 50 mL), and the extract was combined with the organic layer, 
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concentrated, and washed with brine (3 X 50 mL). The combined organic solution was 
concentrated to viscous oil, loaded on a silica gel column and eluted with hexane/ethyl 
acetate (8:1) to yield light yellow viscous oil (2.1 g, 3.3 mmol, 36 % over five steps). 
C32H48N4O6SSi; TLC (Rf=0.3), hexane/ethyl acetate (8:1); 1H NMR (400 MHz, CDCl3) δ 
7.70-7.59 (m, 5H), 7.35-7.27 (m, 5H), 4.60 (s, 2H), 4.10-4.03 (m, 1H), 4.01-3.96 (m, 1H), 
3.85-3.75 (quint., J=5.07 Hz, 2H), 3.66-3.51 (m, 3H), 2.25-2.13 (m, 1H), 2.12-1.98 (m, 1H), 
1.87-1.74 (m, 2H), 1.40 (s, 6H), 1.27-1.15 (m, 1H), 0.95-0.86 (m, 12H), 0.09 (s, 3H), 0.06 (s, 
3H). 13C NMR (101 MHz, CDCl3) δ 153.47, 138.01, 133.05, 131.43, 129.70, 128.37, 127.70, 
127.67, 125.04, 108.88, 82.41, 78.92, 73.46, 71.52, 67.57, 52.15, 40.14, 32.82, 30.89, 29.56, 
27.25, 27.12, 25.81, 17.96, 16.39, -4.40, -4.59. HRESIMS m/z [M+Na]+ cald. 667.2956, 
obsd. 667.2965 (err -1.34 ppm). 
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 Figure 103.  13C of fragment 3. 
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 Figure 104. 1H of fragment 3. 
 
 
Fragment 5: C24-35 
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1) O3, Me2S, Ph3P, 4:1 DCM:MeOH -78oC to RT, 1.5 h
2) Ph3P=CHCO2Et, benzene, 6 h, RT
3) TBSCl, imidazole, DMF 0oC to RT,  3 h
4) DIBAL, DCM, -78oC, 3 h
5) Dess-Martin periodinane, pyridine, DCM, 0oC to RT, ON
6) Ph3P=CHCO2Et, benzene, 6 h, RT
7) AD-mix b, CH3SO2NH2, 1:1 Butanol: H2O, RT, 5 d
8) TBMSOTf, 2,6 lutidine, DCM, RT, ON
 
1) Common intermediate for fragments 5 and 6 (1.2 g, 2.5 mmol) (obtained from Dr. Takashi 
Tomioka) was dissolved in 36 mL of DCM and 9 mL of anhydrous MeOH and cooled to -
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78oC. An ozone stream was bubbled through until the color of the solution turned light blue 
(approximately 3 minutes on this scale), and this color was maintained for 15 min without 
fading after the ozone was removed. Then, an argon stream was bubbled through until the 
solution turned colorless (approximately 15 min). Next, 1.0 mL dimethylsulfide was added to 
consume the rest of the dissolved ozone. Triphenylphosphine (653 mg, 2.49 mmol) was 
added, and the reaction mixture was warmed to RT over 1.5 hr and then concentrated to 
remove the solvent.47 
2) The product was dissolved in anhydrous benzene (10 mL) and treated with Ph3P=CHCO2Et 
(1.07 mg, 3.07 mmol) and stirred for 6 h at RT.  The reaction mixture was concentrated and 
loaded onto silica gel and eluted with hexane/ethyl acetate (3:1) to give a colorless oil. 
3) The product was then dissolved in anhydrous dimethylformamide (DMF) (5 mL), cooled to 
0oC, and imidazole (511 mg, 7.5 mmol, 3 equiv.) and TBSCl (565.2 mg, 3.75 mmol, 1.5 
equiv.) were added.  The solution was allowed to warm to RT and stir for 3 h.  H2O was then 
added to quench the reaction.  The reaction mixture was diluted with ethyl acetate and 
partitioned with H2O and washed with aq. NH4Cl and brine.  The organic layer was 
concentrated, loaded onto a silica gel column and eluted with hexane/ethyl acetate (9:1) to 
yield a light yellow oil (755 mg, 1.1 mmol, 55% yield over 3 steps).  TLC (Rf=0.5), 
hexane/ethyl acetate (8:2). 
4) The purified ester was dissolved in anhydrous DCM (5.5 mL) and cooled to -78oC.  DIBAL 
reagent (1M in toluene) (3.3 mL, 3.3 mmol, 3 equiv.) was added drop wise under argon 
atmosphere. After stirring at -78oC for three hours, 17 mL methanol followed by 17 mL 
saturated Rochelle salt solution was added. The reaction mixture was kept stirring for six 
hours until two clean layers appeared. The aqueous layer was extracted with hexane (3 X 30 
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mL), and the hexane extraction was combined with the organic layer, and then concentrated 
to about 20 mL. The concentrated solution was washed with brine (3 X 20 mL), and then 
further concentrated until all organic solvent was removed to yield light yellow oily crude 
alcohol.55 
5) The crude alcohol was dissolved in anhydrous DCM (11 mL) and cooled to 0oC.  To the 
reaction vessel, pyridine (500 µL) and Dess-Martin periodinane (697 mg, 1.5 mmol 1.5 eq) 
was added and allowed to stir and warm to RT ON.  The reaction mixture was then filtered 
through a coarse fritted disc and washed with DCM (3 X 30 mL). The filtration was 
combined, and the organic solvent was removed by using rotary evaporator.57 
6) The crude aldehyde was dissolved in anhydrous benzene (5 mL) and treated with 
Ph3P=CHCO2Et (4.73 mg, 3.07 mmol) and stirred for 6 h at RT.  The reaction mixture was 
concentrated and loaded onto silica gel and eluted with hexane/ethyl acetate (9:1) to give a 
light yellow oil (589 mg over 3 steps, 75% yield). TLC (RF=0.4), hexane/ethyl acetate (9:1). 
7) The purified α,β-unsaturated ester was dissolved in a 1:1 solution of tert-butanol and water (5 
mL).  To the solution, 828.8 mg of AD-mix β and CH3SO2NH2 (56 mg, 1 equiv.) were 
added.  The reaction was allowed to stir at RT for 5 days.  Then the reaction was quenched 
with Na2SO3 and extracted with ethyl acetate.  The organic layers were combined and 
concentrated.58  The crude product was loaded onto silica gel and eluted with a step gradient 
starting with 100% hexane, 75% hexane: 25% ethyl acetate, 50% hexane: 50% ethyl acetate, 
25% hexane: 75% ethyl acetate and finally 100% ethyl acetate.  The product eluted in the 
50% hexane fraction and yielded a light yellow oil (155 mg, 0.21 mmol, 25% yield).  TLC 
(RF=0.1), hexane: ethyl acetate (9:1).    
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8) The purified diol (25 mg 0.034 mmol) was dissolved in anhydrous DCM (300 µL) and 2,6 
lutidine (17 µL, 5 equiv.) and TBDMSOTf (26 µL, 5 equiv.).  The reaction mixture was 
allowed to stir at RT ON.  Next it was quenched with H2O and partitioned with brine and 
ethyl acetate.59  The organic layer was concentrated and loaded onto silica gel and eluted 
with a step gradient with 100% hexane, 75% hexane: 25% ethyl acetate, 50% hexane: 50% 
ethyl acetate, 25% hexane: 75% ethyl acetate and finally 100% ethyl acetate.  The product 
eluted in the 75% hexane fraction and yielded a light yellow oil (33 mg, 0.034 mmol, 
quantitative yield).  C51H88O9Si4; TLC (RF=0.6), hexane: ethyl acetate (9:1). 1H NMR (400 
MHz, CDCl3) δ 7.76-7.67 (m, 4H), 7.43-7.33 (m, 6H), 7.13 (dd, J=3.29, 15.8 Hz, 1H), 6.06 
(dd, J=2.25, 15.3 Hz, 1H), 4.37-3.76 (m, 9H), 3.36 (q, J=3.3 Hz, 2H), 2.14 (dd, 7.1, 13.8 Hz, 
2H) 1.33 (m, 3H), 1.09 (s, 6H), 0.96-0.79 (m, 27H), 0.16- -0.05 (m, 18H). 13C NMR (101 
MHz, CDCl3) δ 166.46, 147.37, 136.00, 135.76, 133.93, 133.48, 129.41, 127.47, 127.42, 
121.43, 108.68, 78.67, 77.14, 73.72, 72.42, 70.52, 69.46, 68.69, 63.71, 60.30, 31.81, 28.14, 
28.10, 26.96, 25.88, 25.83, 25.77, 19.44, 17.98, 17.84, 14.24, -3.98, -4.02, -4.47, -4.67, -4.90, 
-5.22. HRESIMS m/z [M+Na]+ cald. 979.5398, obsd. 979.5401 (err -0.35 ppm). 
155 
 
 Figure 105.  DEPTQ of fragment 5. 
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 Figure 106.  1H of fragment 5. 
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PART II: EXPLORATION OF MICROBIAL DERIVED NATURAL PRODUCTS 
 
CHAPTER 3 
Isolation, Structure Determination, and Biological Activity of Antifungal Lactone Lipids and 
Other Secondary Metabolites from Sooty Mold (Scorias spongiosa) 
 
CHAPTER 4 
Exploration of Marine Associated Secondary Metabolite Production Using MALDI-MS imaging 
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Microorganisms produce some of the most structurally diverse and novel biologically 
active secondary metabolites identified to date.  They include antibacterial agents (penicillins, 
cephalosporins, aminoglycosides, tetracyclines, etc.), immunosuppressive agents (cyclosporins 
and rapamycin), cholesterol lowering agents (mevastatin and lovastatin), antifungal agents 
(caspofungin), anti-cancer agents (members of the anthracycline family, bleomycin, mitomycin, 
members of the enediynes and staurosporines) and anthelmintics and antiparasitic agents 
(ivermectins).  A 2013 review by Cragg and Newman states that with an estimated less than 1% 
of all microorganism having been cultivated “the microbial universe clearly presents a vast 
untapped resource for drug discovery.”60 In this section, a traditional isolation and elucidation 
project involving a specific tree-insect-fungal relationship is presented.  In addition, MALDI-MS 
imaging was used to verify microbial production sources for marine secondary metabolites 
previously found in sponges thus providing a more environmentally friendly and sustainable 
source for these medicinally relevant natural products.  
Imaging mass spectrometry with the combined advantage of high sensitivity, chemical 
specificity and parallel detection of mass spectrometry with microscopic imaging capabilities has 
emerged as a powerful tool for the investigation of the spatial distribution of intact biomolecules, 
natural products and drugs in biologic systems.61 Most imaging mass spectrometry experiments 
now use secondary ion mass spectrometry (SIMS) and MALDI.62 MALDI is a soft ionization 
technique developed for the analysis of large biomolecules such as proteins and peptides, which 
tend to be fragile and fragment when ionized by more conventional ionization methods. The 
ionization is facilitated by a laser beam and a matrix which assists vaporization and ionization of 
biomolecules and to protect the biomolecule from being destroyed by the direct laser beam.  Since 
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the success of MALDI in ionization of proteins, it has gained significant popularity to detect the 
spatial distribution of high mass biomolecules in tissues.63  
The emergence of MALDI MS  imaging allows for the first time the determination of the 
localization of intact alkaloids, peptides and proteins directly from tissue sections,64 which has a 
major impact on the study of molecular biology and biochemistry.  MALDI MS has recently been 
applied to image small molecule drugs and drug metabolites in tissue, treated cell lines and the 
entire animal.65 This technology provides unambiguous localization information for several small 
molecules simultaneously.66  Of greatest interest to this project, is the utility of this tool in the 
characterization and distribution of natural products from their biosynthetic source or producing 
organism such as bacteria, fungi and hopefully one day dinoflagellates.  The overall goal of this 
research was to isolate and elucidate biologically active compounds from microbial sources and 
explore the production of known microbial products utilizing MALDI-MS imaging. 
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CHAPTER 3: ISOLATION, STRUCTURE DETERMINATION, AND BIOLOGICAL 
ACTIVITY OF ANTIFUNGAL LACTONE LIPIDS AND OTHER SECONDARY 
METABOLITES FROM SOOTY MOLD (SCORIAS SPONGIOSA)
Robert W. Schumacher,†,1 Amanda L. Waters,§,1 Richard A. Schumacher,† Ailish Bateman,† Josie 
Thiele,† Arthur Goldberg,‡ Yike Zou,§ Jiangnan Peng,§,Δ Yuen-Mun Choo,§ and Mark T. Hamann§  
†Department of Science, Pierson High School, Sag Harbor, NY 11963, USA. ‡Department of 
Chemistry, Long Island University, Brookville, NY 11548. §Department of Pharmacognosy, 
Chemistry and Biochemistry, and National Center for Natural Products Research, University of 
Mississippi, MS 38677, USA.  1These authors contributed equally to the work. 
 
Microorganisms, such as fungi, are a proven source of structurally diverse metabolites 
possessing a wide array of biological activity.67 As part of an effort focused on screening for 
biologically active natural products, the secondary metabolites produced by Scorias spongiosa 
have been explored. This is a type of sooty mold in the phylum Ascomycota, one of four major 
phyla of fungi. Species from this phylum have produced a diverse array of biologically active 
secondary metabolites.68 We now report the isolation and structure elucidation of scoriosin (11) a 
new biologically active lactone lipid, as well as the methyl ester (12) along with a known 
compound previously isolated from Aspergillus sp. (figure 107). 
The methanol extract of Scorias spongiosa displayed antimicrobial and antifungal 
activity in disc-diffusion assays. Bioassay-guided fractionation of the crude extract using normal 
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phase flash chromatography, followed by reverse phase HPLC resulted in the isolation of several 
new compounds. Compound 11 was assigned the molecular formula of C23H34O6 (7 DBE) on the 
basis of the HRESIMS data (m/z 405.2277). The ESI-MS spectrum of 11 also displayed a strong 
[M-1] signal at m/z 405.  These data coupled with IR resonances at 3079 (broad) and 1699 
(strong) cm-1 suggested the presence of a carboxylic acid functional group. 
 Figure 107.  Compounds isolated from Scorias spongiosa. 
 
The IR spectra also displayed strong signals at 1757 and 1699 cm-1 supporting the 
presence of multiple carbonyl groups.  Resonances in the UV spectra at 215 and 320 nm 
supported the presence of a conjugated carbonyl system. 
The 13C NMR data and DEPT analysis indicated the presence of 23 carbon signals, 
including 2 methyl groups, 12 methylenes, 3 methines, and 6 quaternary carbons. The carbon 
resonance at δ 174.5 was attributed to the carboxylic function in agreement with the mass-
spectrometry and IR data.  Signals were also assigned to an ester (δ 170.4) and an α,β-
unsaturated ketone (δ 196.4) which was also consistent with the IR spectral data. Other low field 
signals included a 1,2-disubstituted olefin unit (δ 123.4 and 160.8), and three quaternary carbons 
(δ 179.7, 102.8, and 93.8).  These assignments accounted for four of the seven degrees of 
unsaturation in compound 11. 
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The 1H NMR data of 11 included signals assignable to two olefin doublets at δ 7.45 (J = 
5 Hz) and 7.48 (J = 5 Hz); a heterosubstituted methine at δ 4.87 (dd, J = 7, 3 Hz), a diasterotopic 
methylene at δ 2.98 (dd, J = 17, 3 Hz) and 2.73 (dd, J = 17, 7 Hz), a methyl singlet at δ 1.56, a 
methyl triplet at δ 0.81.   The broad signal at δ 1.18, which integrated for 20 protons, was 
characteristic of a straight chain alkyl unit. 
Analysis of the COSY data allowed the construction of three partial structures 
corresponding to C4, C5, C2’, C3’ and C5’-C16’.  Analysis of the HMBC data generated two 
partial structures (figure 108).  Two- and three-bond HMBC correlations from H4 to C1, C3, C5 
and C6 and from H5 to C3, C6 and C4 afforded one partial structure. The alkane chain was 
linked with the diene subunit by analysis of three- and two- bond HMBC correlations from Me-
17’ to C3’ and C5’, H2’ and H3’ to C4’.  However, these two subunits could not be connected 
due to a lack of sufficient HMBC correlations to unambiguously place C(1’) and C(2).  The 
connectivity of these subunits and placement of C1’ and C2 was accomplished by comparison of 
11 with lowdenic acid (14).  The structure of 14, which had the same absence of correlations, 
was elucidated using X-ray crystallography.69  
 Figure 108.  Key HMBC correlations of 11. 
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Compound 12 was structurally similar to 11 with the exception of an additional singlet at 
3.64 ppm in the proton spectra and the addition of 1 carbon at 52.14 ppm.  This was an indication 
of the presence of a methyl ester in place of the carboxylic acid functionality.   
The X-ray diffraction data for 14 only allowed for the relative configuration to be 
assigned.  For 12, GIAO shielding chemical shift analysis was performed40 using Macromodel 
(Version 9.9, Schrodinger LLC) to perform the conformational searches and Gaussian 09 
package to calculate the chemical shift values.  The data for the 2 diastereomers were then 
submitted to DP4 probability analysis to determine the correct relative configuration of C-4 and 
C-4’.  The results showed that there was a 97.7% probability when both the proton and the 
carbon data were taken into account that the relative configuration was opposite for the 2 
stereogenic centers (figure 109).   
 Figure 109. DP4 analysis to determine relative configuration of C-4 and C-4’. 
 
To determine the absolute configuration of the molecules, the ECD spectrum was 
measured and based on comparison with calculated ECD data position 4’ possess (R) absolute 
configuration.  This with the DP4 calculations indicated that the absolute configuration of the 
molecule is 4S,4’R (figure 110). This absolute configuration agrees with the absolute 
configuration of pestalotic acid which was assigned in 2012 using a similar CD approach and 
crystallography techniques which established the relative configuration.70   
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 Figure 110.  Experimental vs computational CD data for 12. 
 
The structure of 11 was highly conjugated with the presence of multiple carbonyl and 
double bond functionalities.  Such a compound has the potential to undergo intramolecular 
tautomerization to give isomers that vary in selected configuration. In the present study, it was 
observed that 11 did undergo tautomerization, which was reflected by changes in the NMR 
spectrum. The NMR spectrum of 11 indicated the presence of a set of minor signals when 
recorded after a period of time. Re-purification of the sample on silica gel gave pure 11 with 
distinctive NMR spectrum initially. However, similar set of minor of NMR signals emerged 
when the sample was analyzed again. The possible tautomerization pathway of 11 is shown in 
figure 111.  This chapter deals with the structure determination of only one isomer, compound 
165 
 
11.  Chemical shifts for 11 were assigned as the Z configuration based on comparison to 
lowdenic acid.69 
 
Figure 111.  Tautomerization pathway of 11. 
 
Scoriosin and its methyl ester displayed significant antifungal activity with IC50 values of 
0.37 and 0.63 µg/mL against Cryptococcus neoformans, respectively (table 8).  These values are 
readily comparable to the control drug amphotericin B which has an IC50 value of 0.35 µg/mL.   
It also displayed antibacterial activity using a disc-diffusion assay (table 9).   
 
Table 8.  Antifungal and antibacterial activity of compounds 11-13. 
IC50* (µg/ml) 
MIC** (µg/ml) 
MFC/MBC*** 
(µg/ml) 
C. 
albicans 
C. 
glabrata 
C. 
krusei 
C. neo 
formans
S. 
aureus MRSA 
E. 
coli 
Scoriosin (11) 
15.29 
NT 
NT 
2.85 
10.00 
10.00 
6.31 
10.00 
10.00 
0.37 
0.63 
0.63 
0.44 
1.25 
20.00 
0.39 
0.63 
10.00 
NA 
Scoriosin Methyl 
Ester (12) NA NA 
20.00 
NT 
NT 
0.63 
1.25 
1.25 
1.08 
2.50 
10.00 
0.71 
1.25 
5.00 
NA 
Methyl Asterrate 
(13) NA NA NA NA NA NA NA 
Amphotericin B 
0.14 
0.63 
1.25 
0.21 
0.63 
0.63 
0.74 
1.25 
1.25 
0.35 
0.63 
0.63 
----- ----- ----- 
Ciprofloxacin ----- ----- ----- ----- 
0.13 
0.50 
0.50 
0.12 
0.50 
0.50 
0.01 
0.03 
0.13 
*The concentration that affords 50% inhibition of growth. **Minimum Inhibitory Concentration 
is the lowest test concentration that allows no detectable growth. ***Minimum Fungicidal/ 
Bactericidal Concentration is the lowest test concentration that kills the organism. NT=Not 
Tested; NA= Not Active 
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Table 9.  Antimicrobial activity of compound 11. 
Test Organism Zone of Inhibitiona 
B. megaterium 23 mm 
B. subtilis 22 mm 
M. luteus 21 mm 
E. coli 0 mm 
aZones of inhibition at 0.5 mg per disc of compound 11. 
 
Scoriosin is a member of a rare class of antifungal agents, which contain a furylidene ring 
joined to a tetrahydrofurandione by a carbon-carbon double bond.  There are only three other 
natural products which contain this functionality.  Italicic acid, isolated from Penicillium italicum 
in 1989, has no reported biological activity.71  Nodulisporacid A,72 isolated from a marine derived 
fungus Nodulisporium sp., shows cytotoxicity and moderate antiplasmoidial activity.73 Pestalotic 
acids were isolated from a plant endophyte Pestalotiopsis yunnanensis.70  The closest analogue 
to scoriosin and its derivatives is lowdenic acid69 which was isolated from a terrestrial fungus 
Verticillium sp. and possesses antifungal and Gram-positive antibacterial activity.  
The biological activity of scoriosin was postulated to be due to the capability of the ring 
system to form six-membered ring chelates,74 and the long lipophilic side chain in the molecule. 
This structural feature is present in lowdenic acid which displays slight antifungal activity and 
pestalotic acids70 which showed antimicrobial activity against Staphlococcus aureus and 
Streptococcus pneumonia.  As mentioned above, italicic acid,71 nodulisporacid,72 and carolic 
acid,75 are the only other compounds containing this or the unsaturated form of this ring system 
as in the case of carolic acid.  None of these compounds contain a long lipophilic side chain; 
italicic acid71 has a four-carbon side chain, nodulisporacid has a five-carbon chain, and carolic 
acid75 lacks a side chain.  However, no activity has been reported for these compounds. 
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Methyl asterrate (13) was isolated from same sooty mold extract as the scoriosin 
molecules. This molecule has been previously isolated in many fungal samples including 
endophytic and leaf litter derived fungi.76 It has shown a wide array of weak activity including 
anti-bacterial, vascular endothelial growth factor (VEGF)-induced tube formation,77 and 
antinematodal.76a   
The elucidation of scoriosin from sooty mold gives us a unique look into the ecological 
relationship of this symbiotic fungus.  The potent antifungal properties of this compound have 
significance for the development of novel antifungal for the treatment of C. neoformans 
infections with far reaching implications for the immunocompromised community. 
 
EXPERIMENTAL SECTION 
General Experimental Procedures 
IR spectra were obtained using a Perkin-Elmer 1600 FT-IR spectrometer.  The UV 
spectrum was obtained using a Hewlett Packard 8452A diode array spectrometer. 1H, 13C NMR, 
HSQC, and HMBC were recorded on a Bruker Avance DRX 400 spectrometer at 400 and 100 
MHz, respectively. ESIMS and HRESIMS were obtained on a Bruker MicroTof mass 
spectrometer. The experimental CD data was collected on an OLIS DSM-20 Circular Dichroism 
Spectrometer using ACN with varying concentrations as stated.  The Calculated CD data was 
obtained using Gaussian 09 with a calculation method in ground-state geometric optimization of 
DFT at 6-31g** and the ECD simulation was completed using TDDFT at 6-31g**.  Optical 
Rotation was determined using an Autopol V polarimeter (Rudolph, Flanders, NJ, USA) with a 
sample tube 0.5 mL of path length 25 mm. 
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Collection of Sample 
Samples of sooty mold were collected in East Hampton during October 2003, and 
identified by the Cornell Plant Disease Diagnostic Clinic, Cornell University, Ithaca, NY as 
Scorias spongiosa. The sooty mold was found growing on Fagus sylvaticus, commonly known 
as beech trees. 
Extraction and Purification 
A 456 gram sample of S. spongiosa was covered in methanol for 24 h and the resulting 
extract filtered to remove insoluble debris. Bioassay guided fractionation using normal phase 
column chromatography (SiO2; methylene chloride/methanol) resulted in the isolation of 25 
grams of a mixture of scoriosin-like compounds. A small amount of this mixture was subjected 
to RP HPLC (Alltech C18 5u; 10 mm x 250 mm; flow rate, 2 mL/min; 100% CH3CN over 20 
min) affording compounds 11, 12, and 13.   
Antimicrobial Assay 
All organisms were obtained from the American Type Culture Collection (Manassas, 
VA) and include the fungi Candida albicans ATCC 90028, C. glabrata ATCC 90030, C. krusei 
ATCC 6258, and Cryptococcus neoformans ATCC 90113 and the bacteria Staphylococcus 
aureus ATCC 29213, methicillin-resistant S. aureus ATCC 33591 (MRS), and Escherichia coli 
ATCC 35218. All organisms were tested using modified versions of the CLSI (formerly 
NCCLS) methods. For all organisms, optical density was used to monitor growth.78  Samples 
(dissolved in DMSO) were serially diluted in 20% DMSO/saline and transferred (10 μL) in 
duplicate to 96 well flat bottom microplates. Inocula were prepared by correcting the OD630 of 
microbe suspensions in incubation broth [RPMI 1640/0.2% dextrose/0.03% glutamine/MOPS at 
pH 6.0 (Cellgro) for Candida spp., Sabouraud Dextrose for C. neoformans, cation-adjusted 
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Mueller-Hinton (Difco) at pH 7.3 for Staphylococcus spp. and E. coli] to afford an assay volume 
of 200 μL and final target inocula of: Candida spp. and C. neoformans.: 1.5 X 103, 
Staphylococcus spp. and E. coli: 5.0 X 105 CFU/mL.  Final sample test concentrations were 
1/100th the DMSO stock concentration. Drug controls [Ciprofloxacin (ICN Biomedicals, Ohio) 
for bacteria and Amphotericin B (ICN Biomedicals, Ohio) for fungi] were included in each 
assay. All organisms are read at either 530 nm using the Biotek Powerwave XS plate reader 
(Bio-Tek Instruments, Vermont) prior to and after incubation: Candida spp. at 35°C for 46-50 h, 
Staphylococcus spp. and E. coli at 35°C for 16-20 h, and C. neoformans at 35°C for 70-74 h. IC50 
values (concentrations that afford 50% inhibition relative to controls) were calculated using 
XLfit 4.2 software (IDBS, Alameda, CA) using fit model 201. The MIC was defined as the 
lowest test concentration that allows no detectable growth. Minimum fungicidal or bactericidal 
concentrations were determined by removing 5 µL from each clear well, transferring to fresh 
media and incubating as previously mentioned. The MFC/MBC was defined as the lowest test 
concentration that kills the organism. 
Computational Calculations 
The calculation procedures were referenced in previous studies.30a, 40 All conformational 
searches were conducted employing Macromodel (Version 9.9, Schrodinger LLC.) program with 
“Mixed torsional/Low Mode sampling” in MMFF force field. The searches were performed in 
the gas phase with a 50 kJ/mol energy window limit and 10,000 maximum number of steps to 
fully explore all low-energy conformers. All minimization processes were carried out utilizing 
Polak-Ribiere Conjugate Gradient (PRCG) method, 10,000 maximum iterations and a 0.001 
convergence threshold. The RS configuration was produced as the mirror image of the SR 
configuration results. 
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The GIAO shielding constants of all conformers within 10 kJ/mol of the global minimum 
were calculated utilizing Gaussian 09 package (Gaussian Inc.) at the B3LYP/6-31G(d,p) level in 
the gas phase. The CS values were calculated according to the equations described in previous 
studies.30a, 40 The calculation of DP4 probability was facilitated using an applet available at 
“http://www-jmg.ch.cam.ac.uk/tools/nmr/DP4/”. The predicted CS values of diastereotopic 
protons were compared with the closet experimental values of those protons unless sufficient 
NMR information was available for the assignment of each proton. 
Spectral Data 
Compound 11 was obtained as a white amorphous solid; [α]26D -20 (c 0.02, CHCl3); IR 
(dry film) 3450, 3079, 1757, 1699, and 1589 cm-1. 1H and 13C NMR data, see table 10. ESIMS 
m/z 405 [M-H]- and 437 [M-H]+ MeOH; HRESIMS m/z 405.2297 (calculated for [C23H34O6 – 
H]-, 405.2277).   UV (95% ethanol), 215 and 325 nm. 
Compound 12 was obtained as a yellowish white amorphous solid; [α]26D -32 (c 0.02, 
CHCl3);  1H and 13C NMR data, see table 11 and figure 110-114. ESIMS m/z 421 [M+H]+ and 863 
[2M+Na]+.  HRESIMS m/z 421.2150 (calculated for [C24H36O6 + H]+, 421.2590). UV (95% 
ethanol), 263 and 325 nm.  
Compound 13 was obtained as a white amorphous solid; 1H, 13C NMR and MS data are in 
agreement with published literature values.76a 
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Table 10. 1H and 13C NMR spectra data of 11 and 12. 
Carbon 
11 
δc  
(ppm) 
12 
δc  
(ppm) 
11 
δh (ppm) 
(Mult., J in Hz) 
12 
δh (ppm) 
(Mult., J in Hz) 
1 
2 
3 
4 
5 
 
6 
7 
1’ 
2’ 
3’ 
4’ 
5’ 
6’ 
7’-13’ 
14’ 
15’ 
16’ 
17’ 
167.9 
93.3 
196.4 
78.6 
36.1 
 
173.9 
---- 
180.3 
123.0 
160.8 
102.1 
37.9 
24.0 
29.5 
31.9 
22.6 
14.1 
23.2 
169.72 
93.67 
196.36 
78.71 
36.04 
 
170.15 
52.13 
179.98 
123.18 
160.33 
102.40 
38.02 
24.04 
29.5 
31.88 
22.66 
14.11 
23.32 
----- 
----- 
----- 
4.87  (dd, 7, 3) 
2.98  (dd, 17, 3) 
2.73  (dd, 17, 7) 
----- 
----- 
----- 
7.45 (d, 5) 
7.48 (d, 5) 
----- 
1.91 (m) 
1.18 (m) 
1.18 (m) 
1.18 (m) 
1.18 (m) 
0.81 (t, 6) 
1.56 (s) 
----- 
----- 
----- 
4.83  (dd, 8,4) 
2.95  (dd, 17, 4) 
2.77  (dd, 17, 7) 
----- 
3.66(s) 
----- 
7.49 (d, 6) 
7.42 (d, 6) 
----- 
1.92 (m) 
1.19 (m) 
1.19 (m) 
1.19 (m) 
1.19 (m) 
0.82 (t, 6) 
1.57 (s) 
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 Figure 112. 1H of 12. 
 
 Figure 113. 13C of 12. 
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Figure 114.  HSQC of 12. 
 
Figure 115. HMBC of 12. 
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Figure 116. COSY of 12. 
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INTRODUCTION 
Over 60% of approved pharmaceuticals are either natural products, derived from natural 
products via semi-synthesis and synthesis, or modeled after natural product prototypes.60, 79  
Natural products have been a vital source for the development of therapeutics dating back to 
2600 BCE in Mesopotamia. The progression of natural products discovery started with plants in 
earliest recorded history, followed by microbial sources in the early 20th century with the 
discovery of antibiotics, and finally the marine environments in the 1970’s with the development 
of underwater diving techniques.60  Marine invertebrates have introduced a wealth of complex 
secondary metabolites as potential drug leads; however, the sustainable supply of these marine 
invertebrate metabolites for development and clinical use remains a challenge.  With the 
development of metagenomics techniques it is possible to assess large amounts of genetic 
information directly from environmental samples and natural products drug discovery has moved 
toward a new frontier in discovery and development. Mining the genetic information associated 
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with the microbiome of macroorganisms has provided unique opportunities to interrogate the 
role of the host’s microbial community in the production of secondary metabolites.80   
Although the oceans represent the largest biosphere on Earth and contain extraordinary 
biological and chemical diversity for the discovery of drug leads, the majority of the potential 
drug-producing groups of marine organisms come from extremely delicate ecosystems that are 
vulnerable to over-harvesting, pollution and climate change.81  Presented here is a minimally 
invasive technique for sustainable natural products exploration involving a phylogenetic analysis 
of the entire microbiome followed by culture approaches to interrogate the most likely drug-
producing organisms.  The approach presented here illustrates the use of exploration of the 
phylogeny of the microbiome leading to the rational selection of culture approaches including a 
focus on biomimetic approaches to yield the biosynthesis and production of the active 
metabolites.  This approach offers opportunities to address both the discovery of unique 
metabolites from silent genes as well as supply from rare and fragile natural product producing 
groups and in both cases is minimally invasive.   
Marine invertebrates, in particular, are composed of diverse microbiomes that are 
challenging to characterize and culture because of their unique relationships developed between 
the host and the environment.16a, 82 Most of these invertebrates have co-evolved with microbial 
assemblages that have become highly specialized and, in many cases, obligate hence the need for 
community analysis and biomimetics to achieve successful microbial cultivation and metabolite 
production.83  The isolation of the same groups of natural products from both macroorganisms 
and microorganisms has led to the hypothesis that the true producers are the microorganisms 
associated with the invertebrates; however, it has been difficult to identify a producing 
microorganism that is truly responsible for the biosynthesis of these complex secondary 
178 
 
metabolites found in the invertebrate.84 Sponges have been equated to natural microbial 
fermenters of the ocean and represent a unique opportunity for mining sustainable microbial 
sources for marine natural products.85  Exploring these unique environmental conditions gives us 
yet another piece of the puzzle to develop efficient biomimetic conditions for the cultivation of 
previously unculturable microbes or the activation of silent genes in established cultures.  The 
manzamine class of alkaloids is a prime example regarding the useful drug potential of unique 
marine structural classes as well as the challenges that arise in supply, optimization and 
preclinical development of complex marine molecules. 
A preeminent example in the field is the story of the didemnins.  Didemnin B has anti-
neoplastic properties and was the first marine drug to be tested in humans. Lack of sustainable 
supply from the tunicate, Trididemnum solidum (Van Name, 1902), hindered further 
advancement.  In 2012, a microbial source was identified from the marine environment by the 
Fenical and Moore groups and along with the identification of the didemnin biosynthetic 
pathway may provide a route for further development.86   
Microbial species have been identified and studied for their symbiotic relationships in 
many marine macroorganisms. Symbiosis between the cyanobacterium Prochloron didemni 
(Lewin, 1977) and the tunicate Lissoclinum patella (Gottschaldt, 1898) has been explored for its 
biosynthetic potential of the patellamide compounds.87 While the biosynthetic gene clusters were 
identified in P. didemni for the production of patellamides, no production was detected when the 
bacterium was separated from the host. Other studies of this symbiosis explain the importance of 
P. didemni in aiding the tunicate in both primary and secondary metabolism to ensure its 
survival,88 exemplifying the need for exploration in host-microbe symbiosis in drug discovery 
and development. 
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The manzamine class of alkaloids offer some remarkable opportunities based on both the 
chemistry and therapeutic potential for this group of metabolites. Manzamine A was originally 
described as a possible cancer lead, but has shown significant activity against the malaria 
parasite Plasmodium falciparum including single dose clearance and a 2-7 fold greater activity 
compared to artemisinin in vitro.89 Mycobacterium tuberculosis and serine/threonine kinases, 
such as GKS3-β and CDK5, are also inhibited.89b, 90 Treatment with manzamine A impedes 
metastasis in cancer cell lines and sensitizes them to TNF-related apoptosis-inducing ligand 
(TRAIL)-induced apoptosis.91 Wright et al. filed a patent for manzamine A  showing that when 
added to a cancer treatment regimen cancer cells became susceptible to other treatments, but 
more importantly cell invasion and tumor metastasis were also inhibited.92 Manzamine A has 
shown promise as a suppressor of hyperlipidemia and atherosclerosis in vivo.93  The manzamine 
family now consists of more than 80 β-carboline-containing manzamine and manzamine-related 
alkaloids isolated across nine genera of marine sponges from distinct geographical areas.94 This 
broad distribution across distantly related sponges suggested the putative role of a 
microorganism for actual biosynthesis of the manzamine alkaloids.95 Hu et al.96 comprehensively 
reviewed and updated the taxonomy and classification of known manzamine-producing sponges, 
and these were summarized recently by Radwan et al.94 An unidentified species of Amphimedon 
(Order Haplosclerida, Family Niphatidae) from Okinawa, and Acanthostrongylophora ingens 
(Thiele, 1899) (Class Demospongiae, Order Haplosclerida, Family Petrosiidae) from the Western 
and Central Indo-Pacific, are the greatest producers of these compounds (figure 117 and tables 
12 and 13).  
Although the manzamine alkaloids possess potent bioactivity, their medicinal potential is 
limited in part by a by lack of constant supply of manzamine as well as key precursors for 
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medicinal chemistry, optimization and preclinical development.97 While there are several 
common sponges that produce large yields of manzamine alkaloids, harvesting of wild 
populations of marine invertebrates is neither practical, nor environmentally sustainable. The 
structural complexity of manzamine and lack of a cost-effective synthesis is currently 
challenging for both medicinal chemistry studies and drug production of a potential antimalarial 
agent.98 Community analysis and biomimetic fermentation approaches hold significant promise 
for a solution to the supply challenges and the availability of a sustainable source for the 
chemically complex precursors that are critical to future medicinal chemistry studies. 
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 Figure 117. Morphological and color variation in Acanthostrongylophora ingens (Thiele, 1899). 
(A) Thick encrusting form with coalescent lobes, maroon exterior, gold interior, from Puerto 
Princessa, Sulu Sea, Philippines, 18 m depth; (B) Close-up of thick encrusting form with 
coalescent lobes, maroon exterior, gold interior, from Ritter Island, Dampier Straits, Papua New 
Guinea, 30 m; (C) Thick encrusting form with coalescent tubes, rusty exterior, gold interior, 
from Biaro, Sulawesi Island, Indonesia, 12 m; (D) Thick encrusting form with low tube oscules 
and coalescent ridges, from Manado, Indonesia; (E) Thick encrusting form with low tube oscules 
and coalescent ridges, from Manado, Indonesia; (F)  Ragged hemispherical form with depressed 
oscules and coalescent ridges, from Manado, Indonesia, note gold interior under heavy maroon 
surface. Images A‒C courtesy of Dr. Patrick L. Colin, Coral Reef Research Foundation (CRRF), 
Palau, Micronesia. 
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Table 11. Revised classification of marine sponge known to yield manzamines and related 
compounds. 
Taxonomy and Classification Locality References Order Family Genus and Species 
HAPLOSCLERIDA 
Topsent 
Chalinidae 
Gray 
Haliclona tulearensis 
Vacelet, Vasseur & 
Lévi, 1976 
East Coast 
South 
Africa 
99 
Haliclona (Rhizoniera) 
sarai Pulitzer-Finali, 
1969 
Bay of 
Naples, 
Italy 
100 
Haliclona (Reniera) sp. 
undet. 
Naples, 
Italy 101 
Haliclona sp. undet Okinawa 89a, 102 
Niphatidae 
van Soest Amphimedon sp. undet. Okinawa 103 
Petrosiidae 
van Soest 
Acanthostrongylophora 
ashmorica Hopper, 
1984 
Philippines 104 
Acanthostrongylophora 
ingens (Thiele, 1899) 
Indonesia, 
Micronesia, 
NW PNG 
105 
Acanthostrongylophora 
sp. undet. Okinawa 106 
Acanthostrongylophora 
sp. undet. Palau 107 
Acanthostrongylophora 
sp. undet. 
Milne Bay, 
NW PNG 108 
Neopetrosia exigua 
(Kirkpatrick, 1900) 
Motupore 
Island, S 
PNG 
109 
Neopetrosia contignata 
(Thiele, 1899) 
Milne Bay, 
MW PNG 110 
Neopetrosia sp. undet. Madang, NW PNG 110 
DICTYOCERATIDA 
Minchin 
Thorectidae 
Bergquist Hyrtios erecta Keller Red Sea 111 
Irciniidae 
Gray 
Ircinia Nardo Okinawa 103a-c 
Ircinia sp. undet  Okinawa 103a-c 
 
  
 Table 12. Morphological and habitat characteristics for specimens currently considered to be species of Acanthostrongylophora 
ingens (Order Haplosclerida, Family Petrosiidae). 
The skeleton of A. ingens ranges in density (thickness of the various tracts and tightness of the general network) from the most dense 
(A) with swathes of thick relatively large regular circular meshes with large open spaces between swathes, secondary and primary 
tracts the same size (thick), to (B) swathes of thickish relatively regular smaller circular meshes with large open spaces between 
swathes, secondary and primary tracts the same size, key characteristics is small circular meshes in swathes, rendering the skeleton 
ladder-like, to (C) less dense than 2, with less regular secondary joint tracts, to the least dense (D) with long fine primary tracts 
emanating through choanosome with irregular thin and angular connections, the tracts are fine and almost wispy, mesohyl more 
abundant than in A or B. 
 92-IND-50 92-IND-82 94-IND-136 00-IND-76 01-IND-35 01-IND-51 01-IND-52 
References Ichiba et al (1994)105a 
Ohtani et al 
(1995)105b 
El Sayed et al 
(2001)105d 
Yousaf et al 
(2002)105l 
Yousaf et al 
(2002)105l 
Yousaf et al 
(2002)105l 
Peng et al 
(2003)105n 
Original 
identification Pachypellina sp. Prianos sp 
Petrosiidae ng 
nsp 
Petrosiidae ng 
nsp 
Petrosiidae ng 
nsp 
Petrosiidae ng 
nsp 
Petrosiidae ng 
nsp 
Location 
Manado Bay, 
Sulawesi, 
Indonesia 
Manado Bay, 
Sulawesi, 
Indonesia 
Manado Bay, 
Sulawesi, 
Indonesia 
Manado Bay, 
Sulawesi, 
Indonesia 
Manado Bay, 
Sulawesi, 
Indonesia 
Manado Bay, 
Sulawesi, 
Indonesia 
Manado Bay, 
Sulawesi, 
Indonesia 
Habitat 10 m silty sand, 37 m reef slope, 20 m reef slope, 10-20 m 
reef slopes, 
verticals, 6-30 m 
reef slopes, 
verticals, 33-40 
m 
silty sand, 6-23 
m 
Density  abundant common common abundant abundant common 
External colour blackish-brown brownish-orange maroon maroon maroon-brown, slightly green uw brown maroon-brown 
Internal color yellowish-brown orange yellow yellow mustard brown tan 
Morphology 
spherical to 
thickly 
encrusting mass 
large coalescent 
tubes 
irregularly 
massive 
irregularly 
massive 
thick encrusting 
variable + 
mounds 
thickly 
encrusting 
thickly 
encrusting + 
fingers 
Smell/exudates   smells   putrid putrid 
Oscule diameter   1-2 cm  5 cm and less 1-2 cm 1-3 cm 
Texture compressible soft, fragile, crumbly tough crumbly tough crumbly tough crumbly 
very soft, 
extremely 
fragile, elastic 
fragile, crumbly 
Strongyle 
spicules 90-140 μm 70-150 μm 80-140 μm 110-140 μm 110-150 μm 100-150 μm 120-150 μm 
Skeleton density B C B B A A D 
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RESULTS AND DISCUSSION 
Herein we report the isolation of manzamine A from a Micromonospora sp. M42 isolated 
from the Indonesian sponge A. ingens (figures 118a and b) using molecular-microbial 
community analysis, targeted microbiology, and Matrix Assisted Laser Desorption Ionization- 
Mass Spectrometry (MALDI-MS) imaging experiments to identify and validate it as a producer 
of the manzamine alkaloids. We began by investigating the entire sponge-associated bacterial 
community using a 16S rRNA gene sequence analysis of the sponge-associated bacterial 
community on a library of 117 clones.  This yielded three dominating groups, deltaproteobacteria 
(30%, n=36), chloroflexi (19%, n=23) and actinobacteria (16%, n=19), the remainder of the 
community includes acidobacteria, gammaproteobacteria, alphaproteobacteria, spirochaetes and 
cytophaga-flexibacter-bacteroides (CFB) related bacteria (figure 119). Actinobacteria are one of 
the major components of the bacterial community, as seen in previously reported sponge 
community analysis.112 
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 Figure 118. Confirmation of manzamine A production by Micromonospora sp. M42 
(a) Acanthostrongylophora ingens, a common Indo-Pacific manzamine producing sponge with 
the image of a colony of Micromonospora sp. strain M42 with orange mycelial growth and black 
spores. (b) Structure of manzamine A. (c) 1H NMR analysis comparison of sponge derived and 
bacterial derived manzamine A. (d) MALDI-MS imaging of manzamine A production on ISP2 
over 10 days.  1st column: manzamine A standard control (10 µg on ISP2 agar); 1st row: 
Producing M42 colonies; 2nd row: MALDI-MS imaging for [M+H]+ (549 m/z);  3rd row: 
MALDI-MS imaging for the [M-OH]+ fragment (532 m/z); 4th row: non-producing M42 which 
sporulates faster; 5th row: MALDI-MS imaging for [M+H]+ (549 m/z) showing no detectable 
production of manzamine A. The extraction of replicate colonies yielded a HRESIMS signal of 
[M+H]+ = 549.3607 m/z (mean error: -2.86 ppm for manzamine A).  (e) Production curve of 
manzamine A from liquid ISP2 culture based on LC-TOF-MS and growth curve of the bacteria 
based on OD600 measurements. 
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 Figure 119. Neighbor-joining phylogenetic tree based on 16S rRNA gene sequence analysis 
showing the bacterial diversity of Acanthostrongylophora sp. 
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Denaturing gradient gel electrophoresis (DGGE) comparison of the sponge bacterial 
community to the surrounding water column (figure 120) showed it to be both distinct and more 
diverse. Isolation of the heterotrophic bacteria yielded ten pure cultures: one 
gammaproteobacteria (M37), two alphaproteobacteria (M31, M36), five firmicutes (M28, M29, 
M39, M34, M40) and three actinomycetes (M41, M42, M62).  
 
                                 
Figure 120. Confirmation of unique bacterial presence in the sponge tissue. 
(a) DGGE analysis of a PCR negative control (C), seawater (W), and Acanthostrongylophora sp. 
(S).  The increase in bands in the sponge sample indicates a higher diversity in the sponge than in 
the surrounding water column. (b) Epifluorescence micrograph section of 
Acanthostrongylophora sp. mesohyl tissue visualized by FISH.  The mesohyl region was 
hybridized with Cy-3 labeled HGC69a probe. Numerous high GC bacteria (possibly 
actinobacteria) were undetectable in the water column, but clearly visible in the sponge. 
Visualization of actinobacteria within A. ingens tissue by fluorescence in-situ hybridization 
(FISH) using a high-GC probe specific for actinobacteria113 revealed distribution throughout the 
sponge. Clusters of 20 to 50 high-GC bacteria were randomly distributed throughout the 
mesohyl. 
C  W  S a 
b 
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Each A. ingens isolate was tested for the presence of manzamines by TLC (figure 121). 
LC-TOF-MS analysis quickly identified a single bacterial strain (M42) producing a compound 
with identical retention time and mass as manzamine A. This strain was identified as a 
Micromonospora sp., closely related to Micromonospora chalcea (X92594) through 
phylogenetic analysis, and thus named Micromonospora sp. M42 (figure 122).  
 
 Figure 121.  TLC of alkaloids produced by M42 in either ISP2 or YM compared to media and 
manzamine A and 8 hydroxymanzamine A standards obtained from the sponge. 
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 Figure 122. Phylogenetic analysis based on 16S rRNA gene sequence of cultured bacteria 
isolated from sponge Acanthostrongylophora sp. noted in bold. 
 
After exhaustive fermentation and isolation studies of M42, it yielded a pure compound 
with the correlating mass and 1H NMR of the sponge derived manzamine A (figure 118c).  To 
optimize production several different media and growth conditions were explored including ISP2 
media (4 g yeast extract, 10 g malt extract, 4 g dextrose/L) with 2% NaCl, ISP2 media with 2% 
artificial ocean, ISP2 with no salts added, YM media (3 g yeast extract, 3 g malt extract, 3 g 
dextrose, 5 g peptone/L) with 2% artificial ocean, M4 media (10 g glucose, 2 g casamino acid, 2 
g yeast extract, 2 g beef extract /L) with 2% artificial ocean, ½ dilution of YM media, marine 
broth 2216 (Difco), and marine broth 2216 (Difco) supplemented with 2 g glucose/L.  Other 
growing conditions such as submerged fermentation, solid state fermentation, fermentation with 
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various resins (XAD 2, XAD7, XAD 1180 and HP20) and fermentation with extracted sponge 
fiber were also explored to optimize yield.  The highest yield achieved was several mg/L in ISP2 
liquid media grown for 7 days at 280C and 150 rpm and the whole culture extracted twice with 
chloroform via liquid-liquid partition.   However, the most reproducible production yield of 
manzamine A was closer to and frequently less than 1 mg/L utilizing the same conditions.    
To further verify the production of manzamine A, MALDI-MS imaging was performed 
(figure 118d).  MALDI-MS imaging was chosen because it gives the widest available mass 
range, as well as having the best established techniques and protocols for experimental 
development and design. The main benefit of this analytical method is the ability to perform a 
time course experiment and see the production of the metabolite in question being produced and 
consumed in its native environment.  Since the first report of MALDI-MS imaging on 
microorganisms was published in 2008, the technique has grown in popularity and shown its 
diverse utility in discovery of new natural products, ecological role via spatial localization 
experiments within colonies, exploration of biosynthetic origins of natural products, and 
metabolic profiles related to phenotypic studies.86, 114 While MALDI-MS imaging has numerous 
benefits, it is important to be aware of its challenges.  The first of which is the application of 
matrix to the sample in order for the ionization process to occur.  This was a particularly 
challenging aspect for confirming manzamine A production.  A matrix has to be identified that 
would allow manzamine A to ionize effectively, but not produce interfering signals.  For this 
reason both ISP2 and YM media from above were analyzed with 4 different matrixes (2,5-
dihydoxybenzoic acid, sinapic acid, 2,5-dihydroxyacetophenone, and α-cyano-4-
hydroxycinnamic acid) and it was found that sinapic acid gave the best ionization with the least 
interference (figure 123).  Manzamine A production over 16 days in liquid culture revealed that 
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manzamine A is initially produced in a linear fashion and then metabolized by the organisms 
resulting in undetectable levels of manzamine A after day 10 (figure 118e). Further stability 
studies revealed that degradation of the metabolite is not caused by solvent; however, we cannot 
rule out external enzymatic degradation. While these experiments show that M42 is capable of 
producing manzamine A, they also introduce complications of further metabolism of the 
molecule. The MALDI-MS imaging results also qualitatively show the same production pattern 
over a 10 day time course.  Another limitation of MALDI-MS imaging is that is can only 
produce qualitative results.  This is due to the inherently imprecise application of matrix leading 
to appreciable pixel-to-pixel variability.115  To minimize these effects on the overall qualitative 
analysis, all colonies (day 0-10) were run at the same time using the same MALDI plate leading 
to only one uniform application of matrix.  Production of manzamine A is not detectable until 
day 4, peaks around day 6 and then is excreted and eventually metabolized by day 10.  The two 
main signals seen in the manzamine A standard are 549 and 532 m/z.  These same masses are 
observed being produced in the colonies in overlapping areas starting at day 5.   
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 Figure 123. Mass spectra of manzamine A standard vs sinapic acid matrix on MALDI. 
There were challenges in choosing the appropriate matrix for MALDI MS imaging.  After 
attempting several different MALDI matrixes, sinapic acid was chosen due to its ability to ionize 
manzamine A well, but without any interfering peaks.  The fragment at 467 m/z was not used for 
imaging due to its low intensity and overlap with the matrix peaks. 
  
Since the MALDI-MS imaging used for this analysis is only capable of giving a low 
resolution mass, six colonies were grown for each day tested above. One colony was used for the 
MALDI-MS imaging, and the remaining 5 colonies for each day through the entire time course 
were combined and extracted with CHCl3 three times with 30 minutes of sonication with each 
extraction.  The extract was then eluted through a silica gel flash column with 100% hexane, 
90% hexane: 10% acetone, 75% hexane: 25% acetone and 100% acetone.  The 75% hexane 
fraction which is the correct polarity for manzamine A based on previous sponge extractions was 
then subjected to high-resolution MS using a Bruker microTOF ESI.  This yielded a HRMS for 
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the microbial extract with a signal at 549.3607 m/z which corresponds to the [M+H]+ of 
manzamine A (mean error: -2.86 ppm).  The standard sponge isolated manzamine A was run 
after this  microbial  product and showed a signal at 549.3638 m/z which corresponds to the 
[M+H]+ of manzamine A (mean error: -8.06 ppm) (figure 124).  Thus providing further evidence 
that the low resolution signal seen in the MALDI-MS imaging is manzamine A when analyzed 
using HRMS.   
The microbial production appears to only produce manzamine A and under some 
conditions small amounts of the 8-hydroxy manzamine A.   Despite the fact that over 80 
manzamine alkaloids are reported in the literature from sponges, it is apparent that all could be 
formed by plausible biotransformation mechanisms involving oxidations and rearrangement.  
Figure 125 provides an overview of the known and plausible biotransformation reactions leading 
to the manzamine alkaloids isolated from sponges beginning with just manzamine A.105m     
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  Figure 124.  HRESIMS from extracts of solid phase growth of M42 on ISP2. 
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 Figure 125. Potential routes for A. ingens derived metabolites.  
Biotransformation results using manzamine standards are displayed as well as plausible 
explanation for related metabolites. Microorganisms: (1). Fusarium solani F0007, (2). 
Micromonospora M42, (3). Fusarium oxysporium f.sp.  gladioli ATCC 1113713, (4) Bacillus sp. 
VAN35 (M28) (5). Streptomyces seokies, (6). Fusarium oxysporium ATCC 760114 (7). 
Nocardia sp ATCC 2114514 were capable of transforming MA into a related metabolite. [(Ref.) 
= 116, Plausible biosynthetic route for manadomanzamines in this reference] 
tryptamine
(ent
) ma
nF
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Further support of the biogenesis of manzamine A by M42 was obtained through 
preliminary biosynthetic studies. In the first biosynthetic scheme proposed for manzamine A,117 a 
pyridinium dimer undergoes a Diels-Alder reaction followed by hydrolysis to generate an 
aldehyde similar to ircinal A. This aldehyde can react with tryptamine through a Pictet-Spengler 
reaction, producing manzamine D in a similar biochemical mechanism as plant strictosidine 
synthase.118 Further oxidation would yield the aromatic β-carboline ring system. To test this 
proposed biosynthetic route, tryptamine and ircinal A were added to M42 cultures in ISP2 media 
and this resulted in an approximate 5-fold increase in manzamine A production demonstrating 
the ability of M42 to convert precursors to manzamine A (figure 126).   This same increase could 
not be seen when tryptophan replaced the tryptamine in culture.  As a control experiment, 
perillaldehyde and tryptamine were added to the culture to see if the Pictet-Spengler reaction 
would occur with a similar aldehyde.  This experiment yielded none of the expected product.  
This confirms that the production is specific to the substrates and will not work on any aldehyde 
tryptamine combination. 
 
 Figure 126. Feeding ircinal and tryptamine results in an increase in manzamine A production. 
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Several attempts have been made to insert a labeled atom into the production media of 
M42 in order to obtain a labeled manzamine A molecule.  All attempts at producing manzamine 
A from the bacteria in minimal media failed.  Manzamine A can only be obtained from rich 
media and any dilution of these media results in drastic reduction or elimination of manzamine A 
production.  Therefore, attempts were made to insert a label into the rich media utilizing [U-13C] 
glucose.  While studies showed that the bacteria produced manzamine A in the presence of [U-
13C] glucose, no incorporation could be observed by MS or NMR due to the low incorporation of 
labeled isotope.  In addition to the labeled glucose several forms of labeled acetate were also 
tested (CD3COONa, CH3COO15NH4, and 13CH313COONa) and gave similar production of 
manzamine A, but not detectable incorporation by MS or NMR.  These results are not 
unexpected due to the richness of the media and other starting materials being available for the 
biosynthesis of manzamine A.  Finally, 15N labeled tryptamine was added to the culture in a 
similar fashion to the precursor directed feeding experiments outlined above.  This yielded 
successful incorporation of 15N based on Elemental Analysis Isotope Ratio Mass Spectrometry 
(EA-IRMS).  Table 14 outlines the part per thousand and standard deviations for M42 produced 
manzamine A, sponge isolated manzamine A, and 15N enriched manzamine A obtained from the 
the above conditions.  The data shows an increase in the presence of 15N compared to the other 
unenriched samples, but only a 2.5 times incorporation of 15N which is enough to be seen via 
EA-IRMS, but not less sensitive techniques such as MA or NMR. 
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Table 13. Analysis of 15N Incorporation by EA-IRMS of 15N-labeled tryptamine by M42 to 
produce 15N labeled manzamine A (MA). 
 
Consistent and stable production of manzamine A by M42 has proven to be challenging. 
In subsequent fermentations over the decade since M42 was originally isolated, a strain of M42 
was identified that does not produce detectable levels of manzamine. However, when returning 
to the original 2002 M42 strain for MALDI-MS imaging, production was again detected.  Figure 
117d shows the non-detectable production of manzamine A in the later strains in contrast to the 
original glycerol stocks of M42.  It is clear from this image that the non-producing strain 
sporolates at least 24 hrs before the original strain and never obtains the deep orange color 
characteristic of M42.  Partial 16S rRNA gene sequences from both strains were amplified and 
sequenced using the primers 27F 5'-AGAGTTTGATCMTGGCTCAG-3' and 1492R 5'-
TACGGYTACCTTGTTACGACTT-3'.119  The sequence was deposited in Genbank under 
accession number EF513641.  The 16S rRNA analysis of these strains showed both to be 
identical.  Further genetic analysis in the differences of these strains is ongoing and may shed 
light on the biosynthesis of the manzamines.  It is possible that the biosynthetic machinery is 
plasmid derived and can be lost or acquired through horizontal gene transfer. The wide 
distribution of manzamine alkaloids in different sponge species suggests that the machinery is 
able to be acquired by multiple microorganisms, most suitably in plasmid form. Other research 
Sample 
Mean 
d13CV-PDB  
(‰) 
St. Dev. 
(‰) 
Mean 
d15NAir  
(‰) 
St. Dev. 
(‰) 
Mean 
15N/14N 
St. Dev. 
 
M42 MA -22.20 0.10 4.21 0.22 0.003692 0.000001 
15N M42 MA -21.99 0.02 1424 125 0.0089 0.0005 
Sponge MA -22.54 0.05 4.26 0.16 0.003692 0.000001 
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suggests that secondary metabolite production can decrease and even become non-existent after 
multiple generations of subcultures as is the case with the camptothecins.120  
The symbiotic relationship between the invertebrate and the bacteria has successfully 
evolved to yield g/L scale production in the sponge versus the less than mg/L scale by the 
microbe. We have seen that manzamine A inhibits the growth of M42 at 12 µg/mL; much larger 
concentrations are found in the sponge, thus supporting the proposed sequestration of large 
amounts of manzamine alkaloids in a manner that is not toxic to the bacterium (figure 127). 
These data indicate that M42 could provide chemical defense for A. ingens in exchange for 
habitat or acting as a natural continuous-flow bioreactor.  One explanation is that manzamine A 
is produced only at low levels by M42 within the sponge and accumulates over the lifetime of 
the sponge.  A second possibility is that M42 is present at high numbers within the sponge; 
however, this seems unlikely due to the lack of representation in the 16S rRNA gene clone 
library from the sponge and detailed fluorescence in situ hybridization (FISH) analysis. A third 
possibility is that M42 is not the only producer but rather the only one that has been cultivated. 
To examine this hypothesis, a primer based on M42 16S rRNA gene was designed and coupled 
to a eubacterial universal primer 1492r.  Using a nested PCR approach, a clone of 16S rRNA 
genes enriched for those related to M42 were obtained. The analysis revealed several sequences 
closely related to M42 that were not previously seen (figure 128). Yet another possibility is the 
transfer of genes horizontally between unrelated bacteria, which would produce multiple 
producers that would avoid detection by homology based approaches. All of these are possible 
explanations for the discrepancy in total yields between the laboratory and the field. 
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 Figure 127. Inhibition of M42 growth by manzamine A.  
Increasing manzamine A concentration inhibits the growth of M42 in a dose dependent fashion. 
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 Figure 128. Increased amplification of actinobacteria. 
Using a universal primer as well as an actinobacteria primer resulted in a higher amplification of 
actinobacteria 16s RNA. This result is consistent with those published by Farris and Olson121. 
 
With the use of community analysis studies, Micromonospora sp. M42 is the first sponge 
associated actinomycete bacteria that has been shown to produce a sponge derived metabolite.122 
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A culturable producing strain provides opportunities for overcoming future supply challenges 
that hinder marine natural products development into usable drugs; however, significant 
improvements in culture and production methods will need to be developed. Despite the 
successful production from a single pure culture, it has become quite evident that significant 
barriers in drug production and successful biomimetics for culture conditions still remain. The 
cumulative data presented confirms that M42 is capable of producing manzamine A, and 
although the yields are not yet sufficient to provide a practical solution for drug development, it 
provides an important starting point for chemical biology, precursor directed feeding 
experiments and improvements in gene expression to generate higher producing strains.  This 
study also illustrates the unique potential for applying molecular phylogeny for the exploration 
of invertebrate microbiomes in the discovery and development of natural products.    
 
EXPERIMENTAL SECTION 
Sponge Sampling and Identification 
Specimens of A. ingens were collected by SCUBA diving in Manado Bay, Indonesia at 
depth between 6 and 33 m. Sponges were transferred directly to plastic bags containing seawater.  
Sponge tissue was stored frozen at -80˚C until used.  The sponge tissue was lyophilized prior to 
molecular manipulation. 
Total DNA Extraction from A. ingens  
DNA was extracted from lyophilized sponge tissue using a bead-beater method adapted 
from Pitcher et al.123  Dried tissue (4 g) was ground with a mortar and pestle and resuspended in 
16 mL of TE buffer and 4 mL of isoamyl alcohol.  The solution was transferred to a 50 mL bead-
beater chamber (Biospec Products, Inc.).  Zirconia/Silica beads (0.1 mm and 1 mm) were added 
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to 1/4 volume of the chamber and homogenized 4 times in 1 min via the bead- beater.  The 
solution was transferred to a 50 mL tube, 10 ml of guanidium thiocyanate buffer was added, 
mixed gently, and transferred to ice.  Ammonium acetate (10 M) was added to a 2.5 M final 
concentration.  Standard phenol/chloroform extraction and chloroform/isoamyl alcohol 
extraction were followed.  DNA was precipitated with cold isopropanol, cleaned with 70% 
(vol/vol) ethanol, and resuspended in TE buffer (pH 8).  DNA was quantified using a UV/Vis 
spectrophotometer. 
Bacterial Clone Library of A. ingens 
 PCR was performed using 100 ng of DNA with universal 16S rRNA gene primers 8-
27f124 and 1492r125 using Hi-Fi Platinum® Taq (Invitrogen).  Cycling conditions were as follow: 
initial denaturation at 94ºC for 5 min, 20 cycles of 94ºC for 30 sec, 48ºC for 2 min, 72ºC for 1.5 
min, and a final extension of 5 min at 72ºC in a PTC-200 MJ-research thermal cycler (Bio-Rad).  
PCR products were purified by electrophoresis in a 1% (wt/vol) agarose gel and bands of 
approximately 1500 bp were excised and recovered using a gel extraction kit (Qiagen, Inc.).  
Purified PCR products were cloned with a TOPO®-XL cloning kit (Invitrogen) according to the 
manufacturer’s instructions.  Sequence of 108 clones (>500 bp) were manually aligned with 
Phydit software.126  The tree was generated by the neighbor-joining algorithm 127 implemented in 
Phydit.  The robustness of inferred tree topologies was evaluated after 1,000 bootstrap 
resamplings of the neighbor-joining data, and only values >50% were shown. 
Isolation and Identification of Sponge-Associated Bacteria 
A sponge microbial extract was obtained by grinding 1 cm3 of sponge tissue in sterile 
artificial seawater using a mortar and pestle.  The extract was plated in a serial dilution (100 to 
10-4) on three different media types and incubated at 30°C for up to 3 weeks. Marine Agar 2216 
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(Difco), a non-selective medium, ISP2 (Difco) and starch casein agar, both improve the growth 
of Actinobacteria and were supplemented with a final concentration of nalidixic acid (10 μg/ml), 
cycloheximide (10 μg/ml), nystatin (25 μg/ml) and 2% (wt/vol) NaCl. One morphotype of each 
bacterial colony was selected and subcultured until pure. Isolates were identified by 16S rRNA 
gene sequence analysis.  Bacterial isolates were grown at 30˚C, in 50 mL broth of the medium 
from which they were originally isolated.  After 5 days of growth, DNA was extracted from cell 
pellets using the Ultra-Clean® Microbial DNA Isolation kit (Mo Bio Laboratories Inc.).  The 16S 
rRNA gene fragments were amplified by PCR using Platinum® Taq DNA polymerase High 
Fidelity, primers 8-27f124, 1492 r125 and sequenced.  Phylogenetic analysis of isolates sequence 
was carried as described above. 
Culture Methods for Micromonospora sp. M42. 
Micromonospora sp. strain M42 was grown in shake flasks and a 20-liter fermenter in 
ISP2 liquid medium with vigorous aeration at 30˚C.  To generate mutants, spores harvested after 
10 days of growth on ISP2 plates were irradiated using a 254 nm UV source to achieve a 99% 
kill rate.  Resultant colonies were inoculated into 50 mL ISP2 liquid cultures and shaken for 4 
days at 30˚C. Ethyl acetate extracts from these cultures were screened by thin layer 
chromatography followed by LC-TOF-MS for manzamine production.  
Extraction and Isolation 
A. ingens were first screened by TLC using the alkaloid specific Draggendorf stain and 
compared to sponge-isolated manzamine A and 8 hydroxymanzamine A standards. M42 was 
extracted with ethyl acetate at room temperature.  The extract was dried and subjected to silica 
gel vacuum-liquid chromatography and eluted beginning with hexane (100%), hexane–acetone 
(9:1, 3:1, 1:1), acetone (100%), chloroform–methanol (1:1) and finally with methanol (100%).  
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Fraction 3, eluted with hexane–acetone (3:1), was subjected to HPLC chromatography 
(Phenomenex  Luna 5 μM 250 x 10.0 mm column, flow rate 3 ml/min, λ 254, 360 nm) using a 
gradient solvent system of acetonitrile and water both with 0.1% TFA to obtain manzamine A 
and B.  
Precursor Directed Biosynthetic Experiments 
Precursor direct biosynthesis was conducted in order to validate production of 
manzamine by the bacteria, increase yields and establish the final steps of manzamine A 
biosynthesis. Commercially available tryptamine and sponge isolated ircinal A were fed to M42.  
A 1 L culture of M42 in ISP2 media supplemented with 2% (wt/vol) NaCl was shaken at 28oC 
and 150 rpm for two days followed by addition of tryptamine and ircinal A (each 25 mg) and 
then continued incubation for an additional three days. Cells and supernatant were separated by 
centrifugation.  The supernatant was extracted with chloroform and evaporated under vacuum.  
The crude extract was passed though SPE C-8 column before analysis using HPLC, LC-TOF and 
NMR.  These experiments were repeated four times yielding an average 5-fold increase in 
manzamine A production.  The same experiments were repeated to obtain 15N-labeled 
manzamine A by substituting 15N-labeled tryptamine. 
LC-TOF- MS and NMR Analysis 
LC-MS analysis was carried out on a Bruker microTOF with electrospray ionization.  
Solutions of standard manzamine A from the sponge and manzamine A and B obtained from a 
microbial source were prepared in methanol and subjected to LCMS using a reverse-phase C8 
column (Phenomenex, 5µ, 4.6 X 150 mm) eluting at 0.4 ml/minute flow rate with 20 minute 
linear gradient from 20% to 100% phase B. Phase A was water and phase B was acetonitrile. The 
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NMR of both the sponge and bacteria associated manzamine A were obtained on a Bruker 400 
MHz NMR in CDCl3.  
EA-IRMS for 15N-labeled Manzamine A 
Samples and references were weighed into tin capsules, sealed, and loaded into an auto-
sampler on a Europa Scientific elemental analyser. They are dropped in sequence into a furnace 
held at 1000 °C and combusted in the presence of oxygen. The tin capsules flash combust, 
raising the temperature in the region of the sample to ~1700 °C. The combusted gases are swept 
in a helium stream over combustion catalyst (Cr2O3), copper oxide wires (to oxidize 
hydrocarbons), and silver wool to remove sulfur and halides. The resultant gases, N2, NOx, H2O, 
O2, and CO2 are swept through a reduction stage of pure copper wires held at 600°C. This 
removes any oxygen and converts NOx species to N2. A magnesium perchlorate chemical trap is 
used to remove water. Nitrogen and carbon dioxide are separated using a packed column gas 
chromatograph held at a constant temperature of 65°C. The resultant nitrogen peak enters the ion 
source of the Europa Scientific 20-20 IRMS first, where it is ionized and accelerated. Nitrogen 
gas species of different mass are separated in a magnetic field then simultaneously measured 
using a Faraday cup collector array to measure the isotopomers of N2 at m/z 28, 29, and 30. After 
a delay the carbon dioxide peak enters the ion source and is ionized and accelerated. Carbon 
dioxide gas species of different mass are separated in a magnetic field then simultaneously 
measured using a Faraday cup collector array to measure the isotopomers of N2 at m/z 44, 45, 
and 46.  Both references and samples are converted to N2 and analyzed using this method. The 
analysis proceeds in a batch process by which a reference is analyzed followed by a number of 
samples and then another reference. 
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MALDI-MS Imaging Experiments 
To prepare colonies for MALDI-MS imaging, 9-15 mL thick ISP2 plates with 2% 
artificial ocean were poured and allowed to set overnight.  5 µL of Micromonospora sp. M42 
was plated in 6 distinct places on the plate.  The bacterium was allowed to grow at 30°C in an 
incubator for 0-10 days.  The plates were removed from the incubator, individual colonies and 
appropriate controls were cut from the agar and placed on a Bruker™ MTP 384 ground steel 
plate using a spatula. This was done slow enough to avoid the trapping of air bubbles underneath 
the media. Then sinapic acid (Sigma Aldrich) was sprinkled on top of the culture using a 20 µm 
sieve (Hogentogler & Co.) Then the colonies were dried in a vacuum oven (VWR 1410) for 8 
hours at 38°C. Then the sample plate was inserted into Bruker™ Autoflex II mass spectrometer 
equipped with Compass 1.1 software suite (consists of FlexImaging 3.0, FlexControl 2.4, and 
FlexAnalysis 2.4). The samples were analyzed in linear positive mode, with 200 µm intervals. 
The spectra were collected in 360–1200 m/z mass range at 200 Hz laser frequency. After data 
acquisition, the data were analyzed using the FlexImaging software.86, 128 
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